HUE034712T2 - Amidszármazék és gyógyszer - Google Patents

Amidszármazék és gyógyszer Download PDF

Info

Publication number
HUE034712T2
HUE034712T2 HUE04807908A HUE04807908A HUE034712T2 HU E034712 T2 HUE034712 T2 HU E034712T2 HU E04807908 A HUE04807908 A HU E04807908A HU E04807908 A HUE04807908 A HU E04807908A HU E034712 T2 HUE034712 T2 HU E034712T2
Authority
HU
Hungary
Prior art keywords
methyl
ylmethyl
ylamino
pyrimidin
benzamide
Prior art date
Application number
HUE04807908A
Other languages
English (en)
Inventor
Tetsuo Asaki
Yukiteru Sugiyama
Jun Segawa
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of HUE034712T2 publication Critical patent/HUE034712T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

(12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9l2O<2006 01> C07D 213174(2006 01> 02.08.2017 Bulletin 2017/31 C07D 239142 <200e 01) C07D 4Ο1Ι14<200β01> C07D 403114 <200e·01) C07D 401104 <200e·01) (21) Application number: 04807908.1 C07D 405I14<2™<»> C07D 417I04<2™”> Α61Κ31Ι496<200β01> A61K 31Ι5Ο6<200β01> n , ..... ~ηηΛ A61P 35102<200601> A61P 43100 <200601> (22) Date of filing: 27.12.2004 (86) International application number: PCT/JP2004/019553 (87) International publication number: WO 2005/063709 (14.07.2005 Gazette 2005/28)
(54) AMIDE DERIVATIVE AND MEDICINE
AMIDDERIVAT UND MEDIZIN DERIVE D’AMIDE ET MEDICAMENT (84) Designated Contracting States: (74) Representative: Vossius &amp; Partner
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Patentanwalte Rechtsanwalte mbB HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR Siebertstrasse 3 81675 Miinchen (DE) (30) Priority: 25.12.2003 JP 2003431398 (56) References cited: (43) Date of publication of application: WO-A-2004/096225 WO-A-2005/016323 20.09.2006 Bulletin 2006/38 WO-A1-02/22597 WO-A1-2004/002963 WO-A1-2004/014903 JP-A- 6 087 834 (73) Proprietor: Nippon Shinyaku Co., Ltd.
Kyoto-shi, · PARISE, R.A. ET AL.: ’Liquid
Kyoto 601-8550 (JP) chromatographic-mass spectrometric assay for quantitation of Imatinib and its main metabolite
(72) Inventors: (CGP 74588) in plasma’ JOURNAL OF
• ASAKI, Tetsuo CHROMATOGRAPHY, B: ANALYTICAL
Uji-shi, Kyoto 611-0041 (JP) TECHNOLOGIES IN THE BIOMEDICAL AND LIFE • SUGIYAMA, Yukiteru SCIENCES vol. 791, no. 1-2, 05 July 2003, pages
Kyoto-shi, 39 - 44, XP004428028
Kyoto 608-8182 (JP) • SEGAWA, Jun Remarks:
Nara-shi, Nara 631-0806 (JP) Thefilecontainstechnicalinformationsubmittedafter the application was filed and not included in this specification
Description
Technical Field [0001] The present invention relates to an amide derivative or a salt thereof, and a pharmaceutical composition comprising an amide derivative or a salt thereof as an active ingredient.
[0002] While BCR-ABL tyrosine kinase (see, for example, Non-Patent Document 1) causes aberrant growth of cells, a compound which inhibits its activity is useful for the prevention or for use in the treatment of diseases caused by the activity of the BCR-ABL tyrosine kinase, for example, chronic myelogenous leukemia, acute lymphoblastic leukemia and acute myelogenous leukemia (see, for example, Non-Patent Document 2).
Background Art [0003] bcr is a gene which exists in the human twenty-second chromosome and abl is a gene which exists in the human ninth chromosome, and Philadelphia chromosome is formed by translocation of the human twenty-second and ninth chromosomes. It is known that a gene product of the chromosome, BCR-ABL, is a protein having tyrosine kinase activity and constantly generates the growth signal to cause aberrant growth of cells (see, for example, Non-Patent Document 2).
[0004] Therefore, inhibition of the BCR-ABL tyrosine kinase activity makes it possible to suppress cell growth caused by the kinase and a compound which inhibits the activity is suited for use as a therapeutic agent for diseases such as chronic myelogenous leukemia, acute lymphoblastic leukemia and acute myelogenous leukemia. Although Glivec® (see, for example, Patent Document 1) has already been put on the market as a drug having the same action, other drugs having the same action mechanism have never been put on the market and thus it has been required to develop more excellent medicines.
[0005] It has recently been reported that recurrence is often recognized in patients wherein remission is attained by administration of Glivec® in BCR-ABL-positive acute lymphoblastic leukemia, in addition to examples of blastic crisis of chronic myelogenous leukemia (see, for example, Non-Patent Document 3). As a result of examination of leukemia cells of the patients suffering from the recurrence of disease, the appearance of a variant such as E255K is recognized (see, for example, Non-Patent Documents 4 to 7). Also in examples of administration of Glivec® to the patients with BCR-ABL-positive acute lymphoblastic leukemia, the appearance of resistant cells which mainly exhibits variation of E255K is recognized (see, for example, Non-Patent Document 8). With an increase in use of Glivec®, resistant patients further increase and thus it is required to develop a therapy.
Patent Document 1: Japanese Unexamined Patent No. 6-87834 Patent Document 2: Pamphlet of International Publication WO 02/22597 Non-Patent Document 1: Shtivelman E, et al.: Nature, 1985, 315, 550-554 Non-Patent Document 2: Daley G Q, et al.: Science, 1990, 247, 824-830 Non-Patent Document 3: Druker B J, et al.: N Engl J Med, 2001, 344, 1038-1042 Non-Patent Document 4: Weisberg E, et al.: Drug Resist Updat, 2001,4, 22-28 Non-Patent Document 5: Gorre Μ E, et al.: Science, 2001,293, 876-880 Non-Patent Document 6: Blagosklonny Μ V: Leukemia, 2002, 16, 570-572 Non-Patent Document 7: Hochhaus A, et al.: Leukemia, 2002, 16, 2190-2196 Non-Patent Document 8: Hofmann W -K, et al.: blood, 2002, 99, 1860-1862 Non-Patent Document 9: Deninger W N, et al.: blood, 2000, 96, 3343-3356 Non-Patent Document 10: J. Org. Chem., 1996, 61, 1133-1135 Non-Patent Document 11: J. Org. Chem., 2000, 65, 1144-1157 Non-Patent Document 12: Reel. Trav. Chim. Pays-Bas., 1950, 69, 673-699 Non-Patent Document 13: J. Heterocycl. Chem., 1970, 7, 1137-1141 Non-Patent Document 14: J. Am. Chem. Soc., 1999, 121,4369-4378 Non-Patent Document 15: Tetrahedron Lett., 1997, 38, 8005-8008 Non-Patent Document 16: J. Med. Chem., 2002, 45, 3406-3417 Non-Patent Document 17: J. Med. Chem., 2000, 43, 3895-3905 Non-Patent Document 18: J. Med. Chem., 2000, 43, 1508-1518 Non-Patent Document 19: J. Med. Chem., 1975, 18, 1077-1088 Non-Patent Document 20: Bioorg. Med. Chem. Lett., 2001, 11, 2235-2239 Non-Patent Document 21: J. Heterocyclic Chem., 2000, 37, 1457-1462
Disclosure of the Invention Problems that the Invention is to Solve [0006] An object of the present invention is to provide a novel amide derivative having an excellent BCR-ABL tyrosine kinase inhibitory activity, or a pharmaceutically acceptable salt thereof.
Means for Solving the Problems [0007] Subject-matter which is not encompassed by the scope of the claims does not form part of the presently claimed invention. The present inventors have intensively studied about various compounds and found that the above object is achieved by a novel amide derivative and a pharmaceutically acceptable salt thereof (hereinafter referred to as a "compound of the present invention"), thereby completing the present invention.
[0008] The present invention is directed to an amide derivative, which is a compound represented by the following general formula [1] in any of the following cases (A) or (C), or a pharmaceutically acceptable salt thereof.
[Chemical 1]
[1] (A) [0009] R1 represents any of groups of the following (1) through (3): (1) -CH2-R11 [R11 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group is substituted by a group selected from the group consisting of oxo, -CH2-R111 (R111 represents a saturated, nitrogen-containing heterocyclic group), asaturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy and (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, and further, may be substituted by 1 or 2 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and di-alkylcarbamoyl], (2) -O-R12 [R12 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group may be substituted by 1 to 3 same or different members selected from the group consisting of oxo, -CH2-R121 (R121 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl], and (3) -CH=R13 [R13 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group may be substituted by 1 to 3 same or different members selected from the group consisting of oxo, -CH2-R131 (R131 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl].
[0010] R2 represents alkyl, halogen, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyl, amino, monoalkylamino, dialkylamino, nitro, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl orcyano.
[0011] R3 represents hydrogen, halogen or alkoxy.
[0012] Het1 represents any of groups of the following chemical formulas [2] to [8], [Chemical 2]
[0013] Het2 represents pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1,2-dihydropyridazinyl (the Het2 may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, halogen and amino).
[0014] Exception is made for a compound wherein R11 is pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl (Each of the pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is substituted by a group selected from the group consisting of oxo, -CH2-R111 (R111 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy and (5-methyl-2-oxo-1,3-dioxol-4-yl)me-thyl, and further, may be substituted by 1 or 2 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl); Het1 is a group of the formula [6]; and Het2 is pyrazinyl or pyridyl which may be substituted by alkyl. (C) [0015] R1 represents any of groups of the following (1) through (3): (1) -CH2-R11 [R11 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group is substituted by a group selected from the group consisting of oxo, -CH2-R111 (R111 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy and (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, and further, may be substituted by 1 or 2 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl], (2) -O-R12 [R12 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group may be substituted by 1 to 3 same or different members selected from the group consisting of oxo, -CH2-R121 (R121 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, di- alkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl], and (3) -CH=R13 [R13 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group may be substituted by 1 to 3 same or different members selected from the group consisting of oxo, -CH2-R131 (R131 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, di-alkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl] [0016] R2 represents alkyl, halogen, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyl, amino, monoalkylamino, dialkylamino, nitro, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl or cyano.
[0017] R3 represents hydrogen, halogen or alkoxy.
[0018] Het1 represents any of groups of the following chemical formulas [9] and [10].
[Chemical 4]
[0019] Het2 represents pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1,2-dihydropyridazinyl, whereby the Het2 may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, halogen and amino.
[0020] Examples of the preferable compounds among compounds of the above formula [1] include amide derivatives of the following (1) to (7), or pharmaceutically acceptable salts thereof: (1) (-)-4-((S)-3-amino-2-oxopyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (2) 4-[(S)-2-(1-pyrrolidinylmethyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (3) 4-[3-(dimethylaminomethyl)azetidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (4) 4-[(S)-3-(1-pyrrolidinyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (5) 4-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyri-midinyl)pyrimidin-2-ylamino]phenyl}benzamide, (6) 4-[(S)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino]phenyl}benzamide, and (7) 4-[(3R,4R)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidi-nyl)pyrimidin-2-ylamino]phenyl}benzamide.
[0021] Furthermore, in the present invention, the amide derivatives of the following (1) to (44), or pharmaceutically acceptable salts thereof can be exemplified: (1) 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide, (2) 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza-mide, (3) 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide, (4) 3,5-dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide, (5) 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphe-nyljbenzamide, (6) 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe nyl}benzamide, (7) 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methyl-phenyl}benzamide, (8) 3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza-mide, (9) 3-fluoromethyl-4-(1-methylpiperidin-4-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide, (10) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phe-nyljbenzamide, (11) 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phe-nyljbenzamide, (12) 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benza-mide, (13) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}ben-zamide, (14) 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (15) 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (16) 4-[(R)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide, (17) 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphe-nyljbenzamide, (18) 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide, (19) 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza-mide, (20) 4-(3-carbamoylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (21) 4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide, (22) 4-(3-carbamoyl-4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide, (23) 4-((S)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (24) 4-((R)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (25) 4-[(S)-3-(N,N-diethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide, (26) 4-[(2R,4S)-4-(dimethylamino)-2-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidi-nyl)pyrimidin-2-ylamino]phenylJbenzamide, (27) 4-((S)-3-aminopiperidinomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide, (28) 4-[(S)-3-(dimethylamino)piperidinomethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (29) 4-((3S,4R)-3-amino-4-methylpyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin- 2-ylamino]phenylJbenzamide, (30) 4-[(3S,4R)-3-(dimethylamino)-4-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidi-nyl)pyrimidin-2-ylamino]phenyl)benzamide, (31) 4-[(S)-3-(methylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide, (32) 4-((S)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (33) 4-((R)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (34) 4-[(3R,4R)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidi-nyl)pyrimidin-2-ylamino]phenylJbenzamide, (35) 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenylJbenza-mide, (36) 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2- (37) 4-[(R)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide, (38) 4-(1-methylpiperazin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]phe-nyl}benzamide, (39) 4-(1-methylpiperazin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylamino]phe-nyljbenzamide, (40) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(4-pyridyl)thiazol-2-ylamino]phenyl}ben- zamide, (41) 4-[(R)-3-(dimethylaminomethyl)pyrrolidine-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phenyl}benzamide, (42) 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide, (43) 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe- nyljbenzamide, and (44) 4-[3-(dimethylamino)azetidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide.
[0022] Further, the present invention is directed to a pharmaceutical composition comprising the compound of the present invention as an active ingredient, for example, a BCR-ABL tyrosine kinase inhibitor. More specifically, the present invention is directed to a pharmaceutical composition as a therapeutic agent for use in treating chronic myelogenous leukemia, a therapeutic agent for use in treating acute lymphoblastic leukemia, or a therapeutic agent for use in treating acute myelogenous leukemia.
[0023] The compound of the present invention has BCR-ABL tyrosine kinase inhibitory activity and is useful as a drug for use in the prevention or treatment of diseases such as chronic myelogenous leukemia, acute lymphoblastic leukemia and acute myelogenous leukemia (see, for example, Non-Patent Document 9).
[0024] The present invention will now be described in detail.
[0025] The "saturated, nitrogen-containing heterocyclic group" includes a 4-to 8-membered saturated ring group which is a saturated ring group having at least one nitrogen atom as an atom composing the ring and also may have 1 to 3 same or different members selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom. When the atom composing the ring is a nitrogen atom or a sulfur atom, the nitrogen atom or the sulfur atom may form an oxide. Examples thereof include pyrrolidinyl, piperidinyl, piperazinyl, azetidinyl, morpholinyl, thiomorpholinyl and hexahydro-1 H-1,4-diazepinyl. However, the "saturated, nitrogen-containing heterocyclic group" of R13 is limited to ones in which the atom composing the ring which links to R13 via a double bond and the atom composing the ring adjacent thereto are carbon atoms, and for example, -CH=R13 includes piperidin-4-ylidenemethyl.
[0026] "Alkyl" includes straight or branched alkyl groups having 1 to 10 carbons, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, n-nonyl and n-decyl. Straight alkyl groups having 1 to 3 carbon atoms are particularly preferred.
[0027] The alkyl moiety of "dialkylaminoalkyl", "alkoxy", "alkoxycarbonyl", "haloalkyl", "hydroxyalkyl", "monoalkylami-no", "dialkylamino", "monoalkylcarbamoyl", "dialkylcarbamoyl", "alkoxyalkyl" and "hydroxyalkyl" includes the above-mentioned alkyl.
[0028] "Halogen" includes fluorine, chlorine, bromine and iodine.
[0029] "Haloalkyl" includes monohaloalkyl, dihaloalkyl and trihaloalkyl, and the halogen moiety of "haloalkyl" includes the above-mentioned halogen. "Haloalkyl" includes fluoromethyl, 2-fluoroethyl, difluoromethyl, trifluoromethyl and 2,2,2-trifluoroethyl.
[0030] "Acyl" includes acyl groups having 1 to 11 carbons, for example, formyl, acetyl, propionyl, butyryl, isobutyryl, benzoyl, 1-naphthoyl and 2-naphthoyl.
[0031] "Pyridyl" includes 2-pyridyl, 3-pyridyl and 4-pyridyl.
[0032] "Pyrimidinyl" includes 2-pyrimidinyl, 4-pyrimidinyl and 5-pyrimidinyl.
[0033] "Pyrazinyl" includes 2-pyrazinyl.
[0034] "Pyridazinyl" includes 3-pyridazinyl and 4-pyridazinyl.
[0035] "1,2-dihydropyridazinyl" includes 1,2-dihydropyridazin-3-yl and 1,2-dihydropyridazin-4-yl.
[0036] The "saturated, cyclic amino group" includes a 4- to 8-membered saturated ring group which is a saturated, cyclic amino group having at least one nitrogen atom as an atom composing the ring and also may have 1 to 3 same or different members selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom. When the atom composing the ring is a nitrogen atom or a sulfur atom, the nitrogen atom or the sulfur atom may form an oxide. Examples thereof include 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 1-azetidinyl, 4-morpholinyl, 4-thiomorpholinyl, hex-ahydro-1H-1,4-diazepin-1-yl.
Best Mode for Carrying Out the Invention [0037] The compound of the present invention can be produced from per se known compound or an intermediate which can be produced with ease, for example, by the following method. In the production of the compound of the present invention, it is common that the raw materials are used for reaction after being,protected with proper protecting groups by the per se known methods, when the raw materials have substituents that affect the reaction. After the reaction, the protecting groups can be removed by per se known methods.
Process 1 [0038] [Chemical 5]
[wherein R1, R2, R3, Het1 and Het2 are as defined above.] [0039] This reaction is a condensation reaction of a compound [11] and a compound [12] and is therefore conducted by per se known methods used in the condensation reactions. A compound [1] can be produced by reacting a carboxylic acid as a compound [12], or a reactive derivative thereof with an amine as a compound [11]. Examples of the reactive derivatives of the compound [12] include those which are usually used in the amide condensation formation reaction, for example, acid halide (e.g., acid chloride, acid bromide, etc.), mixed acid anhydride, imidazolide and active amide. When using the carboxylic acid [12], a condensing agent (e.g., 1 ,T-oxalyldiimidazole, 1-ethyl-3-(3-dimethylaminopro-pyl)carbodiimide, dicyclohexylcarbodiimide, diethyl cyanophosphonate, diphenylphosphoryl azide, 2-chloro-1-methyl-pyridinium iodide, 1 H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate, and benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate) is used and the reaction is conducted at -20°C to 100°C in the presence or absence of a base (e.g., organic base such as triethylamine, N,N-diisopropyl-N-ethylamine, N,N-dimethy-laniline, pyridine, 4-(dimethylamino)pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.). The solvent is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran and diethyl ether; amides such as Ν,Ν-dimethylformamide and Ν,Ν-dimethylacetamide; nitriles such as acetonitrile and propionitrile; hydrocarbons such as benzene and toluene; halogenated hydrocarbons such as chloroform and dichloromethane; and solvent mixtures thereof. In that case, additives (e.g., 1-hydroxybenzotriazole, N-hydroxysuccinimide, etc.) can also be added. The reaction time varies depending on the kinds of the raw material and the condensing agent and the reaction temperature, but usually it is preferably from 30 minutes to 24 hours. The amount of the compound [12] and the condensing agent is preferably 1 to 3 mol per mol of the compound [11], When using an acid halide as the reactive derivative of the compound [12], the reaction is conducted at -20°C to 100°C using a pyridine solvent such as pyridine or 4-methylpyridine or the same base and solvent as those described above. Also 4-(dimethylamino)pyridine can be added as an additive. The reaction time varies depending on the kind of the acid halide and the reaction temperature, but usually it is preferably from 30 minutes to 24 hours.
Preparation process of raw compound [11] for use in process 1 [0040] The compound [11] as the raw compound wherein Het1 is a group of the formula [6] can be prepared, for example, by the same manner as described in Patent Document 1.
[0041] The compound [11] as the raw compound wherein Het1 is a group of the formula [4], [5], [7] or [9] can be prepared by the following manner: [Chemical 6]
[wherein Het1 and Het2 are as defined above; R4 and R5 may be the same or different from each other, and represent alkyl or hydroxy; R6, R7 and R8 represent alkyl; and X1 represents halogen.]
Step 1 [0042] This reaction is a cross-coupling reaction using a compound [13] and an organoboron compound [14] or an organotin compound [15] and can be conducted by perse known methods. For example, this reaction is conducted at 20°C to 200°C in a suitable solvent in the presence of a palladium catalyst. As the palladium catalyst, tetrakis(triphenyl-phosphine)palladium, dichlorobis(triphenylphosphine)palladium and dichlorobis(tri-o-tolylphosphine)palladium are usually used. The reaction solvent is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane; alcohols such as methanol and ethanol; amides such as Ν,Ν-dimethylformamide and Ν,Ν-dimethylacetamide; hydrocarbons such as benzene, toluene and xylene; organic amines such as pyridine and triethylamine; and solvent mixtures thereof. When using the compound [14], the addition of a base (e.g., sodium hydroxide, potassium carbonate, tripotassium phosphate, etc.) is essential. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 1 hour to 48 hours.
Step 2 [0043] This reaction is a reaction of reducing an aromatic nitro group of a compound [16] into an amino group and is therefore conducted by per se known methods used in the reducing reaction. The method includes, for example, a method of treating with zinc or tin under the acidic conditions. According to the catalytic reduction method, for example, hydrogenation can be conducted using platinum, Raney nickel, platinum-carbon (Pt-C), palladium-carbon (Pd-C) or ruthenium complex as the catalyst. In addition, a method of using a sulfide such as sodium dithionite and a method of reducing with ammonium formate or hydrazine in the presence of a metal catalyst are exemplified.
[0044] The compound [13] as the raw compound wherein Het1 is a group of the formula [4] can be prepared, for example, by reacting 2,4-dichloropyridine (prepared, for example, by version of the method described in Non-Patent Document 12) with 2-methyl-5-nitroaniline according to the method of J. P. Wolfe et al. using a palladium catalyst (see Non-Patent Documents 10 and 11). When Het1 is a group of the formula [5], the compound can be prepared, for example, by reacting 1-bromo-3-iodobenzene with 2-methyl-5-nitroaniline. When Het1 is a group of the formula [7], the compound can be prepared, for example, by reacting 2,6-dichloropyrazine with 2-methyl-5-nitroaniline. When Het1 is a group of the formula [9], the compound can be prepared, for example, by reacting 4,6-dichloropirimidine with 2-methyl-5-ni-troaniline. The reaction solvent is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene and xylene; and solvent mixtures thereof. The reaction is conducted at 70°C to 100°C in the presence of a base. Examples of the palladium catalyst include tris(dibenzylideneacetone) dipalladium (0), palladium (II) acetate and tri(o-tolylphos-phine) palladium (0). Usually, the amount of palladium is preferably from 0.5 mol% to 4 mol% based on the halogenated aryl. As a ligand of the palladium catalyst, for example, 1,3-bis(diphenylphosphino)propane, 1,1’-bis(diphenylphosphi-no)ferrocene and (±)-2,2’-bis(diphenylphosphino)-1,1 ’-binaphthyl [(±)-BINAP] can be used. Examples of the base include sodium t-butoxide, potassium t-butoxide, cesium carbonate, potassium carbonate and sodium carbonate. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 1 hour to 36 hours.
[0045] The compound [13] can also be prepared by reacting 2,4-dichloropyridine, for example, when Het1 is a group of the formula [4], or by reacting 4,6-dichloropyrimidine, for example, when Het1 is a group of the formula [9], with 2- methyl-5-nitroaniline at 20°C to 200°C in a suitable solvent or in the absence of a solvent in the presence or absence of a base. Examples of the base include pyridine, triethylamine, N,N-diisopropyl-N-ethylamine, potassium carbonate, sodium hydrogen carbonate and potassium hydroxide. The solvent to be used is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran, dibutyl ether and 1,4-dioxane; amides such as Ν,Ν-dimethylformamide and Ν,Ν-dimethylacetamide; hydrocarbons such as benzene and toluene; alcohols such as ethylene glycol and 2-methoxyethanol; halogenated hydrocarbons such as chloroform and dichlo-romethane; dimethyl sulfoxide; and solvent mixtures thereof. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 1 hour to 24 hours.
[0046] The compound [16a] as the raw compound (compound [16] wherein Het1 is a group of the formula [4]) can also be prepared, for example, by the following manner: [Chemical 7]
[wherein R4, R5, R6, R7, R8 and Het2 are as defined above, and X2 and X3 represent halogen.]
Step 1 [0047] This reaction is a cross-coupling reaction using a compound [17] and an organoboron compound [14] or an organotin compound [15] and can be conducted by the same manner as described above.
Step 2 [0048] A compound [19] is prepared by halogenating a compound [18]. The reaction is therefore conducted by perse known methods. The reaction is usually conducted using phosphorus oxychloride, phosphorus oxybromide, phosphorus pentachoride or phosphorus pentabromide with or without solvent. The reaction solvent is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran, dibutyl ether and 1,4-dioxane; amides such as Ν,Ν-dimethylformamide and Ν,Ν-dimethylacetamide; halogenated hydrocarbons such as chloroform and dichloromethane; and solvent mixtures thereof. The reaction is usually conducted at room temperature to 130°C and usually the reaction time is preferably from 20 minutes to 24 hours.
Step 3 [0049] A compound [16a] can be prepared by reacting the compound [19] with a compound [20] according to the above method using a palladium catalyst (see, for example, Non-Patent Documents 10 and 11).
[0050] A compound [11a] (compound [11] wherein Het1 is a group of the formula [4]) can be prepared by reacting the compound [19] with a compound [21] according to the above method using a palladium catalyst (see, for example, Non-Patent Documents 10 and 11) to give a compound [22] and deprotecting the compound [22].
[Chemical 8]
[wherein Het2 and X3 are as defined above, and R9 represents a protecting group]
Step 1 [0051] The raw compound [21] can be prepared by protecting 2,4-diaminotoluene with a suitable protecting group by perse known methods. Examples of the protecting group include acyl derivatives such as benzoyl, acetyl and formyl; and urethane type derivatives such as benzyloxycarbonyl, t-butoxycarbonyl and 2,2,2-trichloroethoxycarbonyl. A compound [22] can be prepared by reacting the compound [19] with the compound [21] using the above palladium catalyst.
Step 2 [0052] In the deprotection reaction of the compound [22], an acyl type protecting group is removed by hydrolysis using acid or alkali, or removed with ammonia water or hydrazine. Examples of the acid used in the hydrolysis include inorganic acids such as hydrochloric acid and sulfuric acid, and examples of the base include inorganic bases such as sodium hydroxide and potassium hydroxide. The reaction solvent is not specifically limited as far as it is not involved in the reaction and examples thereof include alcohols such as methanol and ethanol; ethers such as tetrahydrofuran and 1,4-dioxane; water; and solvent mixtures thereof. The reaction temperature is from 0°C to 100°C and the reaction time is usually from several minutes to 24 hours. When the protecting group is a urethane type derivative, the protecting group can be removed by hydrogenation using a palladium catalyst, or removed with hydrochloric acid, trifluoroacetic acid, trimethylsilyl iodide or boron trifluoride, although depending on the kind of the protecting group.
[0053] The compound [11b] as the raw compound [11], wherein Het1 is a group of the formula [10], can be prepared by conducting the same method as in, for example, Non-Patent Document 13 to prepare the compound [16b] and then reducing the aromatic nitro group into the amino group as described hereinafter.
[Chemical 9]
[wherein Het2 is as defined above.]
Preparation process of raw compound [12] for use in process 1 [0054] The compound [12a] as the raw compound [12] can be prepared, for example, by the following manner: [Chemical 10]
[wherein R2, R3 and R12 are as defined above, and X4 represents halogen.]
Step 1 [0055] A compound [25] can be prepared through an ether linkage formation between a halogenated aryl [23] and an alcohol [24]. This reaction is a nucleophilic substitution reaction of the compound [23] and alcohols and is conducted by per se known methods. This reaction is conducted in a suitable solvent in the presence of a base. Examples of the preferably used base include any basic material which is usually used (e.g., pyridine, triethylamine), alkoxides of alkali metals (e.g., potassium t-butoxide), metal hydride (e.g., sodium hydride), and inorganic bases (e.g., potassium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium hydroxide). The solvent to be used is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran and 1,4-dioxane; amides such as Ν,Ν-dimethylformamide and Ν,Ν-dimethylacetamide; nitriles such as acetonitrile and propionitrile; hydrocarbons such as benzene and toluene; dimethylsulfoxide; water; and solvent mixtures thereof. The reaction temperature is usually from -78°C to 200°C. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 30 minutes to 24 hours. In addition, in such the substitution reaction, copper powder, copper (I) halide or copper alkoxide is used as a catalyst. As an alternative method, a method of using a palladium catalyst of A. Aranyos, et al. or G. Mann, et al. (see, for example, Non-Patent Documents 14 and 15) can be used to prepare the compound [25] from the halogenated aryl [23] and the alcohol [24],
Step 2 [0056] A compound [12a] can be prepared by hydrolyzing the compound [25], The reaction is usually conducted in a suitable solvent in the presence of an acid ora base. Examples of the acid used in the hydrolysis include inorganic acids such as hydrochloric acid and sulfuric acid, and organic acids such as acetic acid and formic acid, and examples of the base include inorganic bases such as sodium hydroxide and potassium hydroxide. Examples of the reaction solvent include alcohols such as methanol, ethanol and ethylene glycol; ethers such as tetrahydrofuran and 1,4-dioxane; water; and solvent mixtures thereof. The reaction temperature is from 0°C to 200°C and usually the reaction time is preferably from 30 minutes to 24 hours.
[0057] The compound [12b] as the raw compound [12] can be prepared, for example, by the following manner: [Chemical 11]
[wherein R2, R3 and R13 are as defined above; R10 represents alkyl; and Q represents dialkoxyphosphoryl halide salt or dialkoxy phosphoryl.]
Step 1 [0058] This reaction is a Wittig reaction or Horner-Emmons reaction of an organophosphorus compound [26] and a compound [27], and is therefore conducted by per se known methods such as the Wittig reaction or Horner-Emmons reaction. The reaction is conducted in a suitable solvent in the presence of a base at -78°C to 150°C. Examples of the base to be used include n-butyllithium, sodium hydride, sodium ethoxide, potassium t-butoxide and lithium diisopropy-lamide. The solvent to be used is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran and 1,2-dimethoxyethane, amides such as Ν,Ν-dimethylformamide and N,N-dimethylacetamide; alcohols such as methanol and ethanol; hydrocarbons such as n-hexane, benzene and toluene; halogenated hydrocarbons such as chloroform and dichloromethane; dimethylsulfoxide; and solvent mixtures thereof. The reaction time varies depending on the kinds of the raw material and the condensing agent and the reaction temperature, but usually it is preferably from 30 minutes to 24 hours.
[0059] The compound [26] as the raw material is an alkyl(triaryl)phosphonium halide salt or alkyl(dialkoxy)phosphoryl, each of which can be prepared by version of the method described in Non-Patent Documents 16 and 17.
Step 2 [0060] A compound [12b] can be prepared by hydrolyzing the compound [28]. The reaction is usually conducted in a suitable solvent in the presence of an acid ora base. Examples of the acid used in the hydrolysis include inorganic acids such as hydrochloric acid and sulfuric acid, and examples of the base include inorganic bases such as sodium hydroxide and potassium hydroxide. Examples of the reaction solvent include alcohols such as methanol and ethanol; ethers such as tetrahydrofuran and 1,4-dioxane; water; and solvent mixtures thereof. The reaction temperature is from 0°C to 100°C and usually the reaction time is preferably from 30 minutes to 24 hours.
[0061] The compound [12c] as the raw compound [12] can be prepared, for example, by the following manner: [Chemical 12]
[wherein R2, R3, R10, R11, R14 and Q are as defined above.]
Step 1 [0062] This reaction is a Wittig reaction or Horner-Emmons reaction of an organophosphorus compound [26] and a compound [29] or a compound [30], and can be conducted by version of a general method for synthesizing [28] from the above described [26],
Step 2 [0063] A compound [12c] can be prepared by hydrolyzing the compound [31] to prepare a compound [32], and then reducing the compound [32]. Alternatively, the compound [12c] can be prepared by reducing the compound [31] to prepare a compound [33], and then hydrolyzing the compound [33], The hydrolysis reaction can be conducted by version of a general method for synthesizing [12b] from the above described [28], The reduction reaction can be conducted by perse known methods.
[0064] Further, in the case where R11 or R14 is a saturated, cyclic amino group, it can be prepared, for example, by the following method: [Chemical 13]
[wherein R2, R3 and R10 are as defined above; R15 represents a saturated, cyclic amino group; X5 represents a leaving group such as Cl, Br, I, p-toluene sulfonyloxy and methane sulfonyloxy.]
Step 1 [0065] A compound [36] can be prepared by condensing a compound [34] (which can be prepared, for example, by version of the method described in Non-Patent Document 18) with a saturated, cyclic amine [35] (wherein the leaving group X5 represents a leaving group such as halogen, p-toluene sulfonyloxy and methane sulfonyloxy). This reaction is a nucleophilic substitution reaction of the compound [34] and amines and is conducted by per se known methods. This reaction is conducted in a suitable solvent using an excess amine or in the presence of a base. Examples of preferable base include pyridine, triethylamine, N,N-diisopropyl-N-ethylamine, potassium carbonate and sodium hydrogen carbonate. The solvent to be used is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran and diethyl ether; amides such as Ν,Ν-dimethylformamide and N,N-dimethyla-cetamide; nitriles such as acetonitrile and propionitrile; hydrocarbons such as benzene and toluene; alcohols such as methanol and ethanol; water; and solvent mixtures thereof. The reaction temperature is usually from 0°C to 100°C. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 30 minutes to 24 hours.
Step 2 [0066] A compound [12d] can be prepared by hydrolyzing the compound [36].
[0067] This reaction is a hydrolysis reaction of esters, and can be conducted by version of a general method for synthesizing [12b] from the above described [28],
Process 2 [0068] [Chemical 14]
[wherein R1, R2, R3, Het1 and Het2 are as defined above; X6 represents Cl, Br, I or SR16 (wherein R16 represents alkyl).] [0069] A compound [1] can be prepared by reacting a compound [37] with a compound [38]. The reaction is conducted at 20°C to 200°C in the absence of a solvent or a suitable solvent in the presence or absence of a base. Examples of the base include pyridine, triethylamine, N,N-diisopropyl-N-ethylamine, potassium carbonate, sodium hydrogen carbonate and potassium hydroxide. The solvent is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran, dibutyl ether and 1,4-dioxane; amides such as N,N-dimethylformamide and Ν,Ν-dimethylacetamide; hydrocarbons such as benzene and toluene; alcohols such as ethylene glycol and 2-methoxyethanol; halogenated hydrocarbons such as chloroform and dichloromethane; dimethyl sulfoxide; and solvent mixtures thereof. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 1 hour to 24 hours.
[0070] Further, the compound [1] can be prepared by reacting the compound [37] with the compound [38] using a method using the palladium catalyst as described in the process 1 (see, for example, Non-Patent Documents 10 and 11).
[0071] The compound [37] as the raw compound can be prepared, for example, by condensing 2,4-diaminotoluene with carboxylic acid as the compound [12] or a reactive derivative thereof by version of the process 1.
[0072] The compound [38] as the raw compound can be prepared by using 2,6-dibromopyridine, for example, when Het1 is a group of the formula [2]; 3,5-dibromopyridine, for example, when Het1 is a group of the formula [3]; 2,4-dibromopyridine, for example, when Het1 is a group of the formula [4]; 1,3-dibromobenzene, for example, when Het1 is a group of the formula [5]; 2,4-dichloropyrimidine, for example, when Het1 is a group of the formula [6]; and 2,6-dichlo-ropyrazine, for example, when Het1 is a group of the formula [7] in accordance with the process 4 described hereinafter. When Het1 is a group of the formula [4], the compound [38] can also be prepared by the method described in the above-mentioned process 1.
Process 3 [0073] [Chemical 15]
[wherein R1, R2, R3 and Het2 are as defined above.] [0074] A compound [1a] (compound [1] wherein Het1 is a group of the formula [6]) can be prepared by reacting a compound [39] or its acid addition salt with a compound [40], The reaction is conducted at 20°C to 200°C in a suitable solvent. The solvent to be used is not specifically limited as far as it is not involved in the reaction and examples thereof include alcohols such as methanol, ethanol, 2-propanol and 2-methoxyethanol. The amount of the compound [40] to be used is from 1- to 2-fold mol, and preferably from 1- to 1.2-fold mol, per mol of the compound [39]. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 30 minutes to 30 hours. When using the acid addition salt of the compound [39], the reaction can be conducted by adding a suitable base (e.g., potassium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium hydroxide, etc.).
[0075] The compound [39] as the raw compound can be prepared in the form of a free salt or an acid addition salt by reacting the compound [37] with cyanamide by the method described in the document (see, for example, Non-Patent Document 19).
[0076] The compound [40] as the raw compound can be prepared, for example, by version of the method described in Patent Document 1.
Process 4 [0077] [Chemical 16]
[wherein R1, R2, R3, R4, R5, R6, R7, R8, Het1 and Het2 are as defined above; and X7 represents halogen.] [0078] This reaction is a cross-coupling reaction using a compound [41] and an organoboron compound [14] or an organotin compound [15] and can be conducted by perse known methods. For example, this reaction is conducted at 20°C to 200°C in a suitable solvent in the presence of a palladium catalyst. As the palladium catalyst, tetrakis(triphenyl-phosphine)palladium, dichlorobis(triphenylphosphine)palladium and dichlorobis(tri-o-tolylphosphine)palladium are usually used. The reaction solvent is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane; alcohols such as methanol and ethanol; amides such as Ν,Ν-dimethylformamide and Ν,Ν-dimethylacetamide; hydrocarbons such as benzene, toluene and xylene; organic amines such as pyridine and triethylamine; and solvent mixtures thereof. When using the compound [14], the addition of a base (e.g., sodium hydroxide, potassium carbonate, tripotassium phosphate, etc.) is essential. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 1 hour to 48 hours.
[0079] The compound [41] as the raw compound can be prepared, for example, by reacting a compound [37] with 4-hydroxy-2-(methylthio)pyridine when Het1 is a group of the formula [4], or reacting a compound [37] with 4-hydroxy- 2-(methylthio)pyrimidine and treating the reaction product with phosphorus oxychloride (see, for example, Non-Patent Document 20) when Het1 is a group of the formula [6], or reacting by the method described in the document (see, for example, Non-Patent Document 21) using a compound [37] and 2,4-dichloropyrimidine when Het1 is a group of the formula [6],
Process 5 [0080] [Chemical 17]
[wherein R2, R3 and R15, Het1 and Het2 are as defined above; and X8 represents halogen.]
Step 1 [0081] This reaction is conducted by condensing a compound [11] and acid chloride [42] according to the method described in the process 1.
Step 2 [0082] A compound [1 b] (the compound [1] wherein R1 is -CH2-R15) can be prepared by condensing a compound [43] with an amine [35], This reaction is a condensation reaction of acid chloride and amines and is conducted by per se known methods. This reaction is conducted in a suitable solvent using an excess amine or in the presence of a base. Examples of preferable base include pyridine, triethylamine, N,N-diisopropyl-N-ethylamine, potassium carbonate and sodium hydrogen carbonate. The solvent is not specifically limited as far as it is not involved in the reaction and examples thereof include ethers such as tetrahydrofuran, diethyl ether and 1,3-dioxane; amides such as Ν,Ν-dimethylformamide and Ν,Ν-dimethylacetamide; nitriles such as acetonitrile and propionitrile; hydrocarbons such as benzene and toluene; alcohols such as methanol and ethanol; water; and solvent mixtures thereof. The reaction temperature is usually from 0°C to 100°C. The reaction time varies depending on the kind of the raw material and the reaction temperature, but usually it is preferably from 30 minutes to 24 hours.
Process 6 [0083] [Chemical 18]
[wherein R1, R2, R3 and Het2 are as defined above; and X9 represents halogen.] [0084] A compound [1c] (compound [1] wherein Het1 is a group of the formula [10]) can be prepared by reacting a compound [44] and a compound [45] or its acid addition salt to form a ring. This reaction can be conducted by perse known methods as a method for synthesizing a 2-aminothiazole derivative (see, for example, Non-Patent Document 13).
[0085] The amide derivative according to the present invention can be used in the form of a free base as a medicine, however, it can be also used as a pharmaceutically acceptable salt made by the per se known methods. These salts include salts of mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, and salts of organic acids such as acetic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluene sulfonic acid, benzene sulfonic acid and methane sulfonic acid.
[0086] The hydrochloride of the amide derivative according to the present invention, for example, can be obtained by dissolving the amide derivative according to the present invention in an alcohol solution, an ethyl acetate solution or an ether solution of the hydrogen chloride.
[0087] As shown in test examples described hereinafter, the compound of the present invention has high inhibitory activity of BCR-ABL tyrosine kinase as compared with a pyrimidine derivative disclosed specifically in Patent Document 1. Therefore, the compound of the present invention is useful as a preventive or therapeutic agent for diseases involved in BCR-ABL tyrosine kinase, for example, chronic myelogenous leukemia, acute lymphoblastic leukemia and acute myelogenous leukemia.
[0088] When the compound of the present invention is administered as a medicine, it can be administered to mammals, including humans, either by itself or as a pharmaceutical composition in which the compound is contained in a pharmaceutically acceptable non-toxic and inert carrier in the proportion of, for example, 0.1% to 99.5%, or preferably 0.5% to 90%.
[0089] One or more auxiliary agents for formulation such as fillers or a solid, semisolid or liquid diluent are used. It is desirable to administer the pharmaceutical composition in unit dosage form. The pharmaceutical composition of the present invention can be administered intravenously, orally, directly to the target tissue, topically (e.g., transdermally) or rectally. It is a matter of course that a dosage form suitable for any of the administration modes described above is employed. It is desirable to administer orally.
[0090] It is desirable to set the dosage of the compound as a BCR-ABL tyrosine kinase inhibitor or a therapeutic agent for chronic myelogenous leukemia by considering the condition of the patient, such as age, body weight, and the characteristics and severity of the disease and other factors such as the administration route; but usually for adults, an amount in the range of 0.1 mg/person to 1000 mg/person per day, and preferably 1 mg/person to 500 mg/person per day, is generally a dose of the compound of the present invention.
[0091] In some cases, amounts below this range are sufficient, and conversely, in other cases larger amounts are required. It can be administered by dividing the total dosage into two or three doses per day.
Examples [0092] The present invention will now described in more detail by way of Reference Examples, Examples, Test Examples and Formulation Examples of the compound of the present invention.
Reference Example 1 3-ethyl-4-(4-methylpiperazin-1-vlmethyl)benzoyl chloride hydrochloride Step 1 ethyl 3-iodo-4-methylbenzoate [0093] 40.61 g of 3-iodo-4-methylbenzoic acid was suspended in 406 ml of ethanol and 9.1 ml of concentrated sulfuric acid was added, and then the mixture was heated at reflux for 24 hours. After the solvent was distilled off under reduced pressure, the residue was mixed with iced water, made basic with an aqueous saturated sodium hydrogen carbonate solution, followed by extraction with ethyl acetate twice. The extracts were washed in turn with water and saturated saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 44.44 g of a crude product as a brown oily product.
Step 2 ethyl 4-(bromomethyl)-3-iodobenzoate [0094] 44.4 g of ethyl 3-iodo-4-methylbenzoate obtained in the step 1 was dissolved in 550 ml of carbon tetrachloride and 25.3 g of N-bromosuccinimide and 355 mg of benzoyl peroxide were added thereto, and then the reaction solution was heated at reflux under exposure to light from an incandescent lamp (1500 W) for 8 hours. Insolubles were removed by filtration, and then the solvent in the filtrate was distilled off under reduced pressure to obtain 56.99 g of a crude product as reddish violet crystals.
Step 3 ethyl 3-iodo-4-(4-methylpiperazin-1-ylmethyl)benzoate [0095] 57.0 g of ethyl 4-(bromomethyl)-3-iodobenzoate obtained in the step 2 was dissolved in 570 ml of anhydrous tetrahydrofuran and, after adding 22.8 g of potassium carbonate, 12.1 g of N-methylpiperazine in 70 ml of tetrahydrofuran solution was added dropwise over 20 minutes while stirring at room temperature. After stirring at room temperature for 4 hours, insolubles were removed by filtration and the solvent in the filtrate was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 32.9 g of the objective compound as a yellow oily product.
Step 4 ethyl 4-(4-methylpiperazin-1-ylmethyl)-3-(trimethylsilanylethynyl)benzoate [0096] To 3.77 g of ethyl 3-iodo-4-(4-methylpiperazin-1-ylmethyl)benzoate obtained in the step 3, 34 mg of bis(triphe-nylphosphine)palladium(ll) dichloride, 19 mg of copper iodide, 1.65 ml of trimethylsilylacetylene and 38 ml of triethylamine were added in turn and the reaction solution was heated at reflux at 80°C for 2 hours under an argon atmosphere. The reaction solution was air-cooled, insolubles were removed by filtration, the insolubles were washed with ethyl acetate, and then the solvent in the filtrate was distilled off under reduced pressure. Ethyl acetate was added to the residue and the mixture was washed in turn with 5% aqueous ammonia, water and saturated saline, and then the organic layer was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 2.60 g of the objective compound as a yellow oily product.
Step 5 ethyl 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)benzoate [0097] 2.60 g of ethyl 4-(4-methylpiperazin-1-ylmethyl)-3-(trimethylsilanylethynyl)benzoate obtained in the step 4 was dissolved in 13 ml of methanol and 3.0 g of potassium carbonate was added thereto, and then the mixture was stirred at room temperature for one minute. After the solvent was distilled off under reduced pressure, ethyl acetate and water were added to the reaction mixture and the aqueous layer was separated. The organic layer was washed twice with water and with saturated saline, and then dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was dissolved in 26 ml of ethanol and 260 mg of 10% palladium-carbon was added, and then the mixture was hydrogenated at room temperature under 4 atm for 15 hours. The catalyst was removed by filtration and the solvent in the filtrate was distilled off under reduced pressure to obtain 1.83 g of a crude product as a yellow oily product.
Step 6 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)benzoic acid [0098] 1.83 g of ethyl 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)benzoate obtained in the step 5 was dissolved in 20 ml of ethanol and 10 ml of a 1N aqueous sodium hydroxide solution was added thereto, and then the mixture was heated at reflux for 2 hours. The reaction solution was neutralized by adding 10 ml of 1N hydrochloric acid under ice cooling. After water was distilled off under reduced pressure, water was azeotropically removed by adding toluene to the residue to obtain 2.16 g of a crude product as a yellow crystal.
Step 7 3- ethyl-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride hydrochloride [0099] 2.16 g of 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)benzoic acid obtained in the step 6 was dissolved in 8.3 ml of thionyl chloride and the mixture was heated at reflux for 16 hours. After the reaction solution was air-cooled, diethyl ether was added to the reaction solution and the deposited crystal was collected by filtration, and then washed with diethyl ether to obtain a crude product.
Reference Example 2 4- (4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride Step 1 ethyl 4-methyl-3-trifluoromethylbenzoate [0100] This compound was prepared in the same manner as in Reference Example 1 (step 1), except that 4-methyl- 3- trifluoromethylbenzoic acid was used.
Pale yellow oily product
Step 2 ethyl 4-(bromomethyl)-3-trifluoromethylbenzoate [0101] This compound was prepared in the same manner as in Reference Example 1 (step 2), except that ethyl 4-methyl-3-trifluoromethylbenzoate obtained in the step 1 was used. Pale yellow oily product
Step 3 ethyl 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoate [0102] This compound was prepared in the same manner as in Reference Example 1 (step 3), except that ethyl 4- (bromomethyl)-3-trifluoromethylbenzoate obtained in the step 2 was used.
Yellowish brown oily product
Step 4 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoic acid dihydrochloride [0103] This compound was prepared in the same manner as in Reference Example 1 (step 6), except that ethyl 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoate obtained in the step 3 was used, and that the reaction solution was acidified (pH 3) with concentrated hydrochloric acid in place of 1N hydrochloric acid.
Pale brown crystals
Melting point: 233-238°C (with decomposition)
Step 5 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride [0104] This compound was prepared in the same manner as in Reference Example 1 (step 7), except that 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoic acid dihydrochloride obtained in the step 4 was used, and that the reaction was heated at reflux for 24 hours.
Colorless crystals
Reference Example 3 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride dihydrochloride [0105] This compound was prepared in the same manner as in Reference Example 2 (steps 2 to 5), except that methyl 3-methoxy-4-methylbenzoate was used in the step 2.
Colorless crystals
Reference Example 4 3- chloro-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride dihydrochloride [0106] This compound was prepared in the same manner as in Reference Example 2, except that 3-chloro-4-meth-ylbenzoic acid was used in the step 1.
Colorless crystals
Reference Example 5 4- (4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride [0107] This compound was prepared in the same manner as in Reference Example 2, except that N-ethylpiperazine was used in the step 2.
Colorless crystals
Reference Example 6 3,5-dichloro-4-[(S)-3-(dimethvlamino)pyrrolidin-1-ylmethyl1benzoyl chloride hydrochloride Step 1 methyl 3,5-dichloro-4-methylbenzoate [0108] This compound was prepared in the same manner as in Reference Example 1 (step 1), except that 3,5-dichloro-4-methylbenzoic acid (Japanese Unexamined Patent Publication (Kokai) No. 6-192196) was used and methanol was used as the solvent, and that the crude product was purified by silica gel column chromatography.
Pale yellow crystals Melting point: 49-50°C
Step 2 methyl 4-(bromomethyl)-3,5-dichlorobenzoate [0109] This compound was prepared in the same manner as in Reference Example 1 (step 2), except that methyl 3,5-dichloro-4-methylbenzoate obtained in the step 1 was used, and that the reaction was heated at reflux for 2 hours. Orange crystals
Melting point: 63-65°C.
Step 3 methyl 3,5-dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl1benzoate [0110] This compound was prepared in the same manner as in Reference Example 1 (step 3), except that methyl 4-(bromomethyl)-3,5-dichlorobenzoate obtained in the step 2 and (S)-(-)-3-(dimethylamino)pyrrolidine were used, and that the reaction was conducted at room temperature for 17 hours.
Pale yellow oily product
Step 4 3.5- dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]benzoic acid [0111] This compound was prepared in the same manner as in Reference Example 1 (step 6), except that methyl 3,5-dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]benzoate obtained in the step 3 was used and methanol was used as the solvent, and that after methanol was added to the residue and the resulting mixture was stirred, insolubles were removed by filtration and the solvent in the filtrate was distilled off under reduced pressure to obtain the objective compound.
Pale orange amorphous Step 5 3.5- dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl1benzoyl chloride hydrochloride [0112] This compound was prepared in the same manner as in Reference Example 1 (step 7), except that 3,5-dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-l-ylmethyl]benzoic acid obtained in the step 4 was used, and that treatment after the reaction was that thionyl chloride was distilled off under reduced pressure, and then the operation of adding of toluene to the residue, followed by azeotropic removal of thionyl chloride was repeated twice.
Pale yellow crystals
Melting point: 210-219°C (with decomposition)
Reference Example 7 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethylbenzoyl chloride hydrochloride Step 1 ethyl 4-(dimethoxyphosphorylmethyl)-3-trifluoromethylbenzoate [0113] 6.20 g of ethyl 4-(bromomethyl)-3-trifluoromethylbenzoate (Reference Example 2 (step 2)) was dissolved in 12 ml of trimethyl phosphite and the mixture was heated at reflux for 4 hours under an argon atmosphere. After the completion of the reaction, the operation of adding of toluene to the residue, followed by azeotropic removal of trimethyl phosphite was repeated three times. The residue was purified by silica gel column chromatography to obtain 4.96 g of the objective compound as a yellow oily product.
Step 2 ethyl 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethylbenzoate [0114] Under an argon atmosphere, 624 mg of 60% sodium hydride was washed twice with n-hexane, a solution of 4.96 g of ethyl 4-(dimethoxyphosphorylmethyl)-3-trifluoromethylbenzoate obtained in the step 1 and 1.60 ml of N-meth-ylpiperidone dissolved in 50 ml of 1,2-dimethoxyethane was added, and then the mixture was gradually heated up to 85°C and heated at reflux for 1 hour. The reaction solution was air-cooled, mixed with ice water, followed by extraction with ethyl acetate twice. The organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 3.21 g of the objective compound as a yellow oily product.
Step 3 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethylbenzoic acid [0115] This compound was prepared in the same manner as in Reference Example 1 (step 6), except that ethyl 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethylbenzoate obtained in the step 2 was used.
Yellow amorphous
Step 4 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethylbenzoyl chloride hydrochloride [0116] This compound was prepared in the same manner as in Reference Example 1 (step 7), except that 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethylbenzoic acid obtained in the step 3 was used, and that treatment after the reaction was that thionyl chloride was distilled off under reduced pressure, and then the operation of adding of toluene to the residue, followed by azeotropic removal of thionyl chloride was repeated three times.
Green-brown amorphous
Reference Example 8 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethylbenzoyl chloride hydrochloride Step 1 ethyl 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethylbenzoate [0117] 1.57 g of ethyl 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethylbenzoate (Reference Example 7 (step 2)) was dissolved in 32 ml of methanol and 78 mg of 10% palladium-carbon was added, and then the mixture was hydrogenated at room temperature under 1 atm for 24 hours. The catalyst was removed by filtration and the solvent in the filtrate was distilled off under reduced pressure. The mixture was again dissolved in 32 ml of methanol and 78 mg of 10% palladium-carbon was added thereto, and then the mixture was hydrogenated at room temperature under 1 atm for 4 hours. Further, 78 mg of palladium-carbon was added and the mixture was hydrogenated at room temperature under 1 atm for 24 hours. 78 mg of palladium-carbon was further added and the mixture was hydrogenated at room temperature under 1 atm for 19 hours. The catalyst was removed by filtration and the solvent in the filtrate was distilled off under reduced pressure to obtain 1.54 g of the objective compound as a green oily product.
Step 2 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethylbenzoic acid [0118] This compound was prepared in the same manner as in Reference Example 1 (step 6), except that ethyl 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethylbenzoate obtained in the step 1 was used, and that the crude product was mixed with methanol and stirred, insolubles were removed by filtration, thefiltrate was distilled off under reduced pressure, and then the residue was crystallized by adding acetonitrile.
Colorless crystals
Melting point: 247-250°C (with decomposition)
Step 3 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethylbenzoyl chloride hydrochloride [0119] This compound was prepared in the same manner as in Reference Example 1 (step 7), except that 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethylbenzoic acid obtained in the step 2 was used, and that treatment after the reaction was that thionyl chloride was distilled off under reduced pressure, and then the operation of adding of toluene to the residue, followed by azeotropic removal of thionyl chloride was repeated twice.
Pale green crystals
Melting point: 157-164°C (with decomposition)
Reference Example 9 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride hydrochloride Step 1 t-butyl 3-iodo-4-methylbenzoate [0120] 26.20 g of 3-iodo-4-methylbenzoic acid was suspended in 500 ml of t-butyl alcohol and 43.65 g of di-t-butyl dicarbonate was added, and then the mixture was stirred at room temperature. To the mixture was added 1.22 g of 4-(dimethylamino)pyridine, the mixture was stirred at room temperature for 10 minutes, and then the mixture was heated at reflux for 4 hours. After the solvent was distilled off under reduced pressure, the residue was mixed with ethyl acetate and further distilled off under reduced pressure. After 10 ml of ethyl acetate and 30 ml of n-hexane were added to the residue and the resulting mixture was stirred. Insolubles were removed by filtration and the solvent in the filtrate was distilled off under reduced pressure. 30 ml of n-hexane was added to the residue and the same operation as described above was performed with the mixture. The residue was purified by silica gel column chromatography to obtain 22.01 g of the objective compound as a colorless oily product.
Step 2 t-butyl 3-formyl-4-m ethyl benzoate [0121] 7.00 g of t-butyl 3-iodo-4-methylbenzoate obtained in the step 1 was dissolved in 200 ml of anhydrous tetrahy-drofuran and the mixture was stirred under cooling in a dry ice/acetone bath under an argon atmosphere. 15.5 ml of n-butyllithium (1.6 M n-hexane solution) was added dropwise at the internal temperature of -66°C or less. After stirring for 5 minutes, 3.4 ml of Ν,Ν-dimethylformamide was added dropwise over 5 minutes and the mixture was stirred for 50 minutes. 100 ml of water was slowly added dropwise thereto. The mixture was heated up to room temperature, followed by extraction with ethyl acetate. The mixture was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 3.76 g of the objective compound as colorless crystals.
Melting point: 53-55°C
Step 3 t-butyl 3-difluoromethyl-4-methylbenzoate [0122] 3.76 g of t-butyl 3-formyl-4-methylbenzoate obtained in the step 2 was dissolved in 17 ml of anhydrous methylene chloride and 2.71 ml of diethylaminosulfur trifluoride (DAST) was added at room temperature, followed by stirring for 7 hours. The reaction solution was mixed with ethyl acetate, washed with aqueous saturated sodium hydrogen carbonate and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 3.10 g of the objective compound as a pale yellow oily product.
Step 4 t-butyl 4-(bromomethyl)-3-difluoromethylbenzoate [0123] This compound was prepared in the same manner as in Reference Example 1 (step 2), except that t-butyl 3-difluoromethyl-4-methylbenzoate obtained in the step 3 was used.
Step 5 t-butyl 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)benzoate [0124] This compound was prepared in the same manner as in Reference Example 1 (step 3), except that t-butyl 4-(bromomethyl)-3-difluoromethylbenzoate obtained in the step 4 was used.
Colorless oily product
Step 6 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)benzoic acid [0125] This compound was prepared in the same manner as in Reference Example 1 (step 6), except that t-butyl 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)benzoate obtained in the step 5 was used, and that the resulting crude product was mixed with methanol, insolubles were removed by filtration, the filtrate was distilled off under reduced pressure, and then the residue was crystallized from acetonitrile.
Colorless crystals
Melting point: 160-167°C (with decomposition)
Step 7 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride hydrochloride [0126] This compound was prepared in the same manner as in Reference Example 1 (step 7), except that 3-difluor-omethyl-4-(4-methylpiperazin-1-ylmethyl)benzoic acid obtained in the step 6 was used.
Colorless crystals
Melting point: 217-222°C (with decomposition)
Reference Example 10 3-fluoromethyl-4-(1-methylpiperazin-4-ylmethyl)benzoyl chloride hydrochloride Step 1 t-butyl 4-(bromomethyl)-3-iodobenzoate [0127] This compound was prepared in the same manner as in Reference Example 1 (step 2), except that t-butyl 3-iodo-4-methylbenzoate (Reference Example 9 (step 1) was used. Purple oily product
Step 2 t-butyl 3-iodo-4-(1-methylpiperidin-4-ylidenemethyl)benzoate [0128] This compound was prepared in the same manner as in Reference Example 7 (steps 1 and 2), except that t-butyl 4-(bromomethyl)-3-iodobenzoate obtained in the step 1 was used.
Pale yellow oily product
Step 3 t-butyl 3-formyl-4-(1-methylpiperidin-4-ylidenemethyl)benzoate [0129] This compound was prepared in the same manner as in Reference Example 9 (step 2), except that t-butyl 3-iodo-4-(1 -methylpiperidin-4-ylidenemethyl)benzoate obtained in the step 2 was used, and that the resulting crude product was not purified.
Step 4 t-butyl 3-hydroxymethyl-4-(1-methylpiperidin-4-ylidenemethyl)benzoate [0130] 4.75 g of t-butyl 3-formyl-4-(1-methylpiperidin-4-ylidenemethyl)benzoate obtained in the step 3 was dissolved in 47.5 ml of anhydrous methanol and the mixture was stirred under ice-water cooling. 689 mg of sodium borohydride was added thereto and the mixture was stirred under cooling for 3.5 hours. The reaction solution was mixed with ice and an aqueous saturated sodium hydrogen carbonate solution, followed by extraction with ethyl acetate three times, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 2.41 g of the objective compound as a yellow amorphous.
Step 5 t-butyl 3-hydroxymethyl-4-(1-methylpiperidin-4-ylmethyl)benzoate [0131] 2.41 g of t-butyl 3-hydroxymethyl-4-(1-methylpiperidin-4-ylidenemethyl)benzoate obtained in the step 4 was dissolved in methanol and 241 mg of 10% palladium-carbon was added, and then the mixture was hydrogenated at room temperature under 4 atm for 2 hours. 241 mg of 10% palladium-carbon was added and the mixture was further hydrogenated at room temperature under 4 atm for 12 hours. The catalyst was removed by filtration and 482 mg of 10% palladium-carbon was added to the filtrate, and then the mixture was again hydrogenated at room temperature under 4 atm for 22 hours. The catalyst was removed by filtration and the solvent was distilled off under reduced pressure to obtain 2.34 g of the objective compound as a pale green amorphous.
Step 6 t-butyl 3-fluoromethyl-4-(1-methylpiperidin-4-ylmethyl)benzoate [0132] 982 mg of DAST was dissolved in 10 ml of anhydrous dichloromethane and the mixture was stirred under cooling in a dry ice/acetone bath under an argon atmosphere. A solution of 1.77 g of t-butyl 3-hydroxymethyl-4-(1-methylpiperidin-4-ylmethyl)benzoate obtained in the step 5 in 18 ml of anhydrous dichloromethane was added dropwise for 3 hours and the reaction solution was stirred for 2 hours. After heating up to room temperature, saturated sodium hydrogen carbonate was added to the reaction solution to separate the aqueous layer. The aqueous layer was subjected to extraction with ethyl acetate twice. The organic layers were combined and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 954 mg of a crude product as a yellow oily product.
Step 7 3-fluoromethyl-4-(1-methylpiperidin-4-ylmethyl)benzoic acid [0133] This compound was prepared in the same manner as in Reference Example 1 (step 6), except that t-butyl 3-fluoromethyl-4-(1-methylpiperidin-4-ylmethyl)benzoate obtained in the step 6 was used, and that water was distilled off, methanol was added to the residue, insolubles were removed by filtration, and then the solvent in the filtrate was distilled off under reduced pressure.
White amorphous
Step 8 3- fluoromethyl-4-(1-methylpiperidin-4-ylmethyl)benzoyl chloride hydrochloride [0134] This compound was prepared in the same manner as in Reference Example 1 (step 7), except that 3-fluor-omethyl-4-(1-methylpiperidin-4-ylmethyl)benzoic acid obtained in the step 7 was used, and that treatment after the reaction was that thionyl chloride was distilled off under reduced pressure, and then the operation of adding of toluene to the residue, followed by azeotropic removal of thionyl chloride was repeated twice.
Orange amorphous
Reference Example 11 4- (1-methylpiperidin-4-yloxy)-3-trifluoromethylbenzoyl chloride hydrochloride Step 1 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethylbenzonitrile [0135] 6.68 g of potassium t-butoxide was suspended in 40 ml of anhydrous tetrahydrofuran and a solution of 6.85 g of 1 -methyl-4-hydroxypiperidine in 20 ml of anhydrous tetrahydrofuran was added dropwise over 35 minutes while stirring under ice-water cooling and further the mixture was stirred for 30 minutes. On the other hand, 7.50 g of 4-fluoro-3-trifluoromethylbenzonitrile was dissolved in 40 ml of anhydrous tetrahydrofuran, the mixture was stirred under cooling in a dry ice/acetone bath, and the solution prepared earlier was added dropwise at the internal temperature of -70°C. After adding dropwise, the reaction solution was stirred overnight while naturally heating up to room temperature. The reaction solution was ice-cooled, an aqueous saturated ammonium chloride solution and water were added thereto, and then the solvent was distilled off under reduced pressure. The residue was subjected to extraction with ethyl acetate twice. The extracts were washed in turn with water and saturated saline and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 7.31 g of the objective compound as colorless crystals.
Melting point: 66-69°C
Step 2 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethylbenzoic acid [0136] 1.0 g of 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethylbenzonitrile obtained in the step 1 was dissolved in 20 ml of ethanol and 17.6 ml of a 1N aqueous sodium hydroxide solution was added thereto, and the mixture was heated at reflux for 24 hours. After the solvent was distilled off under reduced pressure, water was added to the residue. The aqueous layer was washed once with diethyl ether and neutralized with 17.6 ml of 1N hydrochloric acid under ice-water cooling. After water was distilled off under reduced pressure, the operation of adding methanol to the residue, followed by azeotropic removal of water was repeated three times. After the addition of methanol and stirring, insolubles were removed by filtration and the solvent in the filtrate was distilled off under reduced pressure. The resulting crude crystal was washed with acetonitrile to obtain 0.96 g of the objective compound as colorless crystals.
Melting point: 254°C (with decomposition)
Step 3 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethylbenzoyl chloride hydrochloride [0137] 800 mg of 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethylbenzoic acid obtained in the step 2 was suspended in anhydrous toluene and 0.94 ml ofthionyl chloride and 80 μΙ of anhydrous Ν,Ν-dimethylformamide were added in turn, and then the mixture was heated at reflux for 18 hours. After stirring under ice-water cooling, the deposited crystals were collected by filtration and then washed with toluene to obtain 500 mg of the objective compound as colorless crystals. Melting point: 242°C (with decomposition)
Reference Example 12 4-[(R)-3-(dimethylamino)pyrrolidin-1-ylmethyl)-3-trifluoromethylbenzoic acid [0138] This compound was prepared in the same manner as in Reference Example 2 (steps 1 to 4), except that (R)-(+)- 3- (dimethylamino)pyrrolidine was used in the step 3, and that the reaction solution was neutralized (pH 7) with 1N hydrochloric acid in place of concentrated hydrochloric acid in the step 4 and the crude product was purified by silica gel column chromatography.
Colorless crystals
Melting point: 206-209°C (with decomposition)
Reference Example 13 4- [4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethylbenzoic acid [0139] This compound was prepared in the same manner as in Reference Example 2 (steps 1 to 4), using N-(t-butoxycarbonyl)piperazine in the step 3. However, in the step 4, the reaction was conducted at room temperature for 3 hours; the reaction solution was neutralized (pH 7) with 1N hydrochloric acid in place of concentrated hydrochloric acid, followed by extraction with ethyl acetate; and the resulting crude product obtained by purification with silica gel column chromatography was washed with n-hexane.
Colorless crystals
Melting point: 131-136°C (with decomposition)
Reference Example 14 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl1-3-trifluoromethylbenzoic acid Step 1 ethyl 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-3-trifluoromethylbenzoate [0140] This compound was prepared in the same manner as in Reference Example 2 (step 3), except that 1-(2-hydroxyethyl)piperazine was used.
Yellow oily product
Step 2 ethyl 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl1-3-trifluoromethylbenzoate [0141] 4.50 g of ethyl 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-3-trifluoromethylbenzoate obtained in the step 1 was dissolved in 90 ml of anhydrous dichloromethane and the mixture was stirred under cooling in a dry ice/acetone bath under an argon atmosphere. A solution of 4.03 g of DAST in 50 ml of anhydrous dichloromethane was added dropwise for 20 minutes and the reaction solution was stirred for 10 minutes. The reaction solution was stirred for 1 hour under ice-water cooling and then stirred at room temperature for2 hours. The reaction solution was alkalified (pH 9) by adding ice and 100 ml of an aqueous saturated sodium hydrogen carbonate solution, and then insolubles were removed by filtration. The filtrate was subjected to extraction with ethyl acetate and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 2.16 g of the objective compound as a yellow oily product.
Step 3 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl]-3-trifluoromethylbenzoic acid [0142] This compound was prepared in the same manner as in Reference Example 1 (step 6), except that ethyl 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl]-3-trifluoromethylbenzoate obtained in the step 2 was used, and that after neutralization, the aqueous layer was followed by extraction with ethyl acetate, the separated aqueous layer was mixed with saturated saline, subjected to extraction with ethyl acetate, and further mixed with a table salt, followed by extraction with ethyl acetate five times.
Colorless crystals
Melting point: 152-155°C (with decomposition)
Reference Example 15 4-{4-[2-(t-butyldimethylsilanoxy)ethyl]piperazin-1-ylmethyl}-3-trifluoromethylbenzoic acid Step 1 ethyl 4-[4-(2-(t-butyldimethylsilanoxyethyl)piperazin-1-ylmethyl)-3-trifluoromethylbenzoate [0143] 2.82 g of ethyl 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-3-trifluoromethylbenzoate (Reference Example 14 (step 1)) was dissolved in anhydrous Ν,Ν-dimethylformamide and 1.33 g of imidazole and 1.42 g of t-butyldimethylchlo-rosilane were added in turn, and then the mixture was stirred at room temperature for 1 hour. The reaction solution was mixed with water, followed by extraction with ethyl acetate, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 3.70 g of the objective compound as a pale yellow oily product.
Step 2 4-[4-(2-(t-butyldimethylsilanoxyethyl)piperazin-1-ylmethyl)-3-trifluoromethylbenzoic acid [0144] This compound was prepared in the same manner as in Reference Example 1 (step 6), except that ethyl 4-[4-(2-(t-butyldimethylsilanoxyethyl)piperazin-1-ylmethyl)-3-trifluoromethylbenzoate obtained in the step 1 was used, and that ethanol was used as the solvent and after neutralization, the aqueous layer was subjected to extraction with ethyl acetate twice and the organic layer was washed with saturated saline.
Pale yellow amorphous
Reference Example 16 4-[1-(t-butoxycarboriyl)-2-carbamoylpiperazin-4-ylmethyl1-3-trifluoromethylbenzoic acid Step 1 ethyl 4-(3-carbamoylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoate [0145] This compound was prepared in the same manner as in Reference Example 2 (step 3), except that 2-car-bamoylpiperazine was used.
Colorless oily product
Step 2 ethyl 4-[1-(t-butoxycarbonyl)-2-carbamoylpiperazin-4-ylmethyl1-3-trifluoromethylbenzoate
[0146] 3 .07 g of ethyl 4-(3-carbamoylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoate obtained in the step 1 and 0.20 g of 4-(dimethylamino)pyridine were dissolved in 34 ml of acetonitrile and 1.96 g of di-t-butyl dicarbonate was added thereto, and then the mixture was stirred at room temperature for 3 hours. The deposited crystal was collected by filtration and then washed with a small amount of acetonitrile to obtain 2.08 g of the objective compound as colorless crystals. Melting point: 124-125X
Step 3 4-[1-(t-butoxycarbonyl)-2-carbamoylpiperazin-4-ylmethyl]-3-trifluoromethylbenzoic acid [0147] 2.84 g of ethyl 4-[1-(t-butoxycarbonyl)-2-carbamoylpiperazin-4-ylmethyl]-3-trifluoromethylbenzoate obtained in the step 2 was suspended in 15 ml of methanol and 10 ml of a 1N aqueous sodium hydroxide solution was added thereto, and then the reaction solution was stirred at room temperature for 18 hours. The reaction solution was neutralized by adding 10 ml of 1N hydrochloric acid. The deposited crystal was collected by filtration and then washed with water to obtain 2.51 g of the objective compound as colorless crystals.
Melting point: 230-233°C (with decomposition)
Reference Example 17 4-[(S)-3-(t-butoxycarbonylamino)-2-oxopyrrolidin-1-ylmethyl]-3-trifluoromethylbenzoic acid Step 1 ethyl 4-[(S)-3-(t-butoxycarbonylamino)-2-oxopyrrolidin-1-ylmethyl]-3-trifluoromethylbenzoate [0148] 669 mg of (S)-3-(t-butoxycarbonylamino)pyrrolidin-2-one (J. Med. Chem., 1999, 42, 3557-3571) was dissolved in 30 ml of tetrahydrofuran/N,N-dimethylformamide (9:1) and the mixture was stirred under ice cooling. 60% sodium hydride was added thereto and the mixture was stirred for 20 minutes. A solution (3 ml) of ethyl 4-(bromomethyl)-3-trifluoromethylbenzoate (Reference Example 2 (step 2)) in tetrahydrofuran was added dropwise, followed by stirring at room temperature for 6 hours after removing an ice bath. The reaction solution was poured into an aqueous saturated ammonium chloride solution, followed by extraction with ethyl acetate twice, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 867 mg of the objective compound as pale yellow crystals.
Melting point: 93-95°C
Step 2 4-((S)-3-(t-butoxvcarbonvlamino)-2-oxopyrrolidin-1-ylmethvl)-3-trifluoromethylbenzoic acid [0149] 829 mg of ethyl 4-((S)-3-(t-butoxycarbonylamino)-2-oxopyrrolidin-1-ylmethyl)-3-trifluoromethylbenzoate obtained in the step 1 was dissolved in 5 ml of methanol and 2.9 ml of a 1N aqueous sodium hydroxide solution was added thereto, and then the reaction, solution was stirred at room temperature for 20 hours. The reaction solution was neutralized by adding 2.9 ml of 1N hydrochloric acid and methanol was distilled off under reduced pressure. The residue was mixed with water, followed by extraction with ethyl acetate, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 800 mg of the objective compound as a pale yellow amorphous.
Reference Example 18 4- methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1aniline Step 1 3- (dimethylamino)-1-(5-pyrimidinyl)-2-propen-1-one [0150] 6.01 g of Ν,Ν-dimethylformamide dimethylacetal was added to 1.54 g of 5-acetylpyrimidine (Khim. Geterotsikl. Soedim., 1981, (7), 958-962) and the mixture was heated at reflux for 15 hours. After the reaction solution was aircooled, a small amount of diisopropyl ether was added and the deposited crystal was collected by filtration to obtain 1.52 g of the objective compound as reddish brown crystals.
Melting point: 133-135°C
Step 2 1-(2-methyl-5-nitrophenyl)guanidine [0151] To 135 g of 1-(2-methyl-5-nitrophenyl)guanidine nitrate (Japanese Unexamined Patent Publication (Kokai) No. 6-87834), 21 g of sodium hydroxide in 1.0 L of a cold aqueous solution was directly added, followed by stirring at room temperature for 10 minutes. The crystals were filtered, sufficiently washed with water and then forced-air dried at 60°C to obtain 102 g of the objective compound as pale yellow crystals.
Melting point: 135-142°C
Step 3 1-methyl-4-nitro-2-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1benzene [0152] To 1.51 g of 3-(dimethylamino)-1-(5-pyrimidinyl)-2-propen-1-one obtained in the step 1, 1.66 g of 1-(2-methyl- 5- nitrophenyl)guanidine obtained in the step 2 was added, followed by stirring at 120°C for 2 hours. To the mixture, 2-propanol was added and the crystals were collected by filtration and then washed in turn with 2-propanol and diethyl ether to obtain 1.95 g of the objective compound as pale brown crystals.
Melting point: 200-203°C
Step 4 4- methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]aniline [0153] 18.50 g of 1-methyl-4-nitro-2-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]benzene obtained in the step 3 was suspended in 1.3 L of tetrahydrofuran-methanol (1:1) and 7.40 g of 10% palladium-carbon was added under an argon atmosphere. 9.06 ml of formic acid was added thereto under stirring at room temperature, and then the reaction solution was heated at reflux for 1 hour. After the reaction solution was air-cooled, the catalyst was removed by filtration and washed with methanol, and the solvent in the filtrate was then distilled off under reduced pressure. The residue was dissolved in chloroform. To the residue, an aqueous saturated sodium hydrogen carbonate solution was added to separate the aqueous layer. The aqueous layer was subjected to extraction with chloroform twice. The organic layers were combined and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The amorphous obtained by purification of the residue with silica gel column chromatography was crystallized by adding chloroform to obtain 11.97 g of the objective compound as pale yellow crystals.
Melting point: 164-167°C
Reference Example 19 3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylaniline Step 1 5-bromonicotinoyl chloride [0154] To 5.00 g of 5-bromonicotinic acid, 74 ml of thionyl chloride was added and the mixture was heated at reflux for 6 hours. After the solvent was distilled off under reduced pressure, the crystal was washed with diisopropyl ether and collected by filtration to obtain 4.09 g of the objective compound as colorless crystals.
Melting point: 72-74°C
Step 2 3-acetyl-5-bromopyridine [0155] 1.24 g of ground magnesium chloride was suspended in 13 ml of toluene and 6.2 ml of triethylamine and 2.93 g of diethyl malonate were added in turn. After stirring at room temperature for 1.5 hours, a suspension of 4.08 g of 5-bromonicotinoyl chloride obtained in the step 1 in 10 ml of toluene was added dropwise over 15 minutes, followed by stirring at room temperature for 2 hours. After neutralizing with 40 ml of 1N hydrochloric acid, the aqueous layer was separated. The aqueous layer was further subjected to extraction with diethyl ether and the organic layers were combined, and then the solvent was distilled off under reduced pressure. To the resulting oily product, dimethyl sulfoxide-water (17 ml-0.7 ml) was added, followed by stirring with heating at 150 to 160°C for 2 hours. The reaction solution was air-cooled, and then water was added. Then, the deposited crystals were collected by filtration. The deposited crystals were dissolved in ethyl acetate, washed in turn with water and an aqueous saturated sodium hydrogen carbonate solution and then dried over anhydrous magnesium sulfate. 0.60 g of activated carbon (Kyoryoku Shirasagi MOIWY433) was added and, after standing for 10 minutes, activated carbon was removed by filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.89 g of the objective compound as pale yellow crystals.
Melting point: 87-89.5°C
Step 3 1- (5-bromopyridin-3-yl)-3-(dimethylamino)-2-propen-1-one [0156] To 859 mg of 3-acetyl-5-bromopyridine obtained in the step 2, 563 mg of Ν,Ν-dimethylformamide dimethyl acetal was added and the mixture was heated at reflux for 1 hour. After air cooling, the reaction solution was directly purified by silica gel column chromatography. The resulting crude crystals were washed with diethyl ether and then collected by filtration to obtain 860 mg of the objective compound as yellow crystals.
Melting point: 131-131.5°C
Step 4 2- [4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-1-methyl-4-nitrobenzene [0157] To 833 mg of 1-(5-bromopyridin-3-yl)-3-(dimethylamino)-2-propen-1-one obtained in the step 3 and 634 mg of 1-(2-methyl-5-nitrophenyl)guanidine (Reference Example 6 (step 2)), 7 ml of 2-propanol was added and the mixture was heated at reflux for 17 hours. After the reaction solution was air-cooled, the deposited crystals were collected by filtration and washed with diethyl ether to obtain 823 mg of the objective compound as pale yellow crystals.
Melting point: 206-208°C
Step 5 3- [4-(5-bromopyridin-3-yl)pyrimidin-2-ylaminol-4-methylaniline [0158] To 807 mg of 2-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-1-methyl-4-nitrobenzene obtained in the step 4, 5 ml of concentrated hydrochloric acid was added and a solution of 2.36 g of tin chloride (II) dihydrate in 3.5 ml of concentrated hydrochloric acid was added while stirring with heating at 55°C. The mixture was gradually heated up to 100°C and further stirred with heating at 100°C for 15 minutes. After the reaction solution was air-cooled, water was added and alkalified with a 10% aqueous sodium hydroxide solution. After the addition of chloroform and stirring for a while, insolubles were removed by filtration and the aqueous layer was separated. The aqueous layer was further subjected to extraction with chloroform and the organic layers were combined and, after drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain a crude product. The crude product was crystallized by adding diethyl ether-ethyl acetate and the crystals were collected by filtration to obtain 528 mg of the objective compound as yellow crystals.
Melting point: 129.5-130°C
Reference Example 20 4- methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]aniline Step 1 2-[(6-chloro)pyrimidin-4-ylamino]-1-methyl-4-nitrobenzene
[0159] 2.64 g of 2-methyl-5-nitroaniline and 10.33 g of 4,6-dichloropyrimidine were stirred with heating at 110°C for 16 hours. After air cooling, the reaction solution was dissolved in methanol. An aqueous saturated sodium hydrogen carbonate solution and ethyl acetate were added to separate the aqueous layer. The aqueous layer was further subjected to extraction with ethyl acetate twice. The organic layers were combined and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain a crude product. The crude product was washed with diisopropyl ether to obtain 3.61 g of the objective compound as yellow crystals. Melting point: 161-163°C
Step 2 1-methyl-4-nitro-2-[6-(3-pyridyl)pyrimidin-4-ylamino]benzene [0160] 2.00 g of 2-[(6-chloro)pyrimidin-4-ylamino]-1-methyl-4-nitrobenzene obtained in the step 1 was dissolved in 80 ml of tetrahydrofuran, 1.22 g of diethyl(3-pyridyl)borane and 870 mg of tetrakis(triphenylphosphine)palladium (0) were added in turn, and then the mixture was stirred at room temperature under an argon atmosphere. To the mixture were added 1.27 g of potassium hydroxide and 10 ml of water and then the reaction solution was heated at reflux for 6 hours. The reaction solution was mixed with water, followed by extraction with ethyl acetate three times, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The crude crystals were washed with ethyl acetate to obtain 1.43 g of the objective compound as brown crystals.
Melting point: 187-192°C
Step 3 4-methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]aniline [0161] 1 .85 g of 1-methyl-4-nitro-2-[6-(3-pyridyl)pyrimidin-4-ylamino]benzene obtained in the step 2 was suspended in 74 ml of anhydrous methanol and 555 mg of 10% palladium-carbon was added. 3.80 g of ammonium formate was added under an argon atmosphere and the mixture was heated at reflux at a bath temperature of 90°C for 4 hours. The catalyst was removed by filtration and the solvent in the filtrate was distilled off under reduced pressure. The residue was m ixed with water and was subjected to extraction with ethyl acetate twice. The organic layer was dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was crystallized by adding ethyl acetate to obtain 1.41 g of the objective compound as pale yellow crystals.
Melting point: 176-179°C
Reference Example 21 4-methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylamino1aniline Step 1 1- methyl-4-nitro-2-[6-(5-pyrimidinyl)pyrimidin-4-ylamino]benzene [0162] 3.28 g of 2-[(6-chloro)pyrimidin-4-ylamino]-1-methyl-4-nitrobenzene (Reference Example 20 (step 1)) were dissolved with heating in 130 ml of anhydrous ethanol. 1.69 g of dihydroxy(5-pyrimidinyl)borane was added, and then deaeration was performed, followed by purging with argon. 5.82 g of potassium carbonate and 2.15 g of tetrakis(triphe-nylphosphine)palladium (0) were added in turn, and then the mixture was heated at reflux for 7.5 hours. The reaction solution was mixed with water, followed by extraction with ethyl acetate twice, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was crystallized by adding chloroform-methanol to obtain 808 mg of the objective compound as ocherous crystals.
Melting point: 257-261 °C (with decomposition)
Step 2 4-methyl-3-[6-(5-pyrimidyl)pyrimidin-4-ylamino1aniline [0163] This compound was prepared in the same manner as in Reference Example 20 (step 3), except that 1-methyl-4-nitro-2-[6-(5-pyrimidyl)pyrimidin-4-ylamino]benzene obtained in the step 1 was used, and that the reaction was conducted for 1.5 hours.
Yellow crystals
Melting point: 98-102°C (with decomposition)
Reference Example 22 4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]aniline Step 1 2- [(4-chloro)pyridin-2-ylamino1-1-methyl-4-nitrobenzene [0164] To 2.00 g of 2,4-dichloropyridine, 2.26 g of 2-methyl-5-nitroaniline, 121 mg of palladium (II) acetate, 336 mg of (±)-2,2’-bis(diphenylphosphino)-1,1’-binaphthyl [(±)-BINAP] and 6.16 g of cesium carbonate, 120 ml of toluene was added, and then the mixture was stirred with heating at 70°C for 23 hours under an argon atmosphere. After insolubles were removed by filtration, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain a crude product. The crude product was washed with diethyl ether to obtain 1.22 g of the objective compound as yellow crystals.
Melting point: 130-133°C
Step 2 1-methyl-4-nitro-2-[4-(5-pyrimidiriyl)pyridin-2-ylamino]benzene [0165] To 120 ml of deaerated tetrahydrofuran-water (1:1), 1.73 g of 2-[(4-chloro)pyridin-2-ylamino]-1-methyl-4-ni-trobenzene obtained in the step 1, 890 mg of dihydroxy(5-pyrimidinyl)borane, 3.10 g of potassium carbonate and 1.15 g of tetrakis(triphenylphosphine)palladium (0) were added in turn and the mixture was stirred with heating at 80°C for 46 hours under an argon atmosphere. The reaction solution was diluted with ethyl acetate to separate the aqueous layer, and then the aqueous layerwas furthersubjected to extraction with ethyl acetate. The organic layers were combined and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain a crude product. The crude product was washed with diethyl ether to obtain 820 mg of the objective compound as orange crystals.
Melting point: 229-230°C (with decomposition)
Step 3 4-methyl-3-f4-(5-pyrimidinyl)pyridin-2-ylamino1aniline [0166] 163 mg of 1-methyl-4-nitro-2-[4-(5-pyrimidinyl)pyridin-2-ylamino]benzene obtained in the step 2 was dissolved in 32 ml of tetrahydrofuran-methanol (1:1) and 98 mg of 10% palladium-carbon was added. Furthermore, 284 mg of ammonium formate was added and the mixture was heated at reflux at a bath temperature of 90°C for 40 minutes. The catalyst was removed by filtration and the solvent in the filtrate was distilled off under reduced pressure. To the residue, water and ethyl acetate were added to separate the aqueous layer. The aqueous layer was further subjected to extraction with ethyl acetate. The organic layers were combined and dried over anhydrous magnesium sulfate, and then the solvent was distilled ofF under reduced pressure. The residue was purified by silica gel column chromatography to obtain 149 mg of the objective compound as pale yellow crystals.
Melting point: 179-180°C
Reference Example 23 4-methyl-3-|4-(3-pyridyl)pyridin-2-ylamino1aniline Step 1 1-methyl-4-nitro-2-[4-(3-pyridyl)pyridin-2-ylamino1benzene [0167] This compound was prepared in the same manner as in Reference Example 22 (step 2), except that diethyl(3-pyridyl)borane was used, and that the crude product obtained by purification with silica gel column chromatography was crystallized by adding chloroform-methanol.
Orange crystals
Melting point: 170-173°C (with decomposition)
Step 2 4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino1aniline [0168] To 126 mg of 1-methyl-4-nitro-2-[4-(3-pyridyl)pyridin-2-ylamino]benzene obtained in the step 1,1 ml of concentrated hydrochloric acid was added and a solution of 465 mg of tin chloride (II) dihydrate in 1 ml of concentrated hydrochloric acid was added while stirring with heating at 60°C. The mixture was gradually heated up to 100°C and further stirred with heating at 100°C for 40 minutes. After the reaction solution was air-cooled, water was added and the solution was alkalified with a 10% aqueous sodium hydroxide solution. The reaction solution was subjected to extraction with with ethyl acetate three times and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The resulting crude crystals were washed with a small amount of chloroform and then collected by filtration to obtain 93 mg of the objective compound as pale yellow crystals.
Melting point: 183-186°C
Reference Example 24 1-methylpiperazine-2-carboxamide dihydrochloride Step 1 4-(t-butoxycarbonyl)-1-methylpiperazine-2-carboxamide [0169] A solution of 6.00 g of 4-(t-butoxycarbonyl)piperazine-2-carboxamide and 3.28 g of a 37% aqueous formaldehyde solution in 60 ml of methanol was ice-cooled, and 16.66 g of sodium triacetoxyborohydride was added, followed by stirring at room temperature for 24 hours after removing an ice bath. The reaction solution was again ice-cooled, 3.28 g of a 37% aqueous formaldehyde solution and 16.66 g of sodium triacetoxyborohydride were added thereto. After stirring at room temperature for 16 hours, the reaction solution was diluted with ice water, alkalified with an aqueous saturated sodium hydrogen carbonate solution, followed by extraction with ethyl acetate three times. The organic layers were combined and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 5.42 g of the objective compound as colorless crystals.
Melting point: 137-138°C
Step 2 1-methylpiperazine-2-carboxamide dihydrochloride [0170] 5.40 g of 4-(t-butoxycarbonyl)-1-methylpiperazine-2-carboxamide obtained in the step 1 was dissolved in 29 ml of methanol, 48 ml of hydrochloric acid-methanol (Reagent 10, Tokyo Chemical Industry Co., Ltd.) was added, and the mixture was heated at reflux for 6 hours. The reaction solution was concentrated under reduced pressure and dried under reduced pressure to obtain 5.97 g of a crude product as a blue-green oily product.
Reference Example 25 3-(dimethylaminomethyl)azetidine dihydrochloride Step 1 1-(t-butoxycarbonyl)-3-(dimethylaminomethyl)azetidine [0171] To a solution of 920 mg of 1-(t-butoxycarbonyl)-3-(aminomethyl)azetidine in 18 ml of methanol, 5.66 ml of acetic acid, 4.12 g of a 37% aqueous formaldehyde solution and 3.14 g of sodium triacetoxyborohydride were added in turn, followed by stirring at room temperature for 20 hours. The reaction solution was alkalified by adding an aqueous saturated sodium hydrogen carbonate solution, subjected to extraction with ethyl acetate three times. The organic layers were combined, washed with water and then dried over anhydrous magnesium sulfate. Then, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 673 mg of the objective compound as a colorless oily product.
Step 2 3-(dimethylaminomethyl)azetidine dihydrochloride [0172] This compound was prepared in the same manner as in Reference Example 24 (step 2), except that 1-(t-butoxycarbonyl)-3-(dimethylaminomethyl)azetidine obtained in the step 1 was used.
Pale yellow oily product
Reference Example 26 (S)-3-(N,N-diethylamino)pyrrolidine dihydrochloride Step 1 (S)-1-(benzyloxycarbonyl)-3-(N,N-diethylamino)pyrrolidine [0173] To a solution of 1.40 g of (S)-3-amino-1-(benzyloxycarbonyl)pyrrolidine (J. Med. Chem., 1992, 35,1764-1773) in 28 ml of tetrahydrofuran, 2.6 g of potassium carbonate and 1.0 ml of ethyl iodide were added under ice-cool stirring, followed by stirring for 24 hours. The reaction solution was concentrated under reduced pressure, mixed with water, followed by extraction with ethyl acetate, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.70 g of the objective compound as a yellow oily product.
Step 2 (S)-3-(N,N-diethylamino)pyrrolidine dihydrochloride [0174] 700 mg of (S)-1-(benzyloxycarbonyl)-3-(N,N-diethylamino)pyrrolidine obtained in the step 1 was dissolved in 28 ml of methanol and 70 mg of 10% palladium-carbon was added, and then the mixture was hydrogenated at room temperature under 3 atm for 2 hours. The catalyst was removed by filtration and 10 ml of 10% hydrochloric acid-methanol was added to the filtrate, followed by concentrating under reduced pressure to obtain 576 mg of a crude product. Reference Example 27 (S)-3-(1-pyrrolidinyl)pyrrolidine hydrochloride Step 1 (S)-1-benzyl-3-(1-pyrrolidinyl)pyrrolidine [0175] 2.00 g of (R)-1-benzyl-3-(p-toluenesulfonyloxy)pyrrolidine (J. Med. Chem., 1992,35,4205-4208) was dissolved in 12 ml of ethanol, 1.63 g of pyrrolidine was added, and then the mixture was stirred at 140°C for 20 hours in a sealed tube. The reaction solution was concentrated under reduced pressure, mixed with water, followed by extraction with ethyl acetate, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.97 g of the objective compound as a brown oily product.
Step 2 (S)-3-(1-pyrrolidinyl)pyrrolidine hydrochloride [0176] 0.97 g of (S)-1-benzyl-3-(1-pyrrolidinyl)pyrrolidine obtained in the step 1 was dissolved in 30 ml of ethanol and 4.21 ml of a 1N hydrochloric acid was added. 1.68 g of 10% palladium-carbon was added thereto and then the mixture was hydrogenated at room temperature under normal pressures overnight. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure to obtain 0.74 g of a crude product as a slightly-red oily product.
Reference Example 28 (35.45) -3-(dimethylamino)-4-methoxypyrrolidine dihydrochloride Step 1 (35.45) -1-(t-butoxycarbonyl)-3-(dimethylamino)-4-hydroxypyrrolidine [0177] This compound was prepared in the same manner as in Reference Example 25 (step 1), except that (3S,4S)-1-(t-butoxycarbonyl)-3-hydroxy-4-(methylamino)pyrrolidine (Tetrahedron: Asymmetry, 2001,12, 2989-2997) was used, and that the reaction was conducted for 1 hour under ice cooling, the reaction solution was alkalified with a 1N aqueous sodium hydroxide solution and methanol was mostly distilled off under reduced pressure, followed by extraction with ethyl acetate twice.
Colorless oily product
Step 2 (35.45) -1-(t-butoxycarbonyl)-3-(dimethylamino)-4-methoxypyrrolidine [0178] To a suspension of 448 mg of 60% sodium hydride in 5 ml of anhydrous Ν,Ν-dimethylformamide, 1.59 g of methyl iodide was added and a solution of 2.15 g of (3S,4S)-1 -(t-butoxycarbonyl)-3-(dimethylamino)-4-hydroxypyrrolidine obtained in the step 1 dissolved in 10 ml of anhydrous Ν,Ν-dimethylformamide was added dropwise under ice-cool stirring, followed by stirring at room temperature for 1 hour after removing an ice bath. The reaction solution was ice-cooled and a 1% aqueous acetic acid solution was added dropwise thereto, and then the mixture was subjected to extraction with ethyl acetate twice. The organic layers were combined, washed with saturated saline and then dried over anhydrous sodium sulfate. Then, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 1.10 g of the objective compound as a colorless oily product.
Step 3 (3S,4S)-3-(dimethvlamino)-4-methoxvpyrrolidine dihydrochloride [0179] This compound was prepared in the same manner as in Reference Example 24 (step 2), except that (3S,4S)-1-(t-butoxycarbonyl)-3-(dimethylamino)-4-methoxypyrrolidine obtained in the step 2 was used, and that the reaction was conducted at 80°C for 1.5 hours.
Yellow oily product
Reference Example 29 (2R,4S)-4-(dimethylamino)-2-methylpyrrolidine dihydrochloride Step 1 (2R,4R)-1-(t-butoxycarbonyl)-2-methyl-4-(p-toluenesulfonyloxy)pyrrolidine [0180] To a solution of 1.02 g of (2R,4R)-1-(t-butoxycarbonyl)-4-hydroxy-2-methylpyrrolidine (J. Med. Chem., 1988, 31, 1598-1611) in 10 ml of anhydrous dichloromethane, 1.7 ml of triethylamine and 1.16 g of p-toluenesulfonyl chloride were added, and then the mixture was stirred at room temperature overnight. The reaction solution was mixed with water, and followed by extraction with ethyl acetate twice. The organic layers were combined, washed in turn with water, 1N hydrochloric acid and a 1N aqueous sodium hydroxide solution and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 1.54 g of the objective compound as a colorless oily product.
Step 2 (2R,4S)-1-(t-butoxycarbonyl)-4-(dimethylamino)-2-methylpyrrolidine [0181] To 1.99 g of (2R,4R)-1-(t-butoxycarbonyl)-2-methyl-4-(p-toluenesulfonyloxy)pyrrolidine obtained in the step 1, 50 ml of dimethylamine (2M methanol solution) was added, and then the mixture was stirred at 140°C overnight in a sealed tube. The reaction solution was concentrated under reduced pressure, and then the residue was purified by silica gel column chromatography to obtain 874 mg of the objective compound as a brown oily product.
Step 3 (2R,4S)-4-(dimethylamino)-2-methylpyrrolidine dihydrochloride [0182] This compound was prepared in the same manner as in Reference Example 24 (step 2), except that (2R,4S)-1-(t-butoxycarbonyl)-4-(dimethylamino)-2-methylpyrrolidine obtained in the step 2 was used, and that the reaction was conducted at 80°C for 2 hours.
Brown oily product
Reference Example 30 (S)-3-[N-(t-butoxycarbonyl)-N-methylamino1pyrrolidine Step 1 (S)-1-benzyl-3-[N-(t-butoxycarbonyl)]-N-methylamino]pyrrolidine [0183] 0.67 g of (S)-1-benzyl-3-(methylamino)pyrrolidine (J. Med. Chem., 1992, 35, 4205-4213) was dissolved in 5 ml of dichloromethane, a solution of di-t-butyl dicarbonate in 5 ml of dichloromethane was added thereto, and the mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, and then the crude product was purified by silica gel column chromatography to obtain 0.80 g of the objective compound as a colorless oily product.
Step 2 (S)-3-fN-(t-butoxycarbonyl)-N-methylaminolpyrrolidine [0184] 0.80 g of (S)-1-benzyl-3-[N-(t-butoxycarbonyl)]-N-methylamino]pyrrolidine obtained in the step 1 was dissolved in 18 ml of ethanol, 1.10 g of 10% palladium-carbon was added, and then the mixture was hydrogenated at room temperature under normal pressures overnight. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 0.42 g of the objective compound as a colorless oily product.
Reference Example 31 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide Step 1 4-(bromomethyl)-3-trifluoromethylbenzoic acid [0185] To 60.0 g of 4-methyl-3-trifluoromethylbenzoic acid was added 600 ml of isopropyl acetate. Under stirring at room temperature, a solution of 133.0 g of sodium bromate in 420 ml of water and a solution of 91.7 g of sodium hydrogensulfite in 180 ml of water were added in turn. The mixture was gradually heated from 30°C up to 50°C at intervals of 10°C and stirred until the color of the reaction solution disappeared. The aqueous layer was separated to remove, and to the organic layer were added a solution of 133.0 g of sodium bromate in 420 ml of water and a solution of 91.7 g of sodium hydrogensulfite in 180 ml of water, and then the mixture was gradually heated up to 60°C as above. After separation, to the organic layer were further added a solution of 133.0 g of sodium bromate in 420 ml of water and a solution of 91.7 g of sodium hydrogensulfite in 180 ml of water, and the mixture was gradually heated as above and heated to the temperature the mixture was finally refluxed. After the completion of the reaction, the reaction solution was separated, the organic layer was washed twice with a 5% aqueous sodium thiosulfate solution and twice with 15% saline, dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. To the residue was added 120 ml of n-heptane, the mixture was stirred, and then the crystals were collected by filtration to obtain 50.0 g of the objective compound as colorless crystals.
Melting point: 140-143°C
Step 2 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide [0186] 7.69 g of 4-(bromomethyl)-3-trifluoromethylbenzoic acid obtained in the step 1 was suspended in 154 ml of anhydrous dichloromethane. Under ice-cool stirring, 6.59 ml of oxalyl chloride and 0.1 ml of anhydrous N,N-dimethyl-formamide were added dropwise. Under ice cooling, the mixture was further stirred for 3 hours, and then the reaction solution was concentrated under reduced pressure. To the residue was added 70 ml of anhydrous 1,4-dioxane, and then 7.00 g of 4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]aniline (Reference Example 18) and 4.18 g of potassium carbonate were added in turn, followed by stirring at room temperature for 18 hours. To the reaction solution was added 175 ml of water, and the mixture was violently stirred for one hour. Then, the deposit was collected by filtration and washed in turn with water, a small amount of acetonitrile, ethyl acetate and diisopropyl ether to obtain 8.10 g of the objective compound as pale yellow crystals.
Melting point: 198-202°C (with decomposition)
Reference Example 32 4-(piperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide [0187] This compound was prepared in the same manner as in Example 47, except that piperazine was used, and that piperazine was used in an amount of 10 equivalents based on the raw material.
Pale yellow crystals Melting point: 208-213°C
Reference Example 33 4-(4-methylpiperazin-1-vlmethyl)-3-trifluoromethyl-N-[4-methyl-3-(thioureido)phenyllbenzamide Step 1 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-(3-amino-4-methylphenyl)benzamide [0188] 1.04 g of 2,4-diaminotoluene, 104 mg of 4-(dimethylamino)pyridine and 4.9 ml of N,N-diisopropyl-N-ethylamine were dissolved in 40 ml of acetonitrile. Under ice-cool stirring, 3.70 g of 4-(4-methylpiperazin-1-ylmethyl)-3-trifluorometh-ylbenzoyl chloride dihydrochloride (Reference Example 2) was added by four portions. After stirring for 1 hour, the solvent was distilled ofF under reduced pressure and diluted with water. The reaction solution was alkalified with an aqueous saturated sodium hydrogen carbonate solution, followed by extraction with ethyl acetate twice, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 2.56 g of the objective compound as a pale brown amorphous.
Step 2 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-[3-(3-benzoylthioureido)-4-methylphenyl]benzamide [0189] To a solution of 0.21 g of ammonium thiocyanate in 1.5 ml of acetone was added dropwise a solution of 0.35 g of benzoyl chloride in 0.5 ml of acetone, under stirring at room temperature. After the mixture was refluxed for 15 minutes, a solution of 1.00 g of 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-(3-amino-4-methylphenyl)benza-mide obtained in the step 1 in 4 ml of acetone was added dropwise and the mixture was further heated at reflux for 15 minutes. The reaction solution was air-cooled to room temperature, and then diluted with water. The solution was subjected to extraction with ethyl acetate twice and dried over anhydrous magnesium sulfate. Then, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 0.98 g of the objective compound as colorless crystals.
Melting point: 127-129°C
Step 3 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-[4-methyl-3-(thioureido)phenyl1benzamide [0190] To a solution of 960 mg of 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-[3-(3-benzoylthioureido)-4-methylphenyljbenzamide obtained in the step 2 in 10 ml of methanol was added 4 ml of a 1N aqueous sodium hydroxide solution. The mixture was heated at reflux for 2 hours, and then the solvent was mostly distilled off under reduced pressure and diluted with water. The reaction solution was acidified by adding 6 ml of 1N hydrochloric acid, and then alkalified by adding 28% aqueous ammonia. The deposited crystals were collected by filtration to obtain 718 mg of the objective compound as colorless crystals.
Melting point: 215-216°C (with decomposition)
Reference Example 34 3-(dimethylamino)azetidine dihydrochloride Step 1 1-(t-butoxycarbonyl)-3-(dimethylamino)azetidine [0191] This compound was prepared in the same manner as in Reference Example 25 (Step 1), except that 1-(t-butoxycarbonyl)-3-aminoazetidine was used.
Step 2 3-(dimethylamino)azetidine dihydrochloride [0192] This compound was prepared in the same manner as in Reference Example 25 (Step 2), except that 1-(t- butoxycarbonyl)-3-(dimethylamino)azetidine obtained in the step 1 was used.
Colorless oily product
Reference Example 35 (S)-3-(dimethylaminomethyl)pyrrolidine dihydrochloride Step 1 (R) -1-(t-butoxycarbonvl)-3-(dimethylaminomethyl)pyrrolidine [0193] This compound was prepared in the same manner as in Reference Example 25 (Step 1), except that (R)-3-(aminomethyl)-1-(t-butoxycarbonyl)pyrrolidine was used.
Step 2 (S) -3-(dimethylaminomethyl)pyrrolidine dihydrochloride [0194] This compound was prepared in the same manner as in Reference Example 25 (Step 2), except that (R)-1-(t-butoxycarbonyl)-3-(dimethylaminomethyl)pyrrolidine obtained in the step 1 was used.
Colorless oily product
Reference Example 36 (R) -3-(dimethylaminomethyl)pyrrolidine dihydrochloride Step 1 (S) -1-(t-butoxycarbonyl)-3-(dimethylaminomethyl)pyrrolidine [0195] This compound was prepared in the same manner as in Reference Example 25 (Step 1), except that (S)-3-(aminomethyl)-1-(t-butoxycarbonyl)pyrrolidine was used.
Step 2 (R)-3-(dimethylaminomethyl)pyrrolidine dihydrochloride [0196] This compound was prepared in the same manner as in Reference Example 25 (Step 2), except that (S)-1-(t-butoxycarbonyl)-3-(dimethylaminomethyl)pyrrolidine obtained in the step 1 was used.
Pale yellow oily product
Reference Example 37 (3R,4R)-3-(dimethylamino)-4-methoxypyrrolidine dihydrochloride [0197] This compound was prepared using (3R,4R)-1-(t-butoxycarbonyl)-3-hydroxy-4-(methylamino)pyrrolidine (Tetrahedron: Asymmetry, 2001, 12, 2989-2997) according to the method of Reference Example 28 (Step 1 to Step 3). Colorless oily product [0198] Structural formulas and properties of the following Reference Examples 38 to 81 are shown in Table 1. Reference Example 38 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 39 3-iodo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 40 3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 41 3-fluoro-4-(4-methylpiperazin-1-vlmethyl)-N-{4-methvl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl)benzamide
Reference Example 42 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benza- mide
Reference Example 43 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe- nyl}benzamide
Reference Example 44 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(2-pyrazinyl)pyrimidin-2-ylamino1phenyl}benzamide Reference Example 45 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(6-chloropyridin-3-yl)pyrimidin-2-ylamino1-4-methylphenyl}ben- zamide
Reference Example 46 3- bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl}ben-zamide
Reference Example 4 4- (4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino1-4-methylphe-nyl}benzamide
Reference Example 48 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(1,2-dihydropyridazin-4-yl)pyrimidin-2-ylamino]-4-methylphe- nyl}benzamide
Reference Example 49 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridazinyl)pyrimidin-2-ylamino1phenyl}benzamide Reference Example 50 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 51 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino1phenyl}benzamide Reference Example 52 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino1phenyl}benzamide Reference Example 53 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[2-(3-pyridyl)pyridin-6-ylamino]phenyl}benzamide Reference Example 54 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[3-(3-pyridyl)pyridin-5-ylamino1phenyl}benzamide Reference Example 55 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[3-(3-pyridyl)phenylamino1phenyl}benzamide Reference Example 56 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[2-(3-pyridyl)pyrazin-6-ylamino]phenyl}benzamide Reference Example 57 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[5-(3-pyridyl)-1,2,4-triazin-3-ylamino1phenyl}benzamide Reference Example 58 3- methyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 59 4- (4-methylpiperazin-1-ylmethyl)-3-nitro-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 60 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 61 3.5- dibromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 62 3.5- dimethoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benza-mide
Reference Example 63 3-(N,N-dimethylcarbamoyl)-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phe- nyl}benzamide
Reference Example 64 3-bromo-4-(4-ethylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 65 3-bromo-4-[4-(n-propyl)piperazin-1-ylmethyl]-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 66 3-bromo-4-(N,N-dimethylaminomethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl}benzamide
Reference Example 67 3-bromo-4-(N,N-diethylaminomethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 68 3-bromo-4-(1-pyrrolidinylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl}benzamide Reference Example 69 3-bromo-4-(piperidinomethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide Reference Example 70 3-bromo-4-(morpholinomethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl}benzamide Reference Example 71 3-bromo-4-(cis-3,5-dimethylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl}benza- mide
Reference Example 72 3-bromo-4-(4-methyl-hexahydro-1 H-1,4-diazepin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phe- nyl}benzamide
Reference Example 73 3- bromo-4-(1-piperazinylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benzamide Reference Example 74 4- [4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide
Reference Example 75 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benzamide Reference Example 76 3-methoxycarbonyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}ben- zamide
Reference Example 77 3-cyano-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl}benzamide Reference Example 78 3- bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benzamide hydrochloride
Reference Example 79 4- (4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyl}benzamide hydrochloride
Reference Example 80 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino1-4-methylphe-nyl}benzamide hydrochloride Reference Example 81 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyl}benzamide methanesulfonate [Table 11
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
[0199] The compounds of Reference Examples 38 to 81 were prepared according to the preparation process 1 as described above.
Reference Example 82 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl}benzamide [0200] In the same manner as in Reference Example 31, the objective compound is prepared using 4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]aniline (Patent Document 1).
Example 1 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza- mide [0201] 1.98 g of 4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]aniline (Reference Example 18) was dissolved in 35 ml of anhydrous pyridine and 2.90 g of 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride hydrochloride (Reference Example 9) was added, followed by stirring at room temperature for 2 hours. To the reaction solution, ice water and an aqueous saturated sodium hydrogen carbonate solution were added and then the mixture was subjected to extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The crude crystals were washed with chloroform-diethyl ether (1:1) to obtain 2.66 g of the objective compound as pale brown crystals.
Melting point: 206-207°C
Example 2 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza-mide hydrochloride [0202] 2.66 g of 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide (Example 1) was suspended in 26 ml of ethanol and 4.88 ml of 1 N hydrochloric acid was added thereto, and then the mixture was stirred with heating in a hot bath at 70°C and dissolved. The solvent was distilled off under reduced pressure, and then the crude crystals were washed with ethanol to obtain 2.80 g of the objective compound. Ocherous crystals
Melting point: 264°C (with decomposition)
Elemental analysis (for C2gH30F2N8OTHCI 0.6EtOH)
Calcd.(%): C, 59.59; H, 5.73; N, 18.41 Found (%): C, 59.59; H, 5.71; N, 18.53
Example 3 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide [0203] This compound was prepared in the same manner as in Example 1, except that 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride hydrochloride (Reference Example 1) was used, and that the reaction was conducted at room temperature for 2 days and the crude product was purified by silica gel column chromatography.
Yellow crystals Melting point: 131-134°C
Example 4 3- ethyl-4-(4-methylpiperazin-1-ylmethyl)-N-4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide hydrochloride [0204] This compound was prepared in the same manner as in Example 2, except that 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 3) was used, and that the resulting crude crystals were washed with ethyl acetate.
Yellow crystals
Melting point: 253-255°C (with decomposition)
Elemental analysis (for C^H^NaO-HCl^.lF^O)
Calcd.(%): C, 60.36; H, 6.62; N, 18.77 Found (%): C, 60.10; H, 6.31; N, 18.75
Example 5 4- (1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyl}benzamide [0205] This compound was prepared in the same manner as in Example 1, except that a suspension of 4-(1-methyl-piperidin-4-ylidenemethyl)-3-trifluoromethylbenzoyl chloride hydrochloride (Reference Example 7) in anhydrous tetrahy-drofuran was used, and that the reaction was conducted at room temperature for 21 hours.
Yellow crystals
Melting point: 234-239°C (with decomposition)
Example 6 4-(1-methylpiperidin-4-ylidenemethvl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyDbenzamide hydrochloride [0206] This compound was prepared in the same manner as in Example 2, except that 4-(1-methylpiperidin-4-yliden-emethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 5) was used, and that the resulting crude crystals were washed in turn with ethanol and diethyl ether.
Pale yellow crystals
Melting point: 202-206°C (with decomposition)
Elemental analysis (for Ο30Η28Ρ3Ν7ΟΉΟΙΉ2Ο)
Calcd.(%): C, 58.68; H, 5.09; N, 15.97 Found (%): C, 58.42; H, 4.92; N, 16.10
Example 7 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza- mide [0207] This compound was prepared in the same manner as in Example 1, except that a suspension of 4-(1-methyl-piperidin-4-ylmethyl)-3-trifluoromethylbenzoyl chloride hydrochloride (Reference Example 8) in anhydrous tetrahydro-furan was used, and that the reaction was conducted at room temperature for 21 hours and the resulting crude crystals were washed with ethyl acetate.
Pale yellow crystals
Melting point: 230-233°C (with decomposition)
Example 8 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminolphenyl}benza-mide hydrochloride [0208] This compound was prepared in the same manner as in Example 2, except that 4-(1-methylpiperidin-4-ylmethyl)- 3- trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide(Example7)was used, and that the resulting crude crystals were washed in turn with ethanol and diethyl ether.
Pale yellow crystals
Melting point: 227-231 °C (with decomposition)
Elemental analysis (for 030Η30Ρ3Ν7ΟΉ00.5Η20)
Calcd.(%): C, 59.35; H, 5.31; N, 16.15 Found (%): C, 59.02; H, 5.20; N, 16.08
Example 9 4- (1-methylpiperidin-4-yloxy)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benzamide [0209] This compound was prepared in the same manner as in Example 1, except that 4-(1-methylpiperidin-4-yloxy)- 3- trifluoromethylbenzoyl chloride hydrochloride (Reference Example 11) was used, and that the reaction was conducted at room temperature overnight and the crude product was purified by silica gel column chromatography.
Pale yellow crystals Melting point: 187-191 °C
Example 10 4- (1-methylpiperidin-4-yloxy)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benzamide hydrochloride [0210] This compound was prepared in the same manner as in Example 2, except that 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide(Example9)was used, and that the resulting amorphous was crystallized by adding ethanol-diisopropyl ether.
Yellow crystals
Melting point: 275°C or more
Elemental analysis (for Ο29Η28Ρ3Ν7θ2·ΗΟΙ·0.3Η2Ο)
Calcd.(%): C, 57.53; H, 4.93; N, 16.19 Found (%): C, 57.34; H, 4.99; N, 16.05
Example 11 3,5-dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe- nyl}benzamide [0211] This compound was prepared in the same manner as in Example 1, except that 3,5-dichloro-4-[(S)-3-(dimeth-ylamino)pyrrolidin-1-ylmethyl]benzoyl chloride hydrochloride (Reference Example 6) was used, and that the reaction was conducted at room temperature for 66 hours, the crude product was purified by silica gel column chromatography and the resulting crude crystals were washed with ethyl acetate.
Yellow crystals
Melting point: 215-223°C (with decomposition)
Example 12 (-)-3,5-dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide hydrochloride [0212] This compound was prepared in the same manner as in Example 2, except that 3,5-dichloro-4-[(S)-3-(dimeth-ylamino)pyrrolidin-1-ylmethyl]-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 11) was used, and that the resulting amorphous was crystallized by adding ethyl acetate-ethanol.
Ocherous crystals
Melting point: 161-170°C (with decomposition) [a]D20: -10.03° (c=0.538, methanol)
Elemental analysis (for 029Η3οΟΐ2Ν8ΟΉΟΙΌ.060Η3θθ2θ2Η5 ·1.7Η20) [0213]
Calcd.(%): C, 54.04; H, 5.09; N, 17.24 Found (%): C, 54.41; H, 5.56; N, 16.94
Example 13 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino1-4-methylphenyl)benza- mide [0214] This compound was prepared in the same manner as in Example 1, except that 3-[4-(5-bromopyridin-3-yl)py-rimidin-2-ylamino]-4-methylaniline (Reference Example 19) and 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride dihydrochloride (Reference Example 3) were used, and that the reaction was conducted at room temperature for 17 hours and the crude product was purified by silica gel column chromatography.
Pale yellow crystals Melting point: 168-171°C
Example 14 3- methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino1-4-methylphenyl}benza-mide hydrochloride [0215] This compound was prepared in the same manner as in Example 2, except that 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl}benzamide (Example 13) was used, and that the resulting amorphous was crystallized by adding ethyl acetate.
Pale yellow crystals
Melting point: 168-169°C (with decomposition)
Elemental analysis (for 03οΗ32ΒγΝ702ΉΟΙ·0.30Η3(:0202Ι-Ι5·0.6Η20) Calcd.(%): C, 55.42; H, 5.46; N, 14.50 Found (%): C, 55.42; H, 5.45; N, 14.11
Example 15 4- (4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benza-mide [0216] This compound was prepared in the same manner as in Example 1, except that 4-(4-ethylpiperazin-1-ylmethyl)- 3- trifluoromethylbenzoyl chloride dihydrochloride (Reference Example 5) was used, and that the reaction was conducted at room temperature for 20 hours and the crude product was washed with warmed methanol and then with diethyl ether. Pale yellow crystals
Melting point: 240-244°C (with decomposition)
Example 16 4- (4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza-mide hydrochloride [0217] This compound was prepared in the same manner as in Example 2, except that 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 15) was used.
Pale yellow crystals
Melting point: 256-259°C (with decomposition)
Elemental analysis (for C30H31F3N8OHCI)
Calcd.(%): C, 58.77; H, 5.26; N, 18.28
Found (%): C, 59.47; H, 5.32; N, 18.19 Example 17 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino1-4-methylphe- nyl}benzamide [0218] This compound was prepared in the same manner as in Example 1, except that 3-[4-(5-bromopyridin-3-yl)py-rimidin-2-ylamino]-4-methylaniline (Reference Example 19) and 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride (Reference Example 5) were used, and that the reaction was conducted at room temperature for 24 hours and the amorphous obtained by purification with silica gel column chromatography was crystallized by adding chloroform-diethyl ether (1:1).
Pale yellow crystals Melting point: 178-179°C
Example 18 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphe-nyl}benzamide hydrochloride [0219] This compound was prepared in the same manner as in Example 2, except that 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl}benzamide (Example 17) was used, and that the resulting amorphous was crystallized from ethanol.
Pale yellow crystals
Melting point: 166-172°C (with decomposition)
Elemental analysis (for C31H31BrF3N70HCIO.5H20)
Calcd.(%): C, 53.19; H, 4.75; N, 14.01 Found (%): C, 52.89; H, 4.79; N, 14.05
Example 19 3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benzamide [0220] This compound was prepared in the same manner as in Example 1, except that 3-chloro-4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride dihydrochloride (Reference Example 4) was used, and that the reaction was conducted at room temperature for 18 hours.
Pale yellow crystals
Melting point: 210-227°C (with decomposition)
Example 20 3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide hydrochloride [0221] This compound was prepared in the same manner as in Example 2, except that 3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 19) was used, and that the resulting amorphous was crystallized from ethanol. Pale yellow crystals
Melting point: 197-200°C
Elemental analysis (for C28H2gCIN80'HCI)
Calcd.(%): C, 59.47; H, 5.35; N, 19.81 Found (%): C, 59.73; H, 5.38; N, 19.90
Example 21 3-fluoromethyl-4-(1-methylpiperidin-4-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza- mide [0222] This compound was prepared in the same manner as in Example 1, except that 3-fluoromethyl-4-(1 -methyl- piperidin-4-ylmethyl)benzoyl chloride hydrochloride (Reference Example 10) was used, and that the reaction was conducted at room temperature for 3 days and the amorphous obtained by purification with silica gel column chromatography was crystallized from ethyl acetate.
Pale yellow crystals Melting point: 162-164°C
Example 22 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino1phenyl}benza- mide [0223] This compound was prepared in the same manner as in Example 1, except that 4-methyl-3-[4-(5-pyrimidinyl)py-ridin-2-ylamino]aniline (Reference Example 22) and 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride (Reference Example 2) were used, and that the resulting crude crystals were washed with ethyl acetate. Pale yellow crystals
Melting point: 277°C (with decomposition)
Example 23 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino1phenyl}benza-mide hydrochloride [0224] This compound was prepared in the same manner as in Example 2, except that 4-(4-methylpiperazin-1-ylme-thyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phenyl}benzamide (Example 22) was used. Colorless crystals
Melting point: 203-206°C (with decomposition)
Elemental analysis (for ConHonFoN7OTHCIO.3l-UO)
Calcd.(%): C, 59.71; H, 5.28; N, 16.25 Found (%): C, 59.52; H, 5.34; N, 16.37
Example 24 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethvl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino1phenyl>benzamide [0225] This compound was prepared in the same manner as in Example 1, except that 4-methyl-3-[4-(5-pyrimidinyl)py-ridin-2-ylamino]aniline (Reference Example 22) and 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride (Reference Example 5) were used, and that the resulting crude crystals were washed with ethyl acetate. Pale yellow crystals
Melting point: 256-258°C (with decomposition)
Example 25 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phenyl}benzamide hydrochloride [0226] This compound was prepared in the same manner as in Example 2, except that 4-(4-ethylpiperazin-1-ylmethyl)- 3- trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phenyl}benzamide (Example 24) was used. Colorless crystals
Melting point: 254-256°C (with decomposition)
Elemental analysis (for C31H32F3N7OHCI0.6H2O)
Calcd.(%): C, 59.77; H, 5.53; N, 15.74 Found (%): C, 59.63; H, 5.34; N, 15.63
Example 26 4- (4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide [0227] 200 mg of 4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]aniline (Reference Example 23) was suspended in 4 ml of acetonitrile, and 78.8 mg of 4-(dimethylamino)pyridine and 484 μΙ of N,N-diisopropyl-N-ethylamine were added in turn. Under ice-cooling with stirring, 383 mg of 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride (Reference Example 5) was added, followed by stirring at room temperature for 2 hours. To the reaction solution was added water and the mixture was subjected to extraction with ethyl acetate three times. The organic layers were washed with saturated saline and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 93 mg of the objective compound as pale yellow crystals.
Melting point: 227-229°C (with decomposition)
Example 27 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide hydrochloride [0228] This compound was prepared in the same manner as in Example 2, except that 4-(4-ethylpiperazin-1 -ylmethyl)- 3- trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide (Example 26) was used.
Colorless crystals
Melting point: 230-235°C (with decomposition)
Elemental analysis (for C32H33F 3ν60·ΗΟΙ)
Calcd.(%): C, 62.89; H, 5.61; N, 13.75 Found (%): C, 63.30; H, 5.70; N, 13.65
Example 28 4- (4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino1phenyl}benzamide [0229] This compound was prepared in the same manner as in Example 26, except that 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride (Reference Example 2) was used, and that extraction was conducted five times with chloroform and the resulting crude crystals obtained by purification with silica gel column chromatography were washed with ethyl acetate.
Pale yellow crystals
Melting point: 241-242°C (with decomposition)
Elemental analysis (for C31Fi31F3N6O0.4Fi2O)
Calcd.(%): C, 65.57; H, 5.64; N, 14.80 Found (%): C, 65.31; H, 5.70; N, 14.90
Example 29 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino1phenyl>benzamide methanesulfonate [0230] 1 .21 g of 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phe-nyljbenzamide (Example 28) was suspended in 20 ml of methanol and 140 μΙ of methanesulfonic acid was added, followed by stirring with heating. Insolubles were removed by filtration with heating and the solvent in the filtrate was distilled off under reduced pressure. The residue was crystallized by adding isopropanol and collected by filtration to obtain 1.33 g of the objective compound as pale yellow crystals.
Melting point: 189-191 °C
Elemental analysis (for C31H31F3N6O'CH3SO3H 0.3H2O) Calcd.(%): C, 58.05; H, 5.42; N, 12.69 Found (%): C, 58.05; H, 5.30; N, 12.71
Example 30 4-(1-methylpiperazin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]phenyl}benzamide [0231] This compound was prepared in the same manner as in Example 1, except that 4-methyl-3-[6-(3-pyridyl)pyri-midin-4-ylamino]aniline (Reference Example 20) and 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride (Reference Example 2) were used, and that the reaction was conducted at room temperature for 92 hours and the resulting crude crystals were washed with ethyl acetate.
Colorless crystals
Melting point: 253-254°C (with decomposition)
Example 31 4-(1-methylpiperazin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]phenyl}benzamide hydrochloride [0232] This compound was prepared in the same manner as in Example 2, except that 4-(1-methylpiperazin-4-ylme-thyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]phenyl}benzamide (Example 30) was used, and that the resulting crude crystals were washed in turn with ethanol and diethyl ether.
Pale yellow crystals
Melting point: 190-194°C (with decomposition)
Elemental analysis (for Ο30Η30Ρ3Ν7ΟΉΟΙ·2.5Η2Ο)
Calcd.(%): C, 56.03; H, 5.64; N, 15.25 Found (%): C, 55.67; H, 5.76; N, 15.11
Example 32 4-(1-methylpiperazin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylamino1phenyl}benza- mide [0233] This compound was prepared in the same manner as in Example 1, except that 4-methyl-3-[6-(5-pyrimidinyl)py-rimidin-4-ylamino]aniline (Reference Example 21) and 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylbenzoyl chloride dihydrochloride (Reference Example 2) were used, and that the reaction was conducted at room temperature for 17 hours and the resulting crude crystals were washed with ethyl acetate.
Pale yellow crystals
Melting point: 257-267°C (with decomposition)
Example 33 4-(1-methylpiperazin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylamino1phenyl>benza-mide hydrochloride [0234] This compound was prepared in the same manner as in Example 2, except that 4-(1-methylpiperazin-4-ylme-thyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylamino]phenyl}benzamide (Example 32) was used, and that the resulting crude crystals were washed in turn with ethanol and diethyl ether.
Pale yellow crystals
Melting point: 203-207°C (with decomposition)
Elemental analysis (for 029Η29Ρ3Ν8ΟΉ0Ι·4Η2Ο)
Calcd.(%): C, 51.90; H, 5.71; N, 16.70 Found (%): C, 52.50; H, 5.68; N, 16.24
Example 34 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe- nyl}benzamide [0235] Under an argon atmosphere, 1.71 g of 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl]-3-trifluoromethylbenzoic acid (Reference Example 14) was dissolved in 14 ml of anhydrous Ν,Ν-dimethylformamide and 1.56 g of 2-chloro-1-meth-ylpyridinium iodide was added, followed by stirring at room temperature for 10 minutes. 1.50 g of 4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]aniline (Reference Example 18) and 1.13 ml of N,N-diisopropyl-N-ethylamine were added in turn, followed by stirring at room temperature for 1 hour. 300 ml of water was added to the reaction solution, followed by extraction with ethyl acetate. Two hundred ml of saturated sodium hydrogen carbonate was added to the aqueous layer and the mixture was further extracted with ethyl acetate. The organic layers were combined and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by column chromatography and the crude crystals were washed with diethyl ether-ethyl acetate to obtain 1.68 g of the objective compound as pale yellow crystals.
Melting point: 207-209°C (with decomposition)
Example 35 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminolphe-nyl}benzamide hydrochloride [0236] This compound was prepared in the same manner as in Example 2, except that 4-[4-(2-fluoroethyl)piperazin- 1- ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 34) was used, and that the resulting crude crystals were washed with ethanol.
Pale yellow crystals
Melting point: 213-233°C (with decomposition)
Elemental analysis (for ConHonF^NoO HCl O^HoO)
Calcd.(%): C, 56.77; H, 4.99; N, 17.66 Found (%): C, 56.62; H, 4.99; N, 17.77
Example 36 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe- nyl}benzamide
Step 1 4-{4-[2-(t-butyldimethylsilanoxy)ethyl]piperazin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin- 2- ylaminolphenyl)benzamide [0237] This compound was prepared in the same manner as in Example 34, except that 4-{4-[2-(t-butyldimethylsilan-oxy)ethyl]piperazin-1-ylmethyl}-3-trifluoromethylbenzoic acid (Reference Example 15) was used, and that the resulting amorphous obtained by purification with column chromatography was crystallized from diethyl ether-ethyl acetate.
Pale yellow crystals
Melting point: 193-198°C (with decomposition)
Step 2 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe- nyl}benzamide [0238] 2.03 g of 4-{4-[2-(t-butyldimethylsilanoxy)ethyl]piperazin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl-3-[4-(5-py-rimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was dissolved in 25 ml of anhydrous tetrahydro-furan, followed by stirring under ice-cooling. 5.74 ml of tetrabutyl ammonium fluoride (1M solution in tetrahydrofuran) was added, and the mixture was stirred for 5 minutes, then stirred at room temperature for 22 hours. The reaction solution was diluted with ethyl acetate and washed with water. The washed aqueous layer was subjected to extraction with ethyl acetate four times. The organic layers were combined and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 890 mg of the objective compound as pale yellow crystals.
Melting point: 188-192°C
Example 37 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide hydrochloride [0239] This compound was prepared in the same manner as in Example 2, except that 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 36) was used.
Pale yellow crystals
Melting point: 248-255°C (with decomposition)
Elemental analysis (for C3oH31F3N802 HCI 0.2l-l20)
Calcd.(%): C, 56.95; H, 5.16; N, 17.71 Found (%): C, 56.80; H, 5.06; N, 17.71
Example 38 (+)-4-[(R)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide hydrochloride
Step 1 4-[(R)-3-(dimethylamino)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phenyl}benzamide [0240] This compound was prepared in the same manner as in Example 34, except that 4-[(R)-3-(dimethylamino)pyr-rolidin-1-ylmethyl]-3-trifluoromethylbenzoicacid (Reference Example 12) was used, and that after water and an aqueous saturated sodium hydrogen carbonate solution were added to the reaction solution, the mixture was stirred, and then the deposited crystals were collected by filtration and washed with water.
Yellow crystals
Step 2 (+)-4-[(R)-3-(dimethylamino)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide hydrochloride [0241] This compound was prepared in the same manner as in Example 2, except that 4-[(R)-3-(dimethylamino)pyr-rolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was used, and that the resulting crude crystals were washed in turn with diisopropyl ether and diethyl ether. Pale yellow crystals
Melting point: 178°C (with decomposition) [a]D20: +9.75° (c=1.025, methanol)
Elemental analysis (for C'inH'i1F'iNfiO'HCI'1,5H90)
Calcd.(%): C, 56.29; H, 5.51; N, 17.51 Found (%): C, 56.11; H, 5.43; N, 17.60
Example 39 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino1-4-methylphenyl}benzamide Step 1 4-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4- methylphenyl}benzamide [0242] This compound was prepared in the same manner as in Example 34, except that 4-[4-(t-butoxycarbonyl)pip-erazin-1-ylmethyl]-3-trifluoromethylbenzoic acid (Reference Example 13) and 3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylaniline (Reference Example 19) were used. Pale yellow crystals
Step 2 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl}benzamide [0243] To 214 mg of 4-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyri-midin-2-ylamino]-4-methylphenyl}benzamide obtained in the step 1 was added 1.5 ml of trifluoroacetic acid, followed by stirring at room temperature for 1 hour. The mixture was alkalified (pH 9) by adding 10 ml of a 10% aqueous sodium hydroxide solution to the reaction solution, extracted twice with ethyl acetate, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography and the crude product was crystallized from diethyl ether-ethyl acetate to obtain 99 mg of the objective compound as pale yellow crystals.
Melting point: 195-197°C (with decomposition)
Example 40 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylaminol-4-methylphenyl}benza-mide hydrochloride [0244] This compound was prepared in the same manner as in Example 2, except that 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl}benzamide (Example 39) was used, and that the resulting amorphous was crystallized by adding chloroform-diethyl ether-methanol.
Pale yellow crystals
Melting point: 176-182°C (with decomposition)
Elemental analysis (for C2gH27BrF3N7OTHCM ,5H20)
Calcd.(%): C, 50.48; H, 4.53; N, 14.21 Found (%): C, 50.25; H, 4.21; N, 13.91
Example 41 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide Step 1 4-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phe- nyl}benzamide [0245] This compound was prepared in the same manner as in Example 34, except that 4-[4-(t-butoxycarbonyl)pip-erazin-1-ylmethyl]-3-trifluoromethylbenzoic acid (Reference Example 13) and 4-methyl-3-[4-(3-pyridyl)pyridin-2-ylami-no]aniline (Reference Example 23) were used, and that the resulting crude crystals obtained by purification with silica gel column chromatography were recrystallized from n-hexane-ethyl acetate.
Step 2 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino1phenyl}benzamide [0246] This compound was prepared in the same manner as in Example 39 (Step 2), except that 4-[4-(t-butoxycarb-onyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide obtained in the step 1 was used.
Example 42 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide hydrochloride [0247] This compound was prepared in the same manner as in Example 2, except that 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide (Example 41) was used, and that the resulting amorphous was crystallized by adding isopropanol.
Pale yellow crystals
Melting point: 190-195°C (with decomposition)
Elemental analysis (for Ο30Η29Ρ3Ν6Ο·ΗΟΙ·0.36(ΟΗ3)ΟΗΟΙ-Μ .9H20)
Calcd.(%): C, 57.64; H, 5.89; N, 13.40 Found (%): C, 58.02; H, 5.47; N, 12.97
Example 43 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminolphenyl}benzamide trif-luoroacetate
Step 1 4-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe- nyljbenzamide [0248] This compound was prepared in the same manner as in Example 34, except that 4-[4-(t-butoxycarbonyl)pip-erazin-1-ylmethyl]-3-trifluoromethylbenzoic acid (Reference Example 13) was used.
Pale yellow crystals
Melting point: 182-186°C (with decomposition)
Step 2 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide trif-luoroacetate [0249] To 1.54 g of 4-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)py-rimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was added 15 ml of trifluoroacetic acid, followed by stirring at room temperature for 1 hour. Trifluoroacetic acid was distilled off under reduced pressure, and then the residue was purified by NH silica gel column chromatography (Chromatorex (Fuji Silysia Chemical Co., Ltd.), chloroform-^chloro-form/methanol (10/1)). The resulting amorphous was crystallized from ethyl acetate to obtain 1.23 g of the objective compound.
Pale yellow crystals
Melting point: 199-202°C (with decomposition)
Elemental analysis (for C28H27F3N80 CF3C02H-2H20)
Calcd.(%): C, 51.58; H, 4.62; N, 16.04 Found (%): C, 51.71; H, 4.26; N, 16.13
Example 44 4-(3-carbamoylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}ben- zamide
Step 1 4-[4-(t-butoxycarbonyl)-3-carbamoylpiperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin- 2-ylamino]phenyl}benzamide [0250] This compound was prepared in the same manner as in Example 34, except that 4-[1-(t-butoxycarbonyl)-2-carbamoylpiperazin-4-ylmethyl]-3-trifluoromethylbenzoic acid (Reference Example 16) was used, and that the reaction was conducted at room temperature for 6 hours.
Pale yellow crystals
Melting point: 206-209°C (with decomposition)
Step 2 4-(3-carbamoylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl)ben- zamide [0251] To 1.52 g of 4-[4-(t-butoxycarbonyl)-3-carbamoylpiperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was added 6.0 ml of trifluoroacetic acid, followed by stirring at room temperature for 1 hour. Trifluoroacetic acid was distilled off under reduced pressure, and the residue was dissolved in ethyl acetate, washed in turn with an aqueous saturated sodium hydrogen carbonate solution and water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and then the residue was purified by silica gel column chromatography to obtain 963 mg of the objective compound as pale yellow crystals.
Melting point: 235-238°C Example 45 4-(3-carbamoylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}ben-zamide hydrochloride [0252] This compound was prepared in the same manner as in Example 2, except that 4-(3-carbamoylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 44) was used.
Pale yellow crystals Melting point: 205-208°C
Elemental analysis (for C^h^eFsNgC^'HCM ,3H20)
Calcd. (%): C, 53.47; H, 4.89; N, 19.35 Found (%): C, 53.11; H, 4.92; N, 19.79
Example 46 (-)-4-((S)-3-amino-2-oxopyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- nolphenyljbenzamide
Step 1 4-[(S)-3-(t-butoxycarbonylamino)-2-oxopyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinvl)pyrimi- din-2-ylamino1phenyl}benzamide [0253] Eight hundred mg of 4-[(S)-3-(t-butoxycarbonylamino)-2-oxopyrrolidin-1-ylmethyl]-3-trifluoromethylbenzoic acid (Reference Example 17) was dissolved in 7 ml of anhydrous Ν,Ν-dimethylformamide, and 0.67 ml of N,N-diisopropyl-N-ethylamine and 1.00 g of 1 H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) were added in turn, followed by stirring at room temperature for 30 minutes. 4-Methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]an-iline (Reference Example 18) was added and the mixture was stirred at room temperature for 18 hours. The reaction solution was diluted with water, followed by extraction with ethyl acetate. The organic layer was washed in turn with an aqueous saturated sodium hydrogen carbonate solution and water, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography to obtain 453 mg of the objective compound as a pale yellow amorphous.
Step 2 (-)-4-((S)-3-amino-2-oxopyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phenyl}benzamide [0254] 439 mg of 4-[(S)-3-(t-butoxycarbonylamino)-2-oxopyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamideobtained in the step 1 was added2.0mloftrifluoroaceticacid, followed by stirring at room temperature for 1 hour. Trifluoroacetic acid was distilled off under reduced pressure, and then the residue was dissolved in water and washed with diethyl ether. The mixture was alkalified by adding an aqueous saturated sodium hydrogen carbonate solution to the aqueous layer, followed by extraction with chloroform twice, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and then the residue was purified by silica gel column chromatography, crystallized by adding ethyl acetate to the resulting amorphous and collected by filtration to obtain 244 mg of the objective compound as yellow crystals.
Melting point: 156-159°C (with decomposition) [a]D20: -26.13° (c=0.352, methanol)
Elemental analysis (for C9oH9=F->Nft0'0.5CFIoC09C9FI=O.5FI90)
Calcd. (%): C, 58.53; H, 4.91; N, 18.20 Found (%): C, 58.99; H, 4.88; N, 17.76
Example 47 4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyn-3-trifluoromethvl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- nolphenyl}benzamide [0255] To a solution of 6.00 g of 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide (Reference Example 31) in 60 ml of anhydrous Ν,Ν-dimethylformamide were added 1.51 g of (S)-(-)-3-(dimethylamino)pyrrolidine and 1.83 g of potassium carbonate, followed by stirring at room temperature for 14 hours. To the reaction solution were added water and an aqueous saturated sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography to obtain 4.57 g of pale yellow crystals.
Melting point: 179-183°C (with decomposition)
Example 48 (-)-4-f(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-f4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide hydrochloride [0256] This compound was prepared in the same manner as in Example 2, except that 4-[(S)-3-(dimethylamino)pyr-rolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 47) was used, and that the resulting crude crystals were washed with isopropanol.
Pale yellow crystals
Melting point: 154-158°C (with decomposition) [a]D20: -10.25° (c=0.546, methanol)
Elemental analysis (for ΟοηΗο^οΝοΟΉΟΙ^.δΗρΟ)
Calcd.(%): C, 54.75; H, 5.67; N, 17.03 Found (%): C, 54.72; H, 5.38; N, 16.96
Example 49 4-(3-carbamoyl-4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-f4-(5-pyrimidinvl)pyrimidin-2-vlami- no1phenyl}benzamide [0257] This compound was prepared in the same manner as in Example 47, except that 1-methylpiperazin-2-carbox-amide dihydrochloride (Reference Example 24) was used, and that potassium carbonate was used in an amount of 10 equivalents based on a raw material.
Pale yellow crystals Melting point: 248-253X
Example 50 4-(3-carbamoyl-4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide hydrochloride [0258] This compound was prepared in the same manner as in Example 2, except that 4-(3-carbamoyl-4-methylpiper-azin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 49) was used.
Pale yellow crystals Melting point: 203-208°C
Elemental analysis (for 0'>ηΗ'ίηΡ'ΐΝηΟ?ΉΟΙ·1.7FUO)
Calcd.(%): C, 53.56; H, 5.15; N, 18.74 Found (%): C, 53.53; H, 4.98; N, 18.46
Example 51 4-f(S)-2-(1-pyrrolidinylmethyl)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pvrimidinvl)pyrimidin-2-ylami- no1phenyl}benzamide [0259] This compound was prepared in the same manner as in Example 47, except that (S)-(+)-2-(1-pyrrolidinylme-thyl)pyrrolidine was used.
Pale yellow crystals
Melting point: 147-152°C (with decomposition)
Example 52 (-)-4-[(S)-2-(1-pyrrolidinylmethyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benzamide hydrochloride [0260] This compound was prepared in the same manner as in Example 2, except that 4-[(S)-2-(1-pyrrolidinylme-thyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 51) was used. Pale yellow amorphous [a]D20: -11.00° (c=0.509, methanol)
Elemental analysis (for C33H35F3N80-I-ICIO.5H20)
Calcd. (%): C, 59.86; H, 5.63; N, 16.92 Found (%): C, 59.66; H, 5.89; N, 16.61
Example 53 4-f3-(dimethylaminomethyl)azetidin-1-ylmethvl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- nolphenyDbenzamide [0261] This compound was prepared in the same manner as in Example 47, except that 3-(dimethylaminomethyl)aze-tidine dihydrochloride (Reference Example 25) was used, and that potassium carbonate was used in an amount of 5 equivalents based on a raw material.
Yellow crystals
Melting point: 174-181 °C (with decomposition)
Example 54 4-[3-(dimethylaminomethyl)azetidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no1phenyl)benzamide hydrochloride [0262] This compound was prepared in the same manner as in Example 2, except that 4-[3-(dimethylaminomethyl)aze-tidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 53) was used.
Pale yellow crystals
Melting point: 142-152°C (with decomposition)
Elemental analysis (for ΟοηΗο-^ΝοΟΉΟΙΉρΟ)
Calcd. (%): C, 57.10; H, 5.43; N, 17.76 Found (%): C, 57.41; H, 5.79; N, 17.53
Example 55 4-((S)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}ben- zamide [0263] This compound was prepared in the same manner as in Example 47, except that (S)-(+)-2-methylpiperazine was used.
Yellow crystals Melting point: 193-196°C
Example 56 (+)-4-((R)-3-methylpiperazin-1-ylmethvl)-3-trifluoromethyl-N-{4-methyl-3-f4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyl)benzamide hydrochloride
Step 1 4-((R)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}ben- zamide [0264] This compound was prepared in the same manner as in Example 47, except that (R)-(-)-2-methylpiperazine was used.
Pale yellow crystals
Step 2 (+)-4-((R)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyl}benzamide hydrochloride [0265] This compound was prepared in the same manner as in Example 2, except that 4-((R)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was used.
Yellow crystals
Melting point: 254-258°C
[a]D20: +9.63° (c=0.498, methanol)
Elemental analysis (for CoqHpqFoNoOTHCI O.SCoHcOH HoO)
Calcd. (%): C, 55.85; H, 5.46; N, 17.97 Found (%): C, 55.93; H, 5.33; N, 18.08
Example 57 (-)-4-[(S)-3-(N,N-diethylamino)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methvl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl)benzamide hydrochloride
Step 1 4-[(S)-3-(N,N-diethylamino)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no1phenyl}benzamide [0266] This compound was prepared in the same manner as in Example 47, except that (S)-3-(N,N-diethylamino)pyr-rolidine dihydrochloride (Reference Example 26) was used, and that potassium carbonate was used in an amount of 6 equivalents based on a raw material. Pale yellow crystals
Step 2 (-)-4-[(S)-3-(N,N-diethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide hydrochloride [0267] This compound was prepared in the same manner as in Example 2, exceptthat4-[(S)-3-(N,N-diethylamino)pyr-rolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was used.
Pale yellow crystals
Melting point: 200-202°C
[a]D20: -9.74° (c=0.513, methanol)
Elemental analysis (for 032Η35Ρ3Ν80ΉΟ·2.5Η20)
Calcd.(%): C, 56.01; H, 6.02; N, 16.33 Found (%): C, 56.27; H, 5.94; N, 15.96
Example 58 (-)-4-[(S)-3-(1-pyrrolidinyl)pyrrolidin-1-ylmethyn-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nolphenyljbenzamide hydrochloride
Step 1 4-[(S)-3-(1-pyrrolidinyl)pyrrolidin-1-ylmethyll-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminolphe- nyl}benzamide [0268] This compound was prepared in the same manner as in Example 47, except that (S)-3-(1-pyrrolidinyl)pyrrolidine hydrochloride (Reference Example 27) was used, and that potassium carbonate was used in an amount of 3.8 equivalents based on a raw material.
Yellow crystals
Step 2 (-)-4-[(S)-3-(1-pyrrolidinyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide hydrochloride [0269] This compound was prepared in the same manner as in Example 2, except that 4-[(S)-3-(1-pyrrolidinyl)pyrrolidin- 1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was used.
Yellow crystals
Melting point: 168-171°C
[a]D20: -12.20° (c=1.016, methanol)
Elemental analysis (for CopHooFoNoOHCl-SHoO)
Calcd. (%): C, 55.45; H, 5.82; N, 16.17 Found (%): C, 55.44; H, 5.48; N, 16.06
Example 59 4-[(3S,4S)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino1phenyl}benzamide hydrochloride
Step 1 4-[(3S,4S)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi- din-2-ylamino1phenyl}benzamide [0270] This compound was prepared in the same manner as in Example 47, except that (3S,4S)-3-(dimethylamino)-4-methoxypyrrolidine dihydrochloride (Reference Example 28) was used, and that potassium carbonate was used in an amount of 5 equivalents based on a raw material.
Pale yellow crystals
Melting point: 187-190°C (with decomposition)
Step 2 4-[(3S,4S)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino]phenyl}benzamide hydrochloride [0271] This compound was prepared in the same manner as in Example 2, except that 4-[(3S,4S)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza-mide obtained in the step 1 was used. The crude crystals were washed with isopropanol.
Pale yellow crystals
Melting point: 155-161 °C (with decomposition)
Elemental analysis (for C3-jH33F3NgOI-ICIO.2i-PrOI-M.5H2O)
Calcd. (%): C, 55.64; H, 5.70; N, 16.43
Found (%): C, 55.59; H, 5.37; N, 16.69 Example 60 (-)-4-[(2R,4S)-4-(dimethylamino)-2-methvlpvrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phenyl}benzamide hydrochloride
Step 1 4-[(2R,4S)-4-(dimethylamino)-2-methylpyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi- din-2-ylamino1phenyl>benzamide [0272] This compound was prepared in the same manner as in Example 47, except that (2R,4S)-4-(dimethylamino)- 2-methylpyrrolidine dihydrochloride (Reference Example 29) was used, and that potassium carbonate was used in an amount of 5 equivalents based on a raw material. Pale yellow crystals
Step 2 (-)-4-[(2R,4S)-4-(dimethylamino)-2-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino1phenyl}benzamide hydrochloride [0273] This compound was prepared in the same manner as in Example 2, except that 4-[(2R,4S)-4-(dimethylamino)- 2-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was used.
Yellow crystals
Melting point: 188-193°C
[a]D20: -51.87° (c=0.347, methanol)
Elemental analysis (for 0ο·|ΗοοΡοΝο0Ή0Ι·0.50?Η.=0Η·2Ηο0)
Calcd. (%): C, 55.23; H, 6.13; N, 16.62 Found (%): C, 55.42; H, 6.10; N, 16.96
Example 61 4-((S)-3-aminopiperidinomethyl)-3-trifluoromethyl-N-{4-methyl-3-f4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benza- mide
Step 1 4-[(S)-3-(t-butoxycarbonylamino)piperidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2- ylamino]phenyl}benzamide [0274] This compound was prepared in the same manner as in Example 47, except that (S)-(-)-3-(t-butoxycarbonylami-no)piperidine (Synthetic Communications, 1998, 28, 3919-3926) was used.
Pale yellow amorphous
Step 2 4-((S)-3-aminopiperidinomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza- mide [0275] This compound was prepared in the same manner as in Example 46 (Step 2), except that 4-[(S)-3-(t-butoxy-carbonylamino)piperidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}ben-zamide obtained in the step 1 was used, and that extraction was conducted with a mixed solution of chloroform-methanol (10:1), the solvent was distilled off, and then the resulting crude crystals were washed with diethyl ether.
Pale yellow crystals Melting point: 163-167°C
Example 62 (+)-4-((S)-3-aminopiperidinomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}ben-zamide hydrochloride [0276] This compound was prepared in the same manner as in Example 2, except that 4-((S)-3-aminopiperidinomethyl)- 3- trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 61) was used.
Pale yellow crystals
Melting point: 193-199°C [a]D20: +28.31° (c=0.438, methanol)
Elemental analysis (for 029Η29Ρ3Ν8ΟΉ0Ι·2.1Η2Ο)
Calcd.(%): C, 54.69; H, 5.41; N, 17.59 Found (%): C, 54.33; H, 5.40; N, 18.05
Example 63 4- [(S)-3-(dimethylamino)piperidinomethyl1-3-trifluoromethvl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyl}benzamide [0277] To a suspension of 1.47 g of 4-((S)-3-aminopiperidinomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidi-nyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 61) in 30 ml of methanol were added in turn 3 ml of acetic acid, 2 ml of a 37% aqueous formaldehyde solution and 1.66 g of sodium triacetoxy borohydride, followed by stirring at room temperature for 14 hours. The mixture was alkalified by adding an aqueous saturated sodium hydrogen carbonate solution to the reaction solution, extracted with ethyl acetate twice. The organic layers were combined, washed with water, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.62 g of the objective compound as pale yellow crystals.
Melting point: 160-162°C Example 64 (+)-4-[(S)-3-(dimethylamino)piperidinomethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no1phenyl)benzamide hydrochloride [0278] This compound was prepared in the same manner as in Example 2, except that 4-[(S)-3-(dimethylamino)pip-eridinomethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 63) was used, and that the resulting crude crystals were washed with acetone. Pale yellow crystals
Melting point: 195-198°C [a]D20: +15.92° (c=0.314, methanol)
Elemental analysis (for 031Η33Ρ3Ν8ΟΉ02Η20)
Calcd. (%): C, 56.15; H, 5.78; N, 16.90 Found (%): C, 55.45; H, 5.80; N, 17.30
Example 65 4-((3S,4R)-3-amino-4-methylpyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phenyl}benzamide
Step 1 4-[(3S,4R)-3-(t-butoxycarbonyl)amino-4-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidi- nyl)pyrimidin-2-ylamino1phenyl}benzamide [0279] This compound was prepared in the same manner as in Example 47, except that (3S,4R)-3-(t-butoxycarbo-nyl)amino-4-methylpyrrolidine (Tetrahedron: Asymmetry, 1997, 8, 883-887) was used.
Pale yellow crystals Melting point: 191-201 °C
Step 2 4-((3S,4R)-3-amino-4-me.thylpyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pvrimidinyl)pyrimidin-2-ylami- no1phenyl)benzamide [0280] This compound was prepared in the same manner as in Example 46 (Step 2), except that 4-[(3S,4R)-3-(t-butoxycarbonyl)amino-4-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was used, and that extraction was conducted with a mixed solution of chloroform-methanol (10:1).
Pale yellow crystals
Melting point: 148-155°C (with decomposition)
Example 66 4-[(3S,4R)-3-(dimethylamino)-4-methylpyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi- din-2-ylamino1phenyl}benzamide [0281] This compound was prepared in the same manner as in Example 63, except that 4-((3S,4R)-3-amino-4-meth-ylpyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 65) was used.
Pale yellow crystals
Melting point: 153-156°C (with decomposition)
Example 67 (-)-4-[(3S,4R)-3-(dimethylamino)-4-methylpyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methvl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino1phenyl}benzamide hydrochloride [0282] This compound was prepared in the same manner as in Example 2, except that 4-[(3S,4R)-3-(dimethylamino)-4-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 66) was used.
Pale yellow crystals
Melting point: 164-174°C (with decomposition) [a]D20: -2.43° (c=0.493, methanol)
Elemental analysis (for C31H33F3N80-I-ICIO.5H20)
Calcd. (%): C, 58.53; H, 5.55; N, 17.62 Found (%): C, 58.50; H, 5.73; N, 17.38
Example 68 (-)-4-[(S)-3-(methylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phenyl}benzamide
Step 1 4-{(S)-3-[N-(t-butoxycarbonyl)-N-methylamino1pyrrolidin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidi- nyl)pyrimidin-2-ylamino]phenyl}benzamide [0283] This compound was prepared in the same manner as in Example 47, except that (S)-3-[N-(t-butoxycarbonyl)-N-methylamino]pyrrolidine (Reference Example 30) was used.
Yellow crystals
Step 2 (-)-4-[(S)-3-(methylamino)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phenyl}benzamide [0284] 0.99 g of 4-{(S)-3-[N-(t-butoxycarbonyl)-N-methylamino]pyrrolidin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl- 3- [4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was dissolved in 15 ml of dichlorometh-ane and 10 ml of trifluoroacetic acid was added, followed by stirring at room temperature for 1 hour. The reaction solution was neutralized with a 20% aqueous sodium hydroxide solution and followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate, and then the solvent was distilled ofF under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.70 g of the objective compound as flesh-colored crystals. Melting point: 142-149°C (with decomposition) [a]D20: -7.14° (c=1.007, methanol)
Elemental analysis (for C2gH29F3N8O HCI 0.6H2O)
Calcd. (%): C, 66.75; H, 5.31; N, 19.54 Found (%): C, 66.78; H, 5.30; N, 19.37
Example 69 (-)-4-((S)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyljbenzamide hydrochloride
Step 1 4- ((S)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide [0285] This compound was prepared in the same manner as in Example 63, except that 4-((S)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 55) was used.
Yellow crystals Step 2 (-)-4-((S)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide hydrochloride [0286] This compound was prepared in the same manner as in Example 2, except that 4-((S)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide obtained in the step 1 was used.
Yellow crystals
Melting point: 187-193°C
[a]D20: -5.27° (c=0.379, methanol)
Elemental analysis (for Ο30Η31Ρ3Ν8ΟΉΟΙ·2.6Η2Ο)
Calcd. (%): C, 54.60; H, 5.68; N, 16.98 Found (%): C, 54.46; H, 5.46; N, 16.81
Example 70 4-((R)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe- nyl}benzamide [0287] This compound was prepared in the same manner as in Example 63, except that 4-((R)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 56 (Step 1)) was used.
Yellow powder
Melting point: 246-249°C (with decomposition)
Example 71 (+)-4-((R)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyl}benzamide hydrochloride [0288] This compound was prepared in the same manner as in Example 2, except that 4-((R)-3,4-dimethylpiperazin- 1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 70) was used.
Pale yellow crystals
Melting point: 186-194°C
[a]D20: +5.42° (c=0.369, methanol)
Elemental analysis (for ConH^FoNoO-HClO^CpHcOH^I-UO) Calcd. (%): C, 54.77; H, 5.88; N, 17.04 Found (%): C, 55.04; H, 5.65; N, 16.74
Example 72 4-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl1piperazin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)py-rimidin-2-ylamino]phenyl}benzamide
Step 1 4-(bromomethyl)-5-methyl-1,3-dioxol-2-one [0289] To 403 mg of 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one and 525 mg of sodium bromide was added 0.8 ml of anhydrous Ν,Ν-dimethylformamide, followed by at room temperature for 1.5 hours. To the reaction solution was added 1.2 ml anhydrous acetone, the mixture was further stirred at room temperature for 1 hour, and then insolubles were removed by filtration. Insolubles were washed three times with 0.8 ml of anhydrous acetone, and the resulting pale yellow solution was used in the next reaction.
Step 2 4-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl1piperazin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)py-rimidin-2-ylamino1phenyl}benzamide [0290] To a suspension of 1.22 g of 4-(piperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino]phenyl}benzamide (Reference Example 32) in 5 ml of anhydrous Ν,Ν-dimethylformamide was added 222 mg of potassium hydrogen carbonate, and a solution of 4-(bromomethyl)-5-methyl-1,3-dioxol-2-one obtained in the step 1 in acetone was added dropwise under stirring at room temperature. After stirring at room temperature for 10 hours, the reaction solution was diluted with water and followed by extraction with ethyl acetate five times. The organic layers were washed with water, and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 1.00 g of the objective compound as a pale yellow amorphous.
Example 73 4-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)py-rimidin-2-ylamino]phenyl}benzamide hydrochloride [0291] This compound was prepared in the same manner as in Example 2, except that 4-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide (Example 72) was used, and that the resulting crude crystals were washed with methanol.
Pale yellow crystals
Melting point: 218-226°C (with decomposition)
Elemental analysis (for C33H31F3N804 l-ICI'3l-l20)
Calcd. (%): C, 56.86; H, 4.63; N, 16.07 Found (%): C, 56.55; H, 4.70; N, 16.14
Example 74 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(4-pyridyl)thiazol-2-ylamino]phenyl}benzamide [0292] To 697 mg of 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-[4-methyl-3-(thioureido)phenyl]benzamide (Reference Example 33) were added in turn 3 ml of ethanol, 1.5 ml of water and 1.5 ml of 1 N hydrochloric acid, and the mixture was heated in an oil bath at 65°C. 6 ml of an aqueous solution of 421 mg of 4-(bromoacetyl)pyridine
hydrobromide (J. Heterocycl. Chem., 1970, 7, 1137-1141) was added thereto, and the mixture was stirred for 2 hours. After air-cooling the reaction solution, the reaction solution was diluted with water, alkalified by adding an aqueous saturated sodium hydrogen carbonate solution, followed by extraction with ethyl acetate and dried over anhydrous magnesium sulfate. Then, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 701 mg of the objective compound as colorless crystals. Melting point: 226-227°C
Example 75 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(4-pyridyl)thiazol-2-ylamino1phenyl}benzamide hydrochloride [0293] This compound was prepared in the same manner as in Example 2, except that 4-(4-methylpiperazin-1-ylme-thyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(4-pyridyl)thiazol-2-ylamino]phenyl}benzamide (Example 74) was used.
Pale yellow crystals Melting point: 186-188°C
Elemental analysis (for C2gH2gF3N60S HCI-H20)
Calcd. (%): C, 56.08; H, 5.19; N, 13.53 Found (%): C, 56.37; H, 5.26; N, 13.25
Example 76 4-[3-(dimethylamino)azetidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe- nyljbenzamide [0294] This compound was prepared in the same manner as in Example 47, except that 3-(dimethylamino)azetidine dihydrochloride (Reference Example 34) was used, and that potassium carbonate was used in an amount of 5 equivalents based on a raw material.
Yellow crystals
Melting point: 169-173°C (with decomposition)
Example 77 4-f3-(dimethylamino)azetidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phe-nyDbenzamide hydrochloride [0295] This compound was prepared in the same manner as in Example 2, except that 4-[3-(dimethylamino)azetidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 76) was used.
Pale yellow crystals
Melting point: 159-167°C (with decomposition)
Elemental analysis (for C29H29F3N8OTHCITH20)
Calcd.(%): C, 56.45; H, 5.23; N, 18.16 Found (%): C, 56.35; H, 5.04; N, 17.90
Example 78 4-[(R)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2- ylamino]phenyl}benzamide [0296] This compound was prepared in the same manner as in Example 47, except that (S)-3-(dimethylaminome-thyl)pyrrolidine dihydrochloride (Reference Example 35) was used, and that potassium carbonate was used in an amount of 5 equivalents based on a raw material.
Yellow crystals
Melting point: 159-164°C (with decomposition)
Example 79 4-[(R)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyll-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino1phenyl}benzamide hydrochloride [0297] This compound was prepared in the same manner as in Example 2, except that 4-[(R)-3-(dimethylaminome-thyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 78) was used, and that the crude crystals were washed with isopropanol.
Pale yellow crystals
Melting point: 114-122X (with decomposition)
Elemental analysis (for Ο31Η33Ρ3Ν8Ο·ΗΟΙ·0.5Ι-ΡγΟΗ·0.5Η2Ο)
Calcd. (%): C, 58.61; H, 5.97; N, 16.67 Found (%): C, 58.73; H, 5.87; N, 16.31
Example 80 4-[(S)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2- ylamino]phenyl}benzamide [0298] This compound was prepared in the same manner as in Example 47, except that (R)-3-(dimethylaminome-thyl)pyrrolidine dihydrochloride (Reference Example 36) was used, and that potassium carbonate was used in an amount of 5 equivalents based on a raw material.
Yellow crystals
Melting point: 158-163°C (with decomposition)
Example 81 4-[(S)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide hydrochloride [0299] This compound was prepared in the same manner as in Example 2, except that 4-[(S)-3-(dimethylaminome-thyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide (Example 80) was used, and that the crude crystals were washed with isopropanol.
Pale yellow crystals
Melting point: 114-122°C (with decomposition)
Elemental analysis (for Ο,-,Η,,Ρ,ΝοΟΗΟΙΟ.δί-ΡΓΟΗΟ^Η,Ο) Calcd. (%): C, 59.08; H, 5.86; N, 16.96 Found (%): C, 59.02; H, 5.79; N, 16.62
Example 82 4-[(3R,4R)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi- din-2-ylamino]phenyl}benzamide [0300] This compound was prepared in the same manner as in Example 47, except that (3R,4R)-3-(dimethylamino)-4-methoxypyrrolidine dihydrochloride (Reference Example 37) was used, and that potassium carbonate was used in an amount of 5 equivalents based on a raw material.
Pale yellow crystals Melting point: 185-188°C
Example 83 4-[(3R,4R)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino]phenyl}benzamide hydrochloride [0301] This compound was prepared in the same manner as in Example 2, except that 4-[(3R,4R)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benza-mide (Example 82) was used, and that the crude crystals were washed with isopropanol.
Pale yellow crystals
Melting point: 166-170°C
Elemental analysis (for 03ΐΗ33Ρ3Ν80·Η0Ι·1.5H20)
Calcd. (%): C, 55.56; H, 5.57; N, 16.72 Found (%): C, 55.53; H, 5.19; N, 16.77
Example 84 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethyl-N-{4-methvl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl>benzamide [0302] This compound was prepared in the same manner as in Example 1, except that 4-methyl-3-[4-(3-pyridyl)pyri-midin-2-ylamino]aniline (Patent Document 1) and 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethylbenzoyl chloride hydrochloride (Reference Example 11) were used.
Example 85 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino1phenyl)benza- mide [0303] This compound was prepared in the same manner as in Example 1, except that 4-methyl-3-[4-(3-pyridyl)pyri-midin-2-ylamino]aniline (Patent Document 1) and 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethylbenzoyl chloride hydrochloride (Reference Example 7) were used.
Example 86 4-[(R)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyl1-3-trifluoromethyl-N-{4-methvl-3-[4-(3-pyridyl)pyrimidin-2-ylami- no1phenyl}benzamide [0304] This compound was prepared in the same manner as in Example 47, except that 4-(bromomethyl)-3-trifluor-omethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide (Reference Example 82) and (S)-3-(dimeth-ylaminomethyl)pyrrolidine dihydrochloride (Reference Example 35) were used, and that potassium carbonate was used in an amount of 5 equivalents based on a raw material.
[0305] Structural formulas of Examples 1 to 86 are shown in Table 2.
[Table 2]
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
Test Example 1
Cell growth inhibitory effect [0306] K562 cells and U937 cells (purchased from American Type Culture Collection) were cultured in a RPMI-1640 medium (manufactured by Sigma) containing 10% (v/v) fetal calf serum (FCS) (manufactures by Sigma) (RPMI-1640/FCS). K562 cells and U937 cells were seeded at a density of 5000 cells/100 μΙ/well and 4000 cells/100 μΙ/well in each of 96-hole-plate (manufactured by costar), respectively. The plate was incubated in a C02 incubator overnight. A test drug was prepared with dimethylsulfoxide (DMSO) (manufactured by Nacalai Tesque) in the concentration 1000 times higher than the test concentration (0, 0.00001 to 1 (μΜ). The resulting solution was diluted 500 times in a RPMI-1640/FCS medium and then 100 μΙ of the diluent was added in a well. The plate was incubated in a C02 incubator. After 72 hours, 20 μΙ of Cell counting Kit-8 (5 mmol/l WST-8, 0.2 mmol/l 1-Methoxy PMS, 150 mmol/l NaCI) (manufactured by Dojindo) was added to each well. After reaction for color development in a C02 incubator for 3 hours, an absorbance of form azan, generated by reduction of WST-8 was determined at450nm using Multilevel counter ARVOsx (manufactured by Wallac).
[0307] In the RPMI-1640/FCS medium containing 0.1% DMSO, when absorbance of a region in which cells after culturing in the C02 incubator for 72 hours were seeded is defined as a cell growth inhibition rate of 0% and absorbance of a region in which cells were not seeded is defined as a cell growth inhibition rate of 100%, a log cone value in terms of log (inhibition rate/(100- inhibition rate)) and a plotted IC50 value (μΜ) were calculated. The results are shown in Table 3.
[0308] As a control drug, 4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phe-nyljbenzamide (see Patent Document 1) was used.
[Table 31
(continued)
[0309] As is apparent from the results shown in Table 3, the compounds of the present invention have cell growth inhibitory effect usually stronger compared to a control drug. Further, K562 cells used in Test Example 1 were BCR-ABL positive cells, which had been collected from pleural effusion in a late chronic myelogenous leukemia patient who had been subjected to acute transformation. U937 cells were malignant BCR-ABL negative cells that had been collected from a patient of histiocytic lymphoma. As is apparent from the cell growth inhibitory ratio (U937 cells/K562 cells), the compounds of the present invention are drugs having higher safety (20 times to 8000 times or more) than a control drug. Furthermore, the compounds of the present invention have also a cell growth inhibitory effect on E255K expressing cells, and therefore it can be expected that they exhibit adequate self-phosphorylation inhibitory effect on mutant kinases that would be found in the future. Accordingly, the compounds of the present invention are very useful as a therapeutic agent for use in the treatment of diseases such as chronic myelogenous leukemia, acute lymphoblastic leukemia and acute myelogenous leukemia.
Formulation Example 1 [0310]
Tablet (oral tablet)
Formulation/tablet (in 80 mg)
Compound of Example 1 5.0 mg
Corn Starch 46.6 mg
Crystalline cellulose 24.0 mg
Methyl cellulose 4.0 mg
Magnesium stearate 0.4 mg [0311] The mixed powder of this composition is compressed by a conventional method and molded to make oral tablets. Formulation Example 2
Tablet (oral tablet)
Formulation/tablet (in 80 mg)
Compound of Example 2 5.0 mg
Corn Starch 46.6 mg
Crystalline cellulose 24.0 mg
Methyl cellulose 4.0 mg
Magnesium stearate 0.4 mg [0312] The mixed powder of this composition is compressed by a conventional method and molded to make oral tablets. Industrial Applicability [0313] As described above, since the compound of the present invention is a compound having excellent BCR-ABL tyrosine kinase inhibitory activity, a pharmaceutical composition comprising the compound of the present invention as an active ingredient is useful as a BCR-ABL tyrosine kinase inhibitor, a therapeutic agent for use in treating chronic myelogenous leukemia, a therapeutic agent for use in treating acute myelogenous leukemia and a therapeutic agent for use in treating acute lymphoblastic leukemia for mammals including humans.
Claims 1. An amide derivative, which is a compound represented by the following general formula [1] in any of the following cases (A) or (C), or a pharmaceutically acceptable salt thereof: [Chemical 19] wherein
(A) R1 represents any of groups of the following (1) through (3): (1) -CH2-R11 [R11 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group is mandatorily substituted by a group selected from the group consisting of oxo, -CH2-R111(R111 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, di-alkylaminoalkyl, alkoxy and (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, and may be further optionally substituted by 1 or 2 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcar-bamoyl and dialkylcarbamoyl]; (2) -O-R12 [R12 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group may be substituted by 1 to 3 same or different members selected from the group consisting of oxo, -CH2-R121 (R121 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl]; and (3) -CH=R13 [R13 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group may be substituted by 1 to 3 same or different members selected from the group consisting of oxo, -CH2-R131 (R131 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl]; R2 represents alkyl, halogen, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyl, amino, monoalkylamino, dialkylamino, nitro, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl or cyano; R3 represents hydrogen, halogen or alkoxy;
Het1 represents any of groups of the following chemical formulas [2] to [8]: [Chemical 20]
Het2 represents pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1,2-dihydropropyridazinyl, (the Het2 may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, halogen and amino); excluding compounds wherein R11 is pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, whereby each of the pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is substituted by a group selected from the group consisting ofoxo, -CH2-R111 (R111 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy and (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, and further, may be substituted by 1 or 2 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl; Het1 is a group of the formula [6]; and Het2 is pyrazinyl or pyridyl which may be substituted by alkyl; (C) R1 represents any of groups of the following (1) through (3): (1) -CH2-R11 [R11 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group is substituted by a group selected from the group consisting ofoxo, -CH2-R111 (R111 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxy and (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, and further, may be substituted by 1 or 2 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl]; (2) -0-R12 [R12 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group may be substituted by 1 to 3 same or different members selected from the group consisting of oxo, -CH2-R121 (whereby R121 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylami-noalkyl, dialkylaminoalkyl, alkoxy, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl]; and (3) -CH=R13 [R13 represents a saturated, nitrogen-containing heterocyclic group, whereby the saturated, nitrogen-containing heterocyclic group may be substituted by 1 to 3 same or different members selected from the group consisting of oxo, -CH2-R131 (R131 represents a saturated, nitrogen-containing heterocyclic group), a saturated, nitrogen-containing heterocyclic group, aminoalkyl, monoalkylami-noalkyl, dialkylaminoalkyl, alkoxy, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl]; R2 represents alkyl, halogen, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyl, amino, monoalkylamino, dialkylamino, nitro, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl or cyano; R3 represents hydrogen, halogen or alkoxy;
Het1 represents any of groups of the following chemical formulas [9] and [10]: [Chemical 22]
Het2 represents pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1,2-dihydropyridazinyl, whereby the Het2 may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, halogen and amino. 2. The amide derivative according to claim 1, which is a compound selected from the group consisting of the following compounds (1) to (7), or a pharmaceutically acceptable salt thereof: (1) (-)-4-((S)-3-amino-2-oxopyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (2) 4-[(S)-2-(1-pyrrolidinylmethyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phenyl}benzamide, (3) 4-[3-(dimethylaminomethyl)azetidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (4) 4-[(S)-3-(1-pyrrolidinyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (5) 4-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-ylmethyl}-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (6) 4-[(S)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phenyl}benzamide, and (7) 4-[(3R, 4R)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyri-midinyl)pyrimidin-2-ylamino]phenyl}benzamide. 3. The amide derivative which is a compound selected from the group consisting of the following compounds (1) to (44), or a pharmaceutically acceptable salt: (1) 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamide, (2) 3-ethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}ben-zamide, (3) 4-(1-methylpiperidin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide, (4) 3,5-dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimdin-2-ylamino]phenyl}benzamide, (5) 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methyl-phenyljbenzamide, (6) 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide, (7) 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-meth-ylphenyljbenzamide, (8) 3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}ben-zamide, (9) 3-fluoromethyl-4-(1-methylpiperidin-4-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide, (10) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phe-nyljbenzamide, (11) 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phe-nyljbenzamide, (12) 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phe-nyljbenzamide, (13) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phe-nyljbenzamide, (14) 4-[4-(2-fluoroethyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide, (15) 4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide, (16) 4-[(R)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (17) 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphe-nyljbenzamide, (18) 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridine-2-ylamino]phenylJbenza-mide, (19) 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenylJben-zamide, (20) 4-(3-carbamoylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimdin-2-ylami-nojphenyljbenzamide, (21) 4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (22) 4-(3-carbamoyl-4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (23) 4-((S)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (24) 4-((R)-3-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (25) 4-[(S)-3-(N,N-diethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino]phenyl}benzamide, (26) 4-[(2R, 4S)-4-(dimethylamino)-2-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyri-midinyl)pyrimidin-2-ylamino]phenyl}benzamide, (27) 4-((S)-3-aminopiperidinomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (28) 4-[(S)-3-(dimethylamino)piperidinomethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide, (29) 4-((3S, 4R)-3-amino-4-methylpyrrolidin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phenyl}benzamide, (30) 4-[(3S, 4R)-3-(dimethylamino)-4-methylpyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyri-midinyl)pyrimidin-2-ylamino]phenyl}benzamide, (31) 4-[(S)-3-(methylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (32) 4-((S)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (33) 4-((R)-3,4-dimethylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, (34) 4-[(3R, 4R)-3-(dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyri-midinyl)pyrimidin-2-ylamino]phenyl}benzamide, (35) 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phe-nyljbenzamide, (36) 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylami-no]phenyl}benzamide, (37) 4-[(R)-3-(dimethylaminomethyl)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimi-din-2-ylamino]phenyl}benzamide, (38) 4-(1-methylpiperazin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]phe-nyljbenzamide, (39) 4-(1-methylpiperazin-4-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylami-nojphenyljbenzamide, (40) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(4-pyridyl)thiazol-2-ylamino]phe-nyljbenzamide, (41) 4-[(R)-3-(dimethylaminomethyl)pyrrolidine-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidi-nyl)pyrimidin-2-ylamino]phenyl}benzamide, (42) 4-(1-methylpiperidin-4-ylidenemethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-nojphenyljbenzamide, (43) 4-(1-methylpiperidin-4-yloxy)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamide, and (44) 4-[3-(dimethylamino)azetidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylaminojphenyljbenzamide. 4. A pharmaceutical composition comprising the amide derivative of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof as an active ingredient. 5. A BCR-ABL tyrosine kinase inhibitor comprising the amide derivative of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof as an active ingredient. 6. A therapeutic agent for use in treating chronic myelogenous leukemia comprising the amide derivative of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof as an active ingredient. 7. A therapeutic agent for use in treating acute lymphoblastic leukemia comprising the amide derivative of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof as an active ingredient. 8. A therapeutic agent for use in treating acute myelogenous leukemia comprising the amide derivative of any one of claims 1 to 3 or a salt thereof as an active ingredient.
Patentansprüche 1. Ein Amid-Derivat, welches eine Verbindung ist, dargestellt durch die folgende allgemeine Formel [1] in einem der folgenden Fälle (A) oder (C), oder ein pharmazeutisch verträgliches Salz davon: [Chemische Formel 19]
wobei (A) R1 eine der Gruppen der folgenden (1 ) bis (3) ist: (1) -CH2-R11 [R11 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe, wobei die gesättigte, Stickstoff enthaltende heterocyclische Gruppe zwingend mit einer Gruppe ausgewählt aus der Gruppe bestehend aus Oxo, -CH2-R111 (R111 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe), einer gesättigten, Stickstoff enthaltenden heterocyclischen Gruppe, Aminoalkyl, Monoalkyl-aminoalkyl, Dialkylaminoalkyl, Alkoxy und (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl substituiert ist, und weiter gegebenenfalls mit 1 oder 2 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Alkyl, Alkoxycarbonyl, Halogen, Haloalkyl, Hydroxyalkyl, Amino, Monoalkylamino, Di-alkylamino, Carbamoyl, Monoalkylcarbamoyl und Dialkylcarbamoyl substituiert sein kann]; (2) -O-R12 [R12 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe, wobei die gesättigte, Stickstoff enthaltende heterocyclische Gruppe mit 1 bis 3 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Oxo, -CH2-R121 (R121 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe), einer gesättigten, Stickstoff enthaltenden heterocyclischen Gruppe, Aminoalkyl, Monoalkylaminoalkyl, Dialkylaminoalkyl, Alkoxy, (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl, Alkyl, Alkoxycarbonyl, Halogen, Haloalkyl, Hydroxyalkyl, Amino, Monoalkylamino, Dialkylamino, Carbamoyl, Monoalkylcarbamoyl und Dialkylcarbamoyl substituiert sein kann]; und (3) -CH=R13 [R13 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe, wobei die gesättigte, Stickstoff enthaltende heterocyclische Gruppe mit 1 bis 3 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Oxo, -CH2-R131 (R131 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe), einer gesättigten, Stickstoff enthaltenden heterocyclischen Gruppe, Aminoalkyl, Monoalkylaminoalkyl, Dialkylaminoalkyl, Alkoxy, (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl, Alkyl, Alkoxycarbonyl, Halogen, Haloalkyl, Hydroxyalkyl, Amino, Monoalkylamino, Dialkylamino, Carbamoyl, Monoalkylcarbamoyl und Dialkylcarbamoyl substituiert sein kann]; R2 Alkyl, Halogen, Haloalkyl, Hydroxyalkyl, Alkoxy, Alkoxyalkyl, Alkoxycarbonyl, Acyl, Amino, Monoalkylamino, Dialkylamino, Nitro, Carbamoyl, Monoalkylcarbamoyl, Dialkylcarbamoyl oderCyano ist; R3 Wasserstoff, Halogen oder Alkoxy ist;
Heti eine der Gruppen der folgenden chemischen Formeln [2] bis [8] ist: [Chemische Formel 20]
Het2 Pyridyl, Pyrimidinyl, Pyrazinyl, Pyridazinyl oder 1,2-Dihydropropyridazinyl ist, (Het2 kann mit 1 bis 3 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Alkyl, Halogen und Amino substituiert sein); aussgeschlossen Verbindungen, wobei R11 Pyrrolidinyl, Piperidinyl, Piperazinyl oder Morpholinyl ist, wobei jedes von Pyrrolidinyl, Piperidinyl, Piperazinyl und Morpholinyl substituiert ist mit einer Gruppe ausgewählt aus der Gruppe bestehend aus Oxo, -CH2-R111 (R111 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe), einer gesättigten, Stickstoff enthaltenden heterocyclischen Gruppe, Aminoalkyl, Monoal-kylaminoalkyl, Dialkylaminoalkyl, Alkoxy und (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl, und weiterhin, substituiert sein kann mit 1 oder 2 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Alkyl, Alkoxycarbonyl, Halogen, Haloalkyl, Hydroxyalkyl, Amino, Monoalkylamino, Dialkylamino, Carbamoyl, Monoalkylcarbamoyl und Dialkylcarbamoyl; Heti eine Gruppe der Formel [6] ist; und Het2 Pyrazinyl oder Pyridyl ist, welches mit Alkyl substituiert sein kann; (C) R1 eine der Gruppen der folgenden (1 ) bis (3) ist: (1) -CH2-R11 [R11 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe, wobei die gesättigte, Stickstoff enthaltende heterocyclische Gruppe substituiert ist mit einer Gruppe ausgewählt bestehend aus Oxo, -CH2-R111 (R111 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe), einer gesättigten, Stickstoff enthaltenden heterocyclischen Gruppe, Aminoalkyl, Monoalkylaminoalkyl, Dialkylaminoalkyl, Alkoxy und (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl und weiterhin substituiert sein kann mit 1 oder 2 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Alkyl, Alkoxycarbonyl, Halogen, Haloalkyl, Hydroxyalkyl, Amino, Monoalkylamino, Dialkylamino, Carbamoyl, Monoalkylcarbamoyl und Dialkylcarbamoyl]; (2) -O-R12 [R12 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe, wobei die gesättigte, Stickstoff enthaltende heterocyclische Gruppe substituiert sein kann mit 1 bis 3 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Oxo, -CH2-R121 (wobei R121 eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe ist), einer gesättigten, Stickstoff enthaltenden heterocyclischen Gruppe, Aminoalkyl, Monoalkylaminoalkyl, Dialkylaminoalkyl, Alkoxy, (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl, Alkyl, Alkoxycarbonyl, Halogen, Haloalkyl, Hydroxyalkyl, Amino, Monoalkylamino, Dialkylamino, Carbamoyl, Monoalkylcarbamoyl und Dialkylcarbamoyl]; und (3) -CH=R13 [R13 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe, wobei die gesät- tigte, Stickstoff enthaltende heterocyclische Gruppe substituiert sein kann mit 1 bis 3 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Oxo, -CH2-R131 (R131 ist eine gesättigte, Stickstoff enthaltende heterocyclische Gruppe), einer gesättigten, Stickstoff enthaltenden heterocyclischen Gruppe, Aminoalkyl, Monoalkylaminoalkyl, Dialkylaminoalkyl, Alkoxy, (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl, Alkyl, Alkoxycarbonyl, Halogen, Haloalkyl, Hydroxyalkyl, Amino, Monoal-kylamino, Dialkylamino, Carbamoyl, Monoalkylcarbamoyl und Dialkylcarbamoyl]; R2 Alkyl, Halogen, Haloalkyl, Hydroxyalkyl, Alkoxy, Alkoxyalkyl, Alkoxycarbonyl, Acyl, Amino, Monoalkyl-amino, Dialkylamino, Nitro, Carbamoyl, Monoalkylcarbamoyl, Dialkylcarbamoyl oderCyano ist; R3 Wasserstoff, Halogen oder Alkoxy ist;
Heti einer der Gruppen der folgenden chemischen Formeln [9] und [10] ist: [Chemische Formel 22]
Het2 Pyridyl, Pyrimidinyl, Pyrazinyl, Pyridazinyl oder 1,2-Dihydropyridazinyl ist, wobei Het2 substituiert sein kann mit 1 bis 3 gleichen oder verschiedenen Vertretern ausgewählt aus der Gruppe bestehend aus Alkyl,
Halogen und Amino. 2. Das Amid-Derivat gemäß Anspruch 1, welches eine Verbindung ausgewählt aus der Gruppe bestehend aus den folgenden Verbindungen (1) bis (7), oder einem pharmazeutisch verträglichen Salz davon ist: (1) (-)-4-((S)-3-Amino-2-oxopyrrolidin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamid, (2) 4-[(S)-2-(1-Pyrrolidinylmethyl)pyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino]phenyl}benzamid, (3) 4-[3-(Dimethylaminomethyl)azetidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamid, (4) 4-[(S)-3-(1-Pyrrolidinyl)pyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yl-amino]phenyl}benzamid, (5) 4-{4-[(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-ylmethyl}-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyri-midinyl)pyrimidin-2-ylamino]phenyl}benzamid, (6) 4-[(S)-3-(Dimethylaminomethyl)pyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phenyl}benzamid, und (7) 4-[(3R, 4R)-3-(Dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimi-dinyl)pyrimidin-2-ylamino]phenyl}benzamid. 3. Das Amid-Derivat, welches eine Verbindung ausgewählt aus der Gruppe bestehend aus den folgenden Verbindungen (1) bis (44) ist, oder einem pharmazeutisch verträglichen Salz davon: (1) 3-Difluormethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyl}benzamid, (2) 3-Ethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benz-amid, (3) 4-(1-Methylpiperidin-4-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyl}benzamid, (4) 3,5-Dichloro-4-[(S)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phenyl}benzamid, (5) 3-Methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-brompyridin-3-yl)pyrimidin-2-ylamino]-4-methyl-phenyl}benzamid, (6) 4-(4-Ethylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamid, (7) 4-(4-Ethylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{3-[4-(5-brompyridin-3-yl)pyrimidin-2-ylamino]-4-methyl-phenyljbenzamid, (8) 3-Chlor-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benz-amid, (9) 3-Fluormethyl-4-(1-methylpiperidin-4-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamid, (10) 4-(4-Methylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phe-nyljbenzamid, (11) 4-(4-Ethylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phe-nyljbenzamid, (12) 4-(4-Ethylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phe-nyljbenzamid, (13) 4-(4-Methylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phe-nyljbenzamid, (14) 4-[4-(2-Fluorethyl)piperazin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamid, (15) 4-[4-(2-Hydroxyethyl)piperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yl-amino]phenyl}benzamid, (16) 4-[(R)-3-(Dimethylamino)pyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamid, (17) 4-(1-Piperazinylmethyl)-3-trifluormethyl-N-{3-[4-(5-brompyridin-3-yl)pyrimidin-2-ylamino]-4-methylphe-nyljbenzamid, (18) 4-(1-Piperazinylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(3-pyridyl)pyridine-2-ylamino]phenyl}benzamid, (19) 4-(1-Piperazinylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benz-amid, (20) 4-(3-Carbamoylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamid, (21) 4-[(S)-3-(Dimethylamino)pyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamid, (22) 4-(3-Carbamoyl-4-methylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamid, (23) 4-((S)-3-Methylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamid, (24) 4-((R)-3-Methylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phenyl}benzamid, (25) 4-[(S)-3-(N,N-Diethylamino)pyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino]phenyl}benzamid, (26) 4-[(2R, 4S)-4-(Dimethylamino)-2-methylpyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimi-dinyl)pyrimidin-2-ylamino]phenyl}benzamid, (27) 4-((S)-3-Aminopiperidinomethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyl}benzamid, (28) 4-[(S)-3-(Dimethylamino)piperidinomethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yl-amino]phenyl}benzamid, (29) 4-((3S, 4R)-3-Amino-4-methylpyrrolidin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phenyl}benzamid, (30) 4-[(3S, 4R)-3-(Dimethylamino)-4-methylpyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimi-dinyl)pyrimidin-2-ylamino]phenyl}benzamid, (31) 4-[(S)-3-(Methylamino)pyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamid, (32) 4-((S)-3,4-Dimethylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phenyl}benzamid, (33) 4-((R)-3,4-Dimethylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phenyl}benzamid, (34) 4-[(3R, 4R)-3-(Dimethylamino)-4-methoxypyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyri-midinyl)pyrimidin-2-ylamino]phenyl}benzamid, (35) 4-(1-Methylpiperidin-4-yloxy)-3-trifluormethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phe- nyljbenzamid, (36) 4-(1-Methylpiperidin-4-ylidenemethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylami-no]phenyl}benzamid, (37) 4-[(R)-3-(Dimethylaminomethyl)pyrrolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimi-din-2-ylamino]phenyl}benzamid, (38) 4-(1-Methylpiperazin-4-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]phe-nyl}benzamid, (39) 4-(1-Methylpiperazin-4-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylami-no]phenyl}benzamid, (40) 4-(4-Methylpiperazin-1-ylmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(4-pyridyl)thiazol-2-ylamino]phe-nyl}benzamid, (41) 4-[(R)-3-(Dimethylaminomethyl)pyirolidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phenyl}benzamid, (42) 4-(1-Methylpiperidin-4-ylidenmethyl)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phenyl}benzamid, (43) 4-(1-Methylpiperidin-4-yloxy)-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phe-nyljbenzamid, und (44) 4-[3-(Dimethylamino)azetidin-1-ylmethyl]-3-trifluormethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phenyl}benzamid. 4. Arzneimittel umfassend das Amid-Derivat gemäß einem der Ansprüche 1 bis 3 oder ein pharmazeutisch verträgliches Salz davon als ein aktiver Bestandteil. 5. Ein BCR-ABL Tyrosinkinaseinhibitor umfassend das Amid-Derivat gemäß einem der Ansprüche 1 bis 3 oder ein pharmazeutisch verträgliches Salz davon als ein aktiver Bestandteil. 6. Ein therapeutisches Mittel zur Verwendung in der Behandlung chronischer myeloischer Leukämie, umfassend das Amid-Derivat gemäß einem der Ansprüche 1 bis 3 oderein pharmazeutisch verträgliches Salz davon als ein aktiver Bestandteil. 7. Ein therapeutisches Mittel zur Verwendung in der Behandlung akuter lymphoblastischer Leukämie, umfassend das Amid-Derivat gemäß einem der Ansprüche 1 bis 3 oderein pharmazeutisch verträgliches Salz davon als ein aktiver Bestandteil. 8. Ein therapeutisches Mittel zur Verwendung in der Behandlung akuter myeloischer Leukämie, umfassend das Amid-Derivat gemäß einem der Ansprüche 1 bis 3 oder ein Salz davon als ein aktiver Bestandteil.
Revendications 1. Dérivé d’amide qui est un composé représenté par la formule générale [1] suivante dans l’un quelconque des cas (A) ou (C) suivants, ou un sel pharmaceutiquement acceptable de celui-ci : [Formule chimique 19]
formule dans laquelle (A) R1 représente l’un quelconque des groupes (1) à (3) suivants : (1) -CH2-R11 [R11 représente un groupe hétérocyclique azoté saturé, lequel groupe hétérocyclique azoté saturé est obligatoirement substitué par un groupe choisi dans l’ensemble constitué par oxo, -CH2-R111 (R111 représente un groupe hétérocyclique azoté saturé), un groupe hétérocyclique azoté saturé, aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle, alcoxy et (5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyle, et peut être encore éventuellement substitué par 1 ou 2 éléments identiques ou différents choisis dans l’ensemble constitué par alkyle, alcoxycarbonyle, halogène, halogénoalkyle, hydroxyalk-yle, amino, monoalkylamino, dialkylamino, carbamoyle, monoalkylcarbamoyle et dialkylcarbamoyle] ; (2) -O-R12 [R12 représente un groupe hétérocyclique azoté saturé, lequel groupe hétérocyclique azoté saturé peut être substitué par 1 ou 3 éléments identiques ou différents choisis dans l’ensemble constitué par oxo, -CH2-R121 (R121 représente un groupe hétérocyclique azoté saturé), un groupe hétérocyclique azoté saturé, aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle, alcoxy, (5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyle, alkyle, alcoxycarbonyle, halogène, halogénoalkyle, hydroxyalkyle, amino, monoalkylamino, dialkylamino, carbamoyle, monoalkylcarbamoyle et dialkylcarbamoyle] ; et (3) -CH=R13 [R13 représente un groupe hétérocyclique azoté saturé, lequel groupe hétérocyclique azoté saturé peut être substitué par 1 à 3 éléments identiques ou différents choisis dans l’ensemble constitué par oxo, -CH2-R131 (R131 représente un groupe hétérocyclique azoté saturé), un groupe hétérocyclique azoté saturé, aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle, alcoxy, (5-mé-thyl-2-oxo-1,3-dioxol-4-yl)méthyle, alkyle, alcoxycarbonyle, halogène, halogénoalkyle, hydroxyalkyle, amino, monoalkylamino, dialkylamino, carbamoyle, monoalkylcarbamoyle et dialkylcarbamoyle] ; R2 représente alkyle, halogène, halogénoalkyle, hydroxyalkyle, alcoxy, alcoxyalkyle, alcoxycarbonyle, acy-le, amino, monoalkylamino, dialkylamino, nitro, carbamoyle, monoalkylcarbamoyle, dialkylcarbamoyle ou cyano ; R3 représente l’hydrogène, halogène ou alcoxy ;
Heti représente l’un quelconque des groupes de formules chimiques [2] à [8] suivantes :
Formule chimiaue 201
Het2 représente pyridyle, pyrimidinyle, pyrazinyle, pyridazinyle ou 1,2-dihydropropyridazinyle (Het2 peut être substitué par 1 à 3 éléments identiques ou différents choisis dans l’ensemble constitué par alkyle, halogène et amino) ; à l’exclusion des composés dans lesquels R11 est pyrrolidinyle, pipéridinyle, pipérazinyle ou morpholinyle, chacun des pyrrolidinyle, pipéridinyle, pipérazinyle et morpholinyle étant substitué par un groupe choisi dans l’ensemble constitué paroxo, -CH2-R111 (R111 représente un groupe hétérocyclique azoté saturé), un groupe hétérocyclique azoté saturé, aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle, alcoxy et (5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyle, et en outre pouvant être substitué par 1 ou 2 éléments identiques ou différents choisis dans l’ensemble constitué par alkyle, alcoxycarbonyle, halogène, halogénoalkyle, hydroxyalkyle, amino, monoalkylamino, dialkylamino, carbamoyle, monoalkylcarbamoyle et dialkylcarbamoyle ; Heti est un groupe de formule [6] ; et Het2 est pyrazinyle ou pyridyle qui peut être substitué par alkyle ; (C) R1 représente l’un quelconque des groupes (1) à (3) suivants : (1) -CH2-R11 [R11 représente un groupe hétérocyclique azoté saturé, lequel groupe hétérocyclique azoté saturé est substitué par un groupe choisi dans l’ensemble constitué par oxo, -CH2-R111 (R111 représente un groupe hétérocyclique azoté saturé), un groupe hétérocyclique azoté saturé, aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle, alcoxy et (5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyle, et peut être encore substitué par 1 ou 2 éléments identiques ou différents choisis dans l’ensemble constitué par alkyle, alcoxycarbonyle, halogène, halogénoalkyle, hydroxyalkyle, amino, monoalkylamino, dialkylamino, carbamoyle, monoalkylcarbamoyle et dialkylcarbamoyle] ; (2) -O-R12 [R12 représente un groupe hétérocyclique azoté saturé, lequel groupe hétérocyclique azoté saturé peut être substitué par 1 ou 3 éléments identiques ou différents choisis dans l’ensemble constitué paroxo, -CH2-R121 (R121 représente un groupe hétérocyclique azoté saturé), un groupe hétérocyclique azoté saturé, aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle, alcoxy, (5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyle, alkyle, alcoxycarbonyle, halogène, halogénoalkyle, hydroxyalkyle, amino, monoalkylamino, dialkylamino, carbamoyle, monoalkylcarbamoyle et dialkylcarbamoyle] ; et (3) -CH=R13 [R13 représente un groupe hétérocyclique azoté saturé, lequel groupe hétérocyclique azoté saturé peut être substitué par 1 à 3 éléments identiques ou différents choisis dans l’ensemble constitué par oxo, -CH2-R131 (R131 représente un groupe hétérocyclique azoté saturé), un groupe hétérocyclique azoté saturé, aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle, alcoxy, (5-mé-thyl-2-oxo-1,3-dioxol-4-yl)méthyle, alkyle, alcoxycarbonyle, halogène, halogénoalkyle, hydroxyalkyle, amino, monoalkylamino, dialkylamino, carbamoyle, monoalkylcarbamoyle et dialkylcarbamoyle] ; R2 représente alkyle, halogène, halogénoalkyle, hydroxyalkyle, alcoxy, alcoxyalkyle, alcoxycarbonyle, acy-le, amino, monoalkylamino, dialkylamino, nitro, carbamoyle, monoalkylcarbamoyle, dialkylcarbamoyle ou cyano ; R3 représente l’hydrogène, halogène ou alcoxy ;
Heti représente l’un quelconque des groupes de formules chimiques [9] et [10] suivantes
Het2 représente pyridyle, pyrimidinyle, pyrazinyle, pyridazinyle ou 1,2-dihydropyridazinyle,
Het2 pouvant être substitué par 1 à 3 éléments identiques ou différents choisis dans l’ensemble constitué par alkyle, halogène et amino. 2. Dérivé d’amide selon la revendication 1, qui est un composé choisi dans l’ensemble constitué par les composés (1) à (7) suivants, ou un sel pharmaceutiquement acceptable de celui-ci : (1) (-)-4-((S)-3-amino-2-oxopyrrolidin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (2) 4-[(S)-2-(1-pyrrolidinylméthyl)pyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phényl}benzamide, (3) 4-[3-(diméthylaminométhyl)azétidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (4) 4-[(S)-3-(1-pyrrolidinyl)pyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (5) 4-{4-[(5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyl]pipérazin-1-ylméthyl}-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (6) 4-[(S)-3-(diméthylaminométhyl)pyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phényl}benzamide, et (7) 4-[(3R,4R)-3-(diméthylamino)-4-méthoxypyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimi-dinyl)pyrimidin-2-ylamino]phényl}benzamide. 3. Dérivé d’amide qui est un composé choisi dans l’ensemble constitué par les composés (1) à (44) suivants, ou un sel pharmaceutiquement acceptable de celui-ci : (1) 3-difluorométhyl-4-(4-méthylpipérazin-1-ylméthyl)-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phényl}benzamide, (2) 3-éthyl-4-(4-méthylpipérazin-1-ylméthyl)-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}ben-zamide, (3) 4-(1-méthylpipéridin-4-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phé-nyljbenzamide, (4) 3,5-dichloro-4-[(S)-3-(diméthylamino)pyrrolidin-1-ylméthyl]-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phényl}benzamide, (5) 3-méthoxy-4-(4-méthylpipérazin-1-ylméthyl)-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-méthyl-phényl}benzamide, (6) 4-(4-éthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phé-nyl}benzamide, (7) 4-(4-éthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-mé-thylphényljbenzamide, (8) 3-chloro-4-(4-méthylpipérazin-1-ylméthyl)-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}ben-zamide, (9) 3-fluorométhyl-4-(1-méthylpipéridin-4-ylméthyl)-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phé-nyljbenzamide, (10) 4-(4-méthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phé-nyljbenzamide, (11) 4-(4-éthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phé-nyljbenzamide, (12) 4-(4-éthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phé-nyljbenzamide, (13) 4-(4-méthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phé-nyljbenzamide, (14) 4-[4-(2-fluoroéthyl)pipérazin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phényl}benzamide, (15) 4-[4-(2-hydroxyéthyl)pipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (16) 4-[(R)-3-(diméthylamino)pyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (17) 4-(1-pipérazinylméthyl)-3-trifluorométhyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-méthylphé-nyljbenzamide, (18) 4-(1-pipérazinylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phényl}benzami-de, (19) 4-(1-pipérazinylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}ben-zamide, (20) 4-(3-carbamoylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phényl}benzamide, (21) 4-[(8)-3-(diméthylamino)pyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (22) 4-(3-carbamoyl-4-méthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin- 2-ylamino]phényl}benzamide, (23) 4-((S)-3-méthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phényl}benzamide, (24) 4-((R)-3-méthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phényl}benzamide, (25) 4-[(S)-3-(N,N-diéthylamino)pyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimi-din-2-ylamino]phényl}benzamide, (26) 4-[(2R,4S)-4-(diméthylamino)-2-méthylpyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimi-dinyl)pyrimidin-2-ylamino]phényl}benzamide, (27) 4-((S)-3-aminopipéridinométhyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami- no]phényl}benzamide, (28) 4-[(S)-3-(diméthylamino)pipéridinométhyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (29) 4-((3S,4R)-3-amino-4-méthylpyirolidin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyri-midin-2-ylamino]phényl}benzamide, (30) 4-[(3S,4R)-3-(diméthylamino)-4-méthylpyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimi-dinyl)pyrimidin-2-ylamino]phényl}benzamide, (31) 4-[(S)-3-(méthylamino)pyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phényl}benzamide, (32) 4-((S)-3,4-diméthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phényl}benzamide, (33) 4-((R)-3,4-diméthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phényl}benzamide, (34) 4-[(3R,4R)-3-(diméthylamino)-4-méthoxypyrrolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyri-midinyl)pyrimidin-2-ylamino]phényl}benzamide, (35) 4-(1-méthylpipéridin-4-yloxy)-3-trifluorométhyl-N-{4-méthyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phé-nyljbenzamide, (36) 4-(1-méthylpipéridin-4-ylidèneméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(3-pyridyl)pyrimidin-2-ylami-no]phényl}benzamide, (37) 4-[(R)-3-(diméthylaminométhyl)pyiTolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(3-pyridyl)pyrimi-din-2-ylamino]phényl}benzamide, (38) 4-(1-méthylpipérazin-4-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]phé-nyl}benzamide, (39) 4-(1-méthylpipérazin-4-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylami-no]phényl}benzamide, (40) 4-(4-méthylpipérazin-1-ylméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(4-pyridyl)thiazol-2-ylamino]phé-nyl}benzamide, (41) 4-(R)-3-(diméthylaminométhyl)pyiTolidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)py-rimidin-2-ylamino]phényl}benzamide, (42) 4-(1-méthylpipéridin-4-ylidèneméthyl)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylami-no]phényl}benzamide, (43) 4-(1-méthylpipéridin-4-yloxy)-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phé-nyl}benzamide, et (44) 4-[3-(diméthylamino)azétidin-1-ylméthyl]-3-trifluorométhyl-N-{4-méthyl-3-[4-(5-pyrimidinyl)pyrimidin-2-yla-mino]phényl}benzamide. 4. Composition pharmaceutique comprenant le dérivé d’amide de l’une quelconque des revendications 1 à 3 ou un sel pharmaceutiquement acceptable de celui-ci à titre d’agent actif. 5. Inhibiteur de tyrosine kinase BCR-ABL comprenant le dérivé d’amide de l’une quelconque des revendications 1 à 3 ou un sel pharmaceutiquement acceptable de celui-ci à titre d’agent actif. 6. Agent thérapeutique pour une utilisation dans le traitement d’une leucémie myélogène chronique comprenant le dérivé d’amide de l’une quelconque des revendications 1 à 3 ou un sel pharmaceutiquement acceptable de celui-ci à titre d’agent actif. 7. Agent thérapeutique pour utilisation dans le traitement d’une leucémie lymphoblastique aiguë comprenant le dérivé d’amide de l’une quelconque des revendications 1 à 3 ou un sel pharmaceutiquement acceptable de celui-ci à titre d’agent actif. 8. Agent thérapeutique pour une utilisation dans le traitement d’une leucémie myélogène aiguë comprenant le dérivé d’amide de l’une quelconque des revendications 1 à 3 ou un sel de celui-ci à titre d’agent actif.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • JP 6087834 A [0005] [0151] · JP 6192196 A [0108] • WO 0222597 A [0005]
Non-patent literature cited in the description • SHTIVELMAN E et al. Nature, 1985, vol. 315, · J. Am. Chem. Soc., 1999, vol. 121,4369-4378 [0005] 550-554 [0005] · Tetrahedron Lett., 1997, vol. 38, 8005-8008 [0005] • DALEY G Q et al. Science, 1990, vol. 247, 824-830 · J. Med. Chem., 2002, vol. 45, 3406-3417 [0005] [0005] · J. Med. Chem., 2000, vol. 43, 3895-3905 [0005] • DRUKER B J et al. N Engl J Med, 2001, vol. 344, · J. Med. Chem., 2000, vol. 43, 1508-1518 [0005] 1038-1042 [0005] · J. Med. Chem., 1975, vol. 18, 1077-1088 [0005] • WEISBERG E et al. Drug Resist Updat, 2001, vol. 4, · Bioorg. Med. Chem. Lett., 2001, vol. 11, 2235-2239 22-28 [0005] [0005] • GORREMEetal. Science, 2001, vol. 293, 876-880 · J. Heterocyclic Chem., 2000, vol. 37, 1457-1462 [0005] [0005] • BLAGOSKLONNY Μ V. Leukemia, 2002, vol. 16, · J. Med. Chem., 1999, vol. 42, 3557-3571 [0148] 570-572 [0005] · Khim. Geterotsikl. Soedim., 1981, vol. 7, 958-962 • HOCHHAUS A et al. Leukemia, 2002, vol. 16, [0150] 2190-2196 [0005] · J. Med. Chem., 1992, vol. 35, 1764-1773 [0173] • HOFMANN W -K et al. blood, 2002, vol. 99, · J. Med. Chem., 1992, vol. 35, 4205-4208 [0175] 1860-1862 [0005] · Tetrahedron: Asymmetry, 2001, vol. 12, 2989-2997 • DENINGER W N et al. blood, 2000, vol. 96, [0177] [0197] 3343-3356 [0005] · J. Med. Chem., 1988, vol. 31, 1598-1611 [0180] • J. Org. Chem., 1996, vol. 61, 1133-1135 [0005] · J. Med. Chem., 1992, vol. 35, 4205-4213 [0183] • J. Org. Chem., 2000, vol. 65, 1144-1157 [0005] · Synthetic Communications, 1998, vol. 28,3919-3926 • Reel. Trav. Chim. Pays-Bas., 1950, vol. 69, 673-699 [0274] [0005] · Tetrahedron: Asymmetry, 1997, vol. 8, 883-887 • J. Heterocycl. Chem., 1970, vol. 7,1137-1141 [0005] [0279] [0292]

Claims (2)

  1. Szabadalmi %é»ypöo$gk L Amidsztem#* imsiy a kóvsíkexö ® ábalásos; képlet «ηβΗβ vegyüiet a kövőíkazö: (A) vagy |C) sset# [19, vegyhteij
    ahol a :k%ietbes (A) R! ;eíemés;e a következő {) ;-(3) szerinti csoportok bámtcly iké: (1) >CHrRu [Rl} jdeoH-se tehteá, ustegéntanáimb hetsrociMusóS: csítpofi, áhbl á: i3$m; nitrogénianalnns heterociklusos csoport kőtelezőén sKuhsstlíyált s: köMikéP|k: kötőből választött csoportiül: oxocsoport, Ob-R!!i (R!i' jelentése tel nett, rótrog<xpíosaispá::hetarpC:íRlüsos csoport^: telített, ntttogentartalmó heterociklusos csoport, amioo-alkik oxiaoalklRaípkxvaMl·', diálki?·* amino-alktk alkom- és (5-melil-2OXO-1,3-dioxol~i-Uboedh-csoport, és: továbbá adót: esötbeh siö&amp;$»!tuáit: Mm. &amp; hitess csoportból választón í v&amp;^ j -;mnm taggal; alkik alkoxMisrbotii I-csoport« haloKénatom, haiosik)k hidroxi*á^i (2) -0-1!ΐ |Rr? jelentése telített mtrogémartalmű heterociklusos csoport, ahol a tel ítélt, hitiogéniartalmú: heterociklusos csoport szubsztltuáít telist a következők alkotta csoportból választott N3 azonos vagy különböző taggal: oxocsopott, -CilrR!?i tR!ls jcletééité telített, oiírttgertttírtalnró hererocikhisos csoport), telített, nitrogéntartalmú heterociklusos csoport, £00100-nikií-·, monoaikΠ-ammo-alkil-, dióikiJ-amlnö-aikíi-·. aikoxk <5-metib2~oxO'-l.il3»4ioX'ói|<i’4rtl}túböi^ alkik alko x i - karbon s 1- csoport, halogértatocn, halmaik 11-, hidroxi-alkik aminek moirkuáMkapytsp-cluilkl!-aiomo-·, 'karbamoik ο o: ? o ;;sikiI karb o η o 11 - és dudcli-karhíunoil-csoportj; és (3) -CH:;;R{:i |RH jelentéi teiitett, nitrogéntartalmú hetefocikiusos csoport, ahol « -eliten.. . < ^ - .>. . . .<·. ... '.<_ i . .. . .·:.» ;vW· ,·· «»·» > Λ λ< > .·. ÍSá+ ··> i.· r-í >:·.»Í V.v.őJO :- ,,'S ». „ .- .Λ i. y i vélasxiösí 1-3: azonos vágy Icblbnbőső taggal: őxossóprt, >CHrR”! |R,j!: jéteoisse telített, mtfogéntsáshtsó hetetoctkiosos tsltkb nitrogéniurtabnü heterociklusos csoport, sminfl* alklk sopPMkasP'SD~aM%: $tólirttPibe*aiku··, s&amp;oxk ikoxeUkVoso··! J»dip:p4>4|)Spi:Í^ alkik ídköKRksrbonil-ésogöríi: lalögcostoftk bstós&amp;ik hkíroxl-alkik atoko-, roo^^ljh^I^ tlMklkannoo-, teímaóíK fhöRÖalkkkíPaiPoll·· és diáiké -k«rf>amoil»csop$>«j[j íT jélésPse aMcsepott, halópasiom, luPaikik ydröid-a&amp;d··, alkoxK aikokMkík: aikcPdísrbokk aeik atomo~, tpömsaikskámipö-, vbalkil-ainhto·, Mix<H karban-olk «Kmoalkií-karbaoKÓl·-, dkslkH-karbamöií- vagy staoocsoport; R:s jeistílsso hidtogéíK halogéoaiom vagy alkosiesoport: Heti jeleuíése a következő PM8] kőfalai kőpiesö csoportok bánnelylke: ||Ó, vegyük!]
    Het2 jchrtttssa pírkiik pirtoddmik ptnspbk #iteM!- vagy l# Het2 sxuteitaslt léM a követkczÉs áfkoiís csoportból választott i-3 azonos vagy különböző taggal: dkilcseport, haiogóostom ss smloocsoport;):; kMrva sáskát: a vegytdcíekst, ahol R'! idenfése phrohdímh pipendinit-, piperazsml·· vagy morlblbblcsopöii, ahol a pimdlslklk, pipendnok psperazmsl· és jnorfóUmtesoport mindegyike saífeszt&amp;náR«MveÉeagfc kőiéből választót! csoporttal: oxotaopon. -OHrR,K CRa* jelentése telileftj. oitrogóssiarkbmó bötcbmlfcliísps esoport}.. tpllfett, «avogéotartulmű heterociklusos csoport, amino-adál-, monoaikil-ainiao-alkií-, diaskő-animo-alki!·, alkosd· és k>--oasbk:lv'Or<s^l,>Hlkortd-4-ij}íooPl-csoport, és továbbá szubsztitfM Mm a kö¥«tkex0ií alkopa csoportból vtertok I vagy % mmm vagy kötötted: taggal: alkik aíkoxi4;ffrb<odi-csoport, bak'géoatoío, baloalkü-, hkiroxkílbk asydoo-. moooalkl.i-amlno*s dístkibaiídtsk:,. kárbsoxöli-, jMoaoalkíRkas^kíbóil·' 0» díalkl:blasfisamoll'-cscspoít· kist 1: jelentése a j*>] képktíö csoport.; és Heé2 jdeotése pirazio.ib vágy pirklíkxoport amely sztstettmáh: .lehet kikífesöpoíiki; (C) jeieotése p Rhyetteo (l >43} are#tí csoportok bfedyifce; iJ'5 -CH.'-K1 |R’' κΚ-ηίΟ' h'Hu5! bspov.eoxauIüíü hetertxáklasös csoport.. ahol a tdhetg nltrogéntarmhaú heterociklusos, csoport s/ul'p/titutöt &amp; kővetkezők kőiéből választott csoporttal ovoesopurt. -űt.-'X1'1 (Ri:i jdontáse teUteu, nítrogétttartahrrn heterociklusos csoport), lelheti; rutrogéaiarudntu hetemcikIonos vsöpört, antim-alkII», ttKmoaMkatmn»*al.kd*, •dtalkli-amjno-.alkiK alkoxl* és f5-metd-2*0xo· 1,3-dloK«í"l'!l inteti t'<. söpört, es továbbá szübsztltoált lehet a következők alkotta csoportból választott t \ag> I! azonos vagy klilőnbözö taggal: alkik alkoxt-ksrfeönil-csepori, halogéo&amp;lom, halcalkik hidro\i<alk!l^ amtno-. ntooístlkil-aottFio·-, dldkrl-antíttp-, karbsmoík ':sKíní>alkil--karbá!nO!i és ilaik il •karbatnoil-c.soport'j; (2) |Rw jelentése telned, nitrogétitarsáiftta hstgttsdklbsös csoport, ahol a telített, nitrogéntartalmú heterociklusos csoport szubsztituást Msei s következők alkotta csoportból választott 1-3 azonos vagy különb»# ísggak öJtÖcsígjörb (R!2Í jelentése· telített, nitrogéntartalmú heierődkfesoS Csoport), íslsieit,: bltr^ csoport, trmittö'· aiKth moooaí.kiksn*inókilktk #^Ö'éálSteótálktlsv allöxk 'p^ötetii-l^tto^· 1,341eRőM4i).t»étlk aiksk alkpxi^ariyptlbcsöpós-t, haiogéísatoitk hatodkik hldMxHaltól-, imtno-, sttorasaltól-íunmo-, dialkil-amlruk ka#á»tot.h ιΡόη<«^ϊΙ-ΗηΛηηι#“:ι|$:^
    ^Β»ίη#!^ρφ# (3) .j;RD' jelentőse íétÖSip fskrögfeaartahtíd heierosMtssos jcsóport, ahol tt álltaik tt drogé mMÉPtó háíőrodkkísos csoport szubsxtltoáii lehet a kővetkezők alkotta csopo&amp;héi yiaSdott -14 acottók vagy kölöabö# taggal: óxocsópbrt, (Rw* jelertiése téliéit·, nilTOgéntartaltnó heterociklusos csoport). tehktrt. íősrogéoíartahmt heterodklosös; csoport, amlao-alkik 'nKtnoalkdíamtno-alkil-, diaikiknttino-alkik aiKoxR i 5-metH-2-oxo-t 3-dioxol~4~tlinteti!··, aikik alkoxl-karbonis-esoporí. haíogenaioüt, halódtól·, hidrost-alkü·, amim·-, inottoiiikii-artiitio··, dtaJktkatnloo-, karbamoü^/möiililillrfei^áijiöl^ ás dltdklhknrbamölHSöl^tli :# jelentése alkiksoport, halogén-ltom, haioattók htdroxi-dktl-, dkoxi- ídhoxktlktk aUtoxi-karhonil-, setb, műm*, t5Xirioaifc|l->aKtpío-3 dipiklhminóp mim*, karhatnoik mottoaíkii-karb&amp;tnoik dfalkil- karbraooii· vagy cktaocsoport; R: jelentése ftklmgén-, haiogénatomvagy dkoxtcsoporu Heti jelentése a következő f9j és flOj kémiát kép idd csoportok bármelyike: [22. vegyidet]
    lífci2 jéiétiíése pitid!!··, fjpfóágiátfó* vagy .Ip^l^mípiWátótóJ-cs^TÍ,. ahol a. |:Iéi2 s&amp;tbsztittsán k-b&amp;t a^teatoAv^öl^'-fiS^rthÖl. válssKtotí 141 mmm vagy Mlöaközö taggal: aSkí ScBöppÖ,; titdogétsatotn |s aodnocsopo-l. % Az K igénypont szerinti antudszéromék, *melv a következd i ))-(7) vegyüMpk aik-olta ssopőtifcó) választott algyőiét vagy gyögysaeréB^öliág e!iípdkal« sóig: (t) (-M-g>'.·.-2-smm-v-nv' pírsvhdsn- 1 'ii-meíd; ΐ·a:tk-or-meis’-K- (4-ou-íií-)-{4-(5i>irtmidi«n>paimsdin-2--d -amkso jíem !; bem'.am;d. p)44(S)-2^ Ι-ρ0ΓθΙηϋηΙΙ-ηι^ιΠρΰτυΙϋ»η*Ι*0·η}«}ϋ·3-ηίΠ>)θ}·ϊη»Όΐ»ί4 (4 «tótit-1-f4-p~ SS rimsdssdtpirln s Sd s ss -2 - il -atn inojVn »1} benzannü, ikasdno] festi!· beszatsbd, s l-an i au ] fess Π} bestzatstid, p}4‘-|44P-4tíetíl-4-'öyí!-'l;3-'d:sö:göI''4~Í!tmotí!]pips^^ psrimidín[l]pt(isty^^ {6)4-f(St>:^(dÍ5ttvoi»antlöö»í»eti|]|(ijt^|Miö--Í4ktt^il4Mriflaor*metít^Kpvmat8-.k[4-(5-pháaddi»iy!pfnmkÍ!n-.'-(i-aí»!nc^!<a-«S; bcíw:a!«ki, és pírimiílinkípívímiífirí-2-íl-arstinojiíínti: beií^amkt. 3» Ax snpdsxáTmaglkv amely a kdyePezi: (1)-(44¾ vegy(ífefe&amp; alkotta csoportból váíaszíott vegyöiet vagy gyégyszeföszetüeg elfogadható só|á; {í) 3“íidkK)r-a>B;td-'444-?tmil- t>ígeoíagi-· 14kmetlí>-N- < 4-4heil-2- (4-( l^ pir!!»Íd!raóbpiri«odif)-2· 11·· <» s · i ou j fen 111 benzam ki, p) 3^elsM>#rPtetil*ptpe^án>-í-«t-tnv'tiihM*l4-ntót5t-3-!4'{5'-ptr;nnd«ttihpimnidi»“2--it* arosne jfen i!} benzam sd, (3) 44í~fHetlÍ:--ptperMm-4--íkoH4il}-3--tiÍtdnMtieS!l'-^-k^-ou4i^'••b-t-(:'-pivíoddlról){nriitrvdin-'2--ií-' ajtdnó jico d Ibcazam sd, (4) 3J^&amp;^«((8)4<áin^Í'Sn)!»^m>|ldin-kii'tneti}]-N--{4-mcttl-.3~f4~(5-pir5tn!d»dt}i>Írj»ttdin>-2-ít-- fcodjherasamai. 0VH-í4 ehi-ptiifr.vm É~d nvatdVVo diára aaetb-N-b'-rarad í-Hí«ttknt»!ípsjϊ*ϊϊt-t5«-d-«SriiBO] fcoiíi hi-BSUiJBiil (?Ή-ί4 ejd-pipewra f-b ra^tdV kp okra BPetb-Nd'd44MraMn-vraraloa3-b rabáradra .l-d-aaarad -iraK-íd isöllHMinsímid. tO ' k 0' 4 i4raadd-|bra'u/ra-1 li rae-d'· N j4 raenkk444k'pnanKboblp»Bníbin-k-d' arab»; iViiii: htíssamül 3PdBal+MÍ:ij:feeP^8:^Ó<Íli;:. VK>' -s i 4 racíd pt{\- aran (! n»sd> 5 üdb»' műd \ $4·?\μ! ,-[i í1' ps-ramltahpmdin k tk aodnoUbvallburaaraíd, (1 ? > 4v{4^i}»psp«ra2Í8^1 dl«metH) ;ua i no Honi S} bcs-zaraid, (12)4-id^edkp5pem2!n-d'i:l~m«íi:)^3'4riflunr'níetii'-N·' ^ 4 t il-3 3 ~p4 r s d s s >piríéj s 11 - ásd no] löödilbenzssnidj (,1.¾) 4'p'4a®dJ~p!psy&amp;ííáaí>d:lia5ed|)-'34ridüöP4Sfedl-N:\]4-apetí!-'3r[4-{3'|aridilÍpiddíök2'':ib arai no] fudl 1 bensradd. aminöj&amp;ai 1;· bensSön i d. f] M d^Í4-(2~hidröxí-eil)pspra5íin-i d)dpekd^3-bifíaor-a}eiÍk|4kPknteüÍ-3-f4*p^^ an»io'scad ' t\ s /\nm J, (S6) 4-{; R>- V!d«ru-áika:vdnoia!ni>!ídi«4'o!--raeb]]-v5aadoor.Mradk'N' bbr«<;!Ü-'3"[4a5'1>!S'inbd!ídí ipininidia·-2b!"aímno]:bmd {beozan-id, {Í7) Λ-t I -pipenuiníi-inet il)-3 •tnflaor-mei.d'-'N-p^i^S'-btöra-pindjn-S al)|>1riro«}{»>24l^ín4»»||448^lH Ρ:η;Γ> bemarna ki, (ί||:%Ί*ρΙρΡΐ«ζίηΐ!“^ίΙ>-ΐε“Λ^ι^8^Ρ-τ»δ.0Μ'*Β'^^Μ1;)^Μΐ0έΜΜ^Μ3^0ίί}^»ίΛί,;. (i9>4HÍ'Píp*t^dnsi-nictil;vV.nónaraaaeukN~{d~raed!Níd.-bb^-ni}iiaídinii)pí!-raddín-2-!!-araíaojfen iS}bcn«nnid; (20) 4d3-kari:aott<ákj>ineröziO'ddi-osetií}v>-iridyooo'o<au--NH4aneid2bi4a^aiír;vo«Í!;af}psfan!día"2-ii'' arakra] íudl ] lx-:n/;radii {21 s 4-|(S;k-:>ddunetd-aiidno)psmdi(jin· i di~are;í’j'24ritÍaooovicbk44ddo-aeok244d5idrinn«ib)ílapírí«ddra-2-ií-anna<í|Radi}botv.o«aid. (22) ?»|5ÍpvmHÍ:íí·' Ϊ 'il-'n^fö(il>-'3'trsi1«í>í"'niets!">í^{4^s5>öí:ii-3^|4-'(5-]>h25:n4dÍ!'U2)35S;io>:(áín'-2-i 1-sm i noHbáU iísmionid, (23) 4 -(ÍS)^3^tt'eíil "|>ipera^írí'3-l!"fnelíí>-3 >srifluíír-i?íe£U«N-(4'í'iöí?l"3^[4>{5>píí ϊοΜ<1)ϊΐϊ()ρΐί ϊνϊϊΜ{η^2-Ο1-siniísólfenil} tami^ (24) 4-<(R)-3-metÍl-pipöS'az(n^24^ns«ísl)^33r)2xa>F-m«í5:"N^C4'msi:U''3'|43S-|>srjr5iídins!)í!)Htnid)?í-23|.. am ino | fe«M) benaaraMi Ρ5)'·4-{'{Β^^>Ν“0ΐ6ΐΐ1-8ΐηί0ο)ρί»0Κ^Ιή^1^ΙΙ*ϊη0ί·ΙΙ·^3'4Η0«0^«50ΰ)“Η-{4:^η8ίΐ)*3-[4-(5- psr!:m5dsr41)pifhí42iin-2“)^am!rai]íer4i)berimn>sd:; (2$) 4-((21(, ^V^Cdimeíö-amino^-'m'etí^piíyolídin-S-i^metíU-S^fifkor-msty-^f^^^^M^^'S- pjHPítdbiÍi^ifysjáio^il’&amp;fiimolfeaiilbenzmjHd·» :sm ino] Sínílf basg&amp;m ίο (. (28) 44(8)-3- (diaiét) Kaonoo)piperidinO'-sn8í2j^34f-ii)4ö^meni''Nv (4 'Tíí^íí^S --(4-.-((.5 ^-ϊ>ϊ.ϊτ ϊΐϊί iíi ϊϊϊϊ I íí'íí.tíO'í'í íí-I -•am:iK>] feriÜ) ixm/mnid. (29) 4-((38,4li)^3-smlaö-4-!ríeüi'p!íTi>ÍKÍ)a'· i 4Nnöd)}-3 -0il3aer-p5éd)-Ní44--ínatib3'-(4'-(3' pisiSddinÍl}plrimidk^2-si-a£ninöjtenií|Í5an2aS!Íd, (30) 44(38, 4R3-3-(d!metii-areiac4-4--meíi0pirmódÍ8“S'íi'mő0l|-3'-iT50Í5«M4«tik:l4''í4^mis0Í-3-'|443" pMmktell)pki:oxid^24Wami«<(|lf-n!ií1)§a^svd, il-aaTinoJíeíiís) bénassaid, (3234-((8>3>4-dimen('p;p«raxin-(-iS-med!)-3“ÍTÍPuor-níatil-:N“(4-me:dl”3-|44:3ií)fdnidÍÍdl)pír)K!Í!lÍ!í'2-iP íHninojisniij benssmsid, (33) 4-0iR)-3,4-disísdi-piperaxin']-ii-meÍd)-3-írii)uör“rnsPl-N“(4-metii“3”[4-(S'-p!risnsdiniS)pirimidin'-34i-ami nö]fen i 1} bs n«ass id, (34) 4-((38, 4R),34d)4RUÍ-S4?ift£4y4>aneíp8i-piríx4idib-1-41-850()11-3^541)150^-^00:-14-(4-5^05:11-3--14-(3- P isi díi síin í |)piriκ)] d Í0·-2 -5 í > aOppO ] feíÚ:Í}'bga£833íjd-> (3 5 > 4-< 3 - sl^s et 51 - p>(p?eii ii ín -4'4! - ísx i)?t) 11 u c>í - í; s <í : (8 >4 -- (4 - í ?\©í: 0-3 - [4-(:3- p i?' í <) i í } (> i ?r mi id i ?> -3v- i I - 8mÍ55ojíöm1) beTióamld, (36)4-5 l-met5l'piporidss5-4'-ÍHdÓ!5-n5S5Íi)-3dT5055<a'-f5>o(i(-1S-{4-!nöti!-3--[4:-(3-p!íií1ií)pÍ5-5inidi5'í->2-)!-art? «só ]f én i í) benxasn? dv l3?)4'i(Rh3-(UitneU]'amm©-metiUpiyroHdÍ8-1 -) l-m e t s 1 ] -3 - m lí «όΓ-ίΐ^ξ íl {4-«té ΐ 1 (--3^(4-0-. piridiÍ)pÍ5485!áis>~2-i1-aí35Í:n8]|bR;|)beaK883Íd, (34) 4-4í-«?agjM->p!pem^fe^4N}5íítö)43-'ídŐ«8íM«otö^N-|4«a«t(li-'3*[6“(3*pb:MiÍ)p!í'ini{d(n*4>'i.I.i- ^ Jé<iS-jiíMmíáííií-0p^ö»<iíft“4 «· *1« í«sk5ö:]l««l||b««:Kansli!, amsnft)fe«ii) beaxa;T?id: m í} 4-'í(R)'-3-'(díinetii'-a;«?no-índ:ts spsmkiiibv I 'á!-u5€bl]-34n|]uor-mí;bi'-N' ( ?'n^ui -5'f'b{5·· p5rsmkbníi)pbinííásn'2''ii'-iarbno'|fen5Ubenaa!nid, •4#^ í-p$j^gíáíift~4-í aadnoilfebOlNb^bídidi íHs4(, hcíj! mpe Ja Is <ns íí i<k>tnt \ 1I metif 4 \ !-(3']s 3sí'íü sanpammkn-Jl ti (4^-4^1-.:3¾¾^ :i 4l:*möítlj*.Hrl8uoy~máí.íI^H$^^ am;no]fc!S!ljb«í:a?:ar!ic!. 4 Győgyyzarós-zeti készítmény amvk !attalma,v.» 3/ {·>. ι&amp;.όηνρΜ$# $&amp;$neiyílce petifttl abp<5s2ánnö^|íör '•ya^igy%ysi^m2^5ÍegíeNogadh.rt« sóját hatóanyagként
  2. 5, BOR-áBL iíroén Mmte: inhibitor, amely bíítaim&amp;saa m. 1-3. igénypontok Mrmeiylke szerinti arntótóilMt^'omg^iiyégys^^^l^'^ga^^^jlthatöaijyagkém;. ük Isklplás ss;er .ki^mkws tmelögén ienkémia kezelésében .töti&amp;iő alkalmazása, amely mMsxmzm m 1-3:, m^: elíögsdlistó -sóját liídósnyagkent, 7. lerántás &amp;mr;· akat itóíMsiasáös {e^^«la.';fe5séléísÉi®5. 3öí*Sbő· alkalmazásra, amely tartalmazra m 1-#. i^pypefbölí feármelyife szermii amidszámtazekm xmgy gyógvsxemszeíiieg elfogadható sóját hahkswagkám; is, íVrápsás szer akut mmkmén leukémia kezdésében történő alkalmazásra, amely tartalmazza p 1-3. Igénypontok bármelyike szerinti amidsrármazékel vagy sóját halóaapmkeök
HUE04807908A 2003-12-25 2004-12-27 Amidszármazék és gyógyszer HUE034712T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003431398 2003-12-25

Publications (1)

Publication Number Publication Date
HUE034712T2 true HUE034712T2 (hu) 2018-02-28

Family

ID=34736430

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE04807908A HUE034712T2 (hu) 2003-12-25 2004-12-27 Amidszármazék és gyógyszer

Country Status (19)

Country Link
US (1) US7728131B2 (hu)
EP (2) EP1702917B1 (hu)
JP (3) JPWO2005063709A1 (hu)
KR (1) KR100848067B1 (hu)
CN (2) CN100526298C (hu)
AU (1) AU2004309248B2 (hu)
BR (1) BRPI0418074B8 (hu)
CA (1) CA2551529C (hu)
CY (1) CY1120169T1 (hu)
DK (1) DK1702917T3 (hu)
ES (1) ES2651615T3 (hu)
HU (1) HUE034712T2 (hu)
LT (1) LT1702917T (hu)
MX (1) MXPA06007237A (hu)
PL (1) PL1702917T3 (hu)
PT (1) PT1702917T (hu)
RU (1) RU2410375C9 (hu)
SI (1) SI1702917T1 (hu)
WO (1) WO2005063709A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
JP2007297306A (ja) * 2006-04-28 2007-11-15 Kaneka Corp 光学活性３−（１−ピロリジニル）ピロリジンの製造法
WO2007137981A1 (en) * 2006-05-25 2007-12-06 Novartis Ag Inhibitors of tyrosine kinases
MX2009006536A (es) * 2006-12-22 2009-06-26 Novartis Ag Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
US8153792B2 (en) * 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
CN102548987B (zh) * 2009-07-14 2014-04-16 江苏迈度药物研发有限公司 作为激酶抑制剂的氟取代化合物及其使用方法
CN104402860A (zh) * 2010-05-19 2015-03-11 江苏豪森药业股份有限公司 甲磺酸伊马替尼中间体的制备方法
CN102477009B (zh) * 2010-11-23 2014-01-01 清华大学深圳研究生院 取代的（s）-苯甲磺酰基吡咯烷-3-氨基衍生物及其制备方法与应用
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) * 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
FR2980477B1 (fr) * 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
CA2871453A1 (en) 2012-04-24 2013-10-31 Chugai Seiyaku Kabushiki Kaisha Quinazolinedione derivative
AR090836A1 (es) 2012-04-24 2014-12-10 Chugai Pharmaceutical Co Ltd Derivados de benzamida
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CN104876879B (zh) * 2015-04-14 2018-05-18 中国科学院合肥物质科学研究院 一种bcr-abl激酶抑制剂
CN106187995A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含酰胺键杂环类化合物及其制备方法和应用
EP3313530B1 (en) * 2015-06-26 2022-10-05 Dana Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
JP6994715B2 (ja) * 2017-10-04 2022-02-04 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CA3132730A1 (en) * 2019-03-05 2020-09-10 Hongyi & Associates Llc Compounds for treating neurodegenerative diseases and cancers
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (hu) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2004002963A1 (ja) * 2002-06-28 2004-01-08 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
CN100491374C (zh) * 2002-08-02 2009-05-27 Ab科学公司 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
US20070191267A1 (en) * 2003-04-28 2007-08-16 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
US20070032521A1 (en) * 2003-08-15 2007-02-08 Ab Science Use of c-kit inhibitors for treating type II diabetes

Also Published As

Publication number Publication date
CN101456841B (zh) 2012-01-25
LT1702917T (lt) 2017-12-11
RU2410375C2 (ru) 2011-01-27
US7728131B2 (en) 2010-06-01
CN100526298C (zh) 2009-08-12
EP1702917A1 (en) 2006-09-20
RU2410375C9 (ru) 2017-08-02
RU2006126974A (ru) 2008-01-27
WO2005063709A1 (ja) 2005-07-14
US20080293940A1 (en) 2008-11-27
JPWO2005063709A1 (ja) 2007-07-19
KR100848067B1 (ko) 2008-07-23
PL1702917T3 (pl) 2018-02-28
CN101456841A (zh) 2009-06-17
JP2012121893A (ja) 2012-06-28
EP3299358A1 (en) 2018-03-28
BRPI0418074A (pt) 2007-04-17
CA2551529A1 (en) 2005-07-14
SI1702917T1 (en) 2018-01-31
DK1702917T3 (da) 2017-11-13
AU2004309248B2 (en) 2009-11-05
CN1898208A (zh) 2007-01-17
EP1702917A4 (en) 2009-06-03
KR20060127901A (ko) 2006-12-13
AU2004309248A1 (en) 2005-07-14
CA2551529C (en) 2011-02-01
EP1702917B1 (en) 2017-08-02
PT1702917T (pt) 2017-11-14
MXPA06007237A (es) 2006-08-18
BRPI0418074B8 (pt) 2021-05-25
BRPI0418074B1 (pt) 2019-06-18
JP2014196291A (ja) 2014-10-16
CY1120169T1 (el) 2018-12-12
ES2651615T3 (es) 2018-01-29

Similar Documents

Publication Publication Date Title
HUE034712T2 (hu) Amidszármazék és gyógyszer
EP1533304B1 (en) Amide derivative
AU2015303641B2 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
JP5740409B2 (ja) キナーゼ阻害剤
CA2729495C (en) Pyrimidine derivatives as kinase inhibitors
DK2428508T3 (en) Diamino heterocyclic carboxamide COMPOUND
CN102250065B (zh) 取代的三嗪苯脲衍生物及其用途
TW201834651A (zh) 化合物
AU2003242591A1 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
KR102388312B1 (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
AU2003261807A1 (en) Azaarene derivatives
CA2463822A1 (en) Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
HUE034979T2 (hu) Aminopirimidin-származékok a kináz-aktivitás modulátoraiként történõ alkalmazásra
KR102445744B1 (ko) Smac 모방체로서의 6-알키닐 피리딘 유도체
KR20180019443A (ko) 1,6-이치환된 인돌 화합물을 함유하는 약물 내성 및 부작용이 저감된 만성골수성백혈병 치료제
KR101127725B1 (ko) 아미드 유도체